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Abstract: 
Neuropeptide FF (FLFQPQRFa, NPFF) is considered as a potent opioid-modulating peptide. 
It exhibits the opioid-modulation effect by activating two G protein-coupled receptors, 
NPFF1 and NPFF2. Several observations suggest that the anti-opioid effect of NPFF is more 
likely mediated by a cross-talk between NPFF and opioid receptors in the same neuron 
rather than an indirect effect due to a neuronal circuitry. Nevertheless, the precise 
molecular mechanisms underlying the cross-talk between both receptors remain need to be 
investigated. 
This work is composed of two main parts: 
1) Neuropeptide FF receptors and the molecular mechanisms of their anti-opioid effect 
We tested both direct and anti-opioid activities of NPFF receptors on Ca2+ transient induced 
by depolarization in mouse dorsal raphe nucleus (DRN) neurons. The NPFF receptor 
preferentially coupled with Gi/o proteins, which induced the direct activity. Different 
threshold to observe the direct and anti-opioid effect of NPFF suggested that the specific 
anti-opioid activity of NPFF receptors was not a direct consequence of their activity on Ca2+ 
transients. Furthermore, we studied the molecular mechanisms underlying the cross-talk 
between NPFF and NOP (Nociceptin/Orphanin FQ, N/OFQ) receptors in mouse DRN 
neurons and SH-SY5Y human neuroblastoma cells. Data from Ca2+ imaging, [35S]GTPγS 
binding assay and western blot indicated that cholesterol-rich lipid rafts, which acted as a 
―platform‖, were involved in NPFF anti-N/OFQ effect, and the siRNA interference data 
showed that GRK2 protein mediated this process. 
2) The potential role of Neuropeptide FF in anti-depressant response 
In order to test the potential role of Neuropeptide FF in anti-depression, the NPFF analogue 
1DMe was locally injected into mouse DRN. We observed a decrease of immobility time and 
an increase of grooming time, in tail suspension test and splash test, respectively, after 
1DMe treatment. RF9, the specific antagonist of NPFF receptors, reversed the 
anti-depression effect of 1DMe. Referencing the strong anti-depression effect of NOP 
receptor antagonists after DRN injection and the cellular anti-N/OFQ activity of NPFF 
receptors in this nucleus, the hypothesis that the anti-depression effect of NPFF may due to 
its cellular anti-N/OFQ activity is interesting to be further verified. 
 
Keywords: Neuropeptide FF receptor, Anti-opioid, Membrane/lipid rafts, NOP receptor, Mu-opioid receptor, 
Calcium, [35S]GTPγS 
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Résumé: 
Le Neuropeptide FF (FLFQPQRFa, NPFF) est un neurotransmetteur peptidique, 
caractérisé par son activité pharmacologique anti-opioïde. Ce peptide active deux 
récepteurs couplés aux protéines G, NPFF1 et NPFF2. De nombreuses données 
suggèrent que le NPFF module l'activité opioïde par un effet direct sur les récepteurs 
opioïdes situés sur les mêmes neurones plutôt que via un effet indirect dû à une 
modification d'un circuit neuronal. Néanmoins, les mécanismes moléculaires 
sous-jacents de ce cross-talk entre les récepteurs sont encore mal compris. 
Ce travail est composé de deux parties principales: 
1) les mécanismes anti-opioïdes médiés par les récepteurs du Neuropeptide FF 
Nous avons testé les activités directes et anti-opioïdes des récepteurs NPFF sur les 
canaux calciques voltage-dépendants activés par dépolarisation sur des neurones 
du noyau raphé dorsal (DRN) de souris. Le récepteurs NPFF dans ces neurones sont 
préférentiellement couplés aux protéines G de type Gi/o. Les effets directs et 
anti-opioïdes induits par les récepteurs NPFF interviennent dans des gammes de 
concentration différentes indiquant que l'activité anti-opioïde spécifique n'est pas 
une conséquence directe de leur activité sur les canaux calciques. De plus, nous 
avons comparé ces interactions entre récepteurs NPFF et NOP (nociception, N/OFQ) 
observés sur des neurones dissociés de souris avec celles observés sur une lignée 
cellulaire de neuroblastome humain, SH-SY5Y. Les données obtenues en imagerie 
calcique et dans le test de stimulation de liaison du [35S]GTPyS aux protéines G, 
montrent un rôle potentiel important des radeaux membrane/lipides (rafts), qui 
agirait comme une plateforme de signalisation dans les effets du NPFF. 
2) le rôle du Neuropeptide FF dans la dépression 
Afin de tester le rôle potentiel pharmacologique du NPFF dans la dépression, des 
injections locales du 1DMe, un analogue du NPFF, ont été réalisées dans le DRN de 
souris. Nous avons observé une forte activité de cet analogue dans le test de 
suspension de la queue test et dans le "splash test", comme respectivement une 
diminution des temps d'immobilité et une augmentation du temps de toilettage. Du 
fait de l'existence d'un fort effet antidépressif des antagonistes des récepteurs NOP 
après injection dans le DRN et de l'effet cellulaire anti-N/OFQ du NPFF que nous 
avons démontré, il est plausible d'envisager que le NPFF possède un effet 
antidépressif via son action anti-opioïde sur les récepteurs nociceptine. 
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Introduction 
Introduction 
 
1. The neuropeptide FF system 
1.1.  The neuropeptide FF and related peptides 
The neuropeptide FF (FLFQPQRFa) and related peptides NPAF, NPSF and NPVF 
belong to the family of mammalian RF-amide peptides which all share a conserved 
carboxy-terminal Arg-Phe-NH2 sequence (Figure 1). Historically, the tetrapeptide 
Phe–Met–Arg–Phe–NH2 (FMRF-NH2), which has been isolated in 1977 by Price and 
Greenberg, was the first peptide identified with an Arg-Phe-amide C-terminus (Price 
and Greenberg, 1977). Thereafter, using specific antibodies against the peptide, 
FMRF-NH2 immunoreactive peptides were observed in several species (Boer et al., 
1980; Dockray et al., 1983). 
 
 
 
Figure 1: Members of the mammalian RFamide family. These include the prolactin releasing peptide (PrRP) family, 
the family of NPFF (and related peptides NPAF, NPSF, and NPVF), human RFamide related peptides (hRFRPs), 
metastin/kisspeptins and QRFP family. Specific receptors for each family of peptides have been identified, 
although in a number of instances cross-talk amongst these peptides and their receptors exists (denoted by 
arrows). From (Jhamandas and Goncharuk, 2013) 
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In 1985, Yang and colleagues isolated the first two mammalian FMRF-NH2-like 
peptides from bovine brain (Yang et al., 1985), the neuropeptide FF (NPFF, 
FLFQPQRFa) and the neuropeptide AF (NPAF, AGEGLSSPFWSLAAPQRFa, also 
called NPSF in rodents for the last eight residues), which were from the same 
precursor pro-NPFFA (Perry et al., 1997; Vilim et al., 1999) (Figure 2). However, it 
was not NPFF, but an 11 amino acids peptide, that released in humans, rats, mice 
and bovine, such as NPA-NPFF in rats and SQA-NPFF in mice (Vilim et al., 1999) 
(Figure 2). Similarly, EFW-NPSF and QFW-NPSF were released in rats and mouse, 
respectively (Vilim et al., 1999) (Figure 2). 
 
MDSRQAAALLVLLLLIDG-GCAEGPGGQQE-DQLSAEEDSEPLPPQDA------QTSGSL   52 
MDARQAAALLLVLLLVTDWSHAEGPGGRDGGDQIFMEEDSGAHPAQDA------QTPRSL   54 
MDSK-WAALLLLLLLLLNWGHTEEAGSWGE-DQVFAGEDKGPHPPQYAHIPDRIQTPGSL   58 
MDSK-WAAVLLLLLLLRNWGHAEEAGSWGE-DQVFAEEDKGPHPSQYAHTPDRIQTPGSL   58 
 
LHYLLQAMERPGRSQAFLFQPQRFGRNTQGSWRNEWLSPRAGEGLNSQFWSLAAPQRFGKK   113 
LRSLLQAMQRPGRSPAFLFQPQRFGRNTRGSWSNKRLSPRAGEGLSSPFWSLAAPQRFGKK   113 
FRVLLQAMDTPRRSPAFLFQPQRFGRSAWGSWSKEQLNPQARQ-----FWSLAAPQRFGKK   114 
MRVLLQAMERPRRNPAFLFQPQRFGRNAWGPWSKEQLSPQARE-----FWSLAAPQRFGKK   114 
 
 
Figure 2: Sequences of the precursor ProNPFFA and the predicted peptides of human, bovine, mouse and rat. The 
matured peptides were labeled in red. For each peptide, C termini are followed by amide donor glycines and 
consensus processing sites. Modified from (Vilim et al., 1999) 
 
Subsequently, a gene encodes precursor pro-NPFFB was cloned in humans, 
bovine, rats and mice (Hinuma et al., 2000) (Figure 3). The precursor releases 
peptides, except RFRP-2, ending with representative RFamide sequence of the NPFF 
family. In addition, the precursor pro-NPFFB putatively generates three peptides in 
humans and bovine (RFRP-1 to 3) and two in rodents (RFRP-1 and RFRP-3) 
(Hinuma et al., 2000) (Figure 3). In bovine hypothalamus extract, the RFRP-1 (35 
amino acids, also called GnIH) was found (Fukusumi et al., 2001), while the RFRP-3 
(28 amino acids, also called NPVF) was only found in a longer form (Yoshida et al., 
2003) (Figure 3). 
Human 
Bovine 
Mouse 
Rat 
Human 
Bovine 
Mouse 
Rat 
NPFF NPSF 
NPAF 
 3 
Introduction 
 
MEIISSKLFILLTLATSSLLTSNIFCADELVMSNLHSKENYDKYSEPRGYP--KGERSLN     58 
MEIISLKRFILLMLATSSLLTSNIFCTDESRMPNLYSKKNYDKYSEPRGDLGWEKERSLT     60 
MEIISLKRFILLTVATSSFLTSNTFCTDEFMMPHFHSKEGDGKYSQLRGIPKGEKERSVS     60 
MEIISSKRFILLTLATSSFLTSNTLCSDELMMPHFHSKEGYGKYYQLRGIPKGVKERSVT     60 
 
FEELKDWGPKNVIKMSTPAVNKMPHSFANLPLRFGRNVQEERSAGATANLPLRSGRNMEV     118 
FEEVKDWAPK--IKMNKPVVNKMPPSAANLPLRFGRNMEEERSTRAMAHLPLRLGKNRED     118 
FQELKDWGAKNVIKMSPAPANKVPHSAANLPLRFGRTIDEKRSPAARV--------NMEA     112 
----KD------IKMSPAPANKVPHSAANLPLRFGRNIEDRRSPRARA--------NMEA     102 
 
SLVRRVPNLPQRFGRTTTAKSVCRMLSDLCQGSMHSPCANDLFYSMTCQHQEIQNPDQKQ     178 
SLSRWVPNLPQRFGRTTTAKSITKTLSNLLQQSMHSPSTNGLLYSMACQPQEIQNPGQKN     178 
GTRSHFPSLPQRFGRTTAR--SPKTPADLPQKPLHSLGSSELLYVMICQHQEIQSPGGKR     170 
GTMSHFPSLPQRFGRTTARR-ITKTLAGLPQKSLHSLASSELLYAMTRQHQEIQSPGQEQ     161 
 
SRRLLFKKIDDAELKQEK                        196 
LRRRGFQKIDDAELKQEK                        196 
TRRGAFVETDDAERKPEK                        188 
PRKRVFTETDDAERKQEKIGNLQPVLQGAMKL       193 
 
 
Figure 3: Sequences of the precursor ProNPFFB and the predicted peptides of human, bovine, mouse and rat. The 
matured peptides were labeled in red. For each peptide, C termini are followed by amide donor glycines and 
consensus processing sites. Modified from (Hinuma et al., 2000) 
 
1.1.1.  Distribution of NPFF and related peptides 
1.1.1.1. Peptides derived from precursor ProNPFFA 
The distribution of NPFF was primarily studied in rat CNS by using antibodies 
against the peptide. The NPFF like immunoreactivity was found with high density in 
spinal cord, hypothalamus, pituitary and bridge / medulla, while the density of 
immunoreactivity in the cortex and hippocampus was quite low (Majane et al., 1989, 
Panula et al., 1996). The highest density of immunoreactivity was found in the 
posterior pituitary, in which region, the NPFF came from hypothalamic fibers 
projecting to the neurohypophysis. Many cell bodies containing NPFF were also 
found in the hypothalamus, particularly at the intermediolateral-median-kernel, 
and their presence suggested a role of NPFF in food intake and neuroendocrine 
Human 
Bovine 
Mouse 
Rat 
Human 
Bovine 
Mouse 
Rat 
Human 
Bovine 
Mouse 
Rat 
Human 
Bovine 
Mouse 
Rat 
RFRP-1 RFRP-2 
RFRP-3 
NPVF 
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regulation. Furthemore, many cell bodies of solitary tract nucleus also contain 
neuropeptide FF, highlighting the role of NPFF in cardiovascular regulation. 
The neural pathways containing NPFF were also determined by combined using 
of antegrade or retrograde tracer and immunohistochemistry technology. Neurons 
in the medial hypothalamus projected bilaterally to solitary tract nucleus, lateral 
septum nucleus, periaqueductal gray matter and hypothalamic nuclei (Aarnisalo 
and Panula, 1995). The cell bodies of solitary tract nucleus projected meanwhile to 
the contralateral nucleus, lateral parabrachial nucleus and the ipsilateral nucleus 
ambiguus (Kivipelto and Panula 1991). In spinal cord, NPFF like immunoreactivity 
was very concentrated at a modest rostrocaudal gradient, particularly at surface 
layers I and II (Majane et al., 1989). The presence of NPFF at superficial layers of the 
dorsal horn of spinal cord, the periaqueductal gray matter and the parabrachial 
nucleus suggests NPFF plays a role in the mechanisms of nociception. 
 
Data from in situ hybridization studies in rats showed a strong expression of the 
mRNA of precursor Pro-NPFFA at solitary tract nucleus and superficial layers of the 
dorsal horn of spinal cord. A more moderate staining was observed in the supraoptic 
and paraventricular hypothalamic nuclei (Vilim et al., 1999). The presence of the 
mRNA is correlated with the displayed NPFF like immunoreactivity in these regions. 
 
1.1.1.2. Peptides derived from precursor Pro-NPFFB 
Data from quantitative RT-PCR in rats showed a strong expression of the mRNA 
of precursor Pro-NPFFB in the hypothalamus and eye, in contrast, the expression of 
that in testes was low (Hinuma et al., 2000). 
In situ hybridization studies refined these results and showed that the mRNA of 
RFRP like peptides was mainly distributed in the periventricular nucleus and 
neurons located between the ventromedial nucleus and dorsomedial nucleus of the 
hypothalamus (Hinuma et al., 2000). 
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The RFRP-1 and RFRP-3 were relatively restricted to central nervous system, 
particularly in the hypothalamus, thalamus, midbrain, optic nerve (only for RFRP-1), 
medulla oblongata, striatum, pituitary (RFRP-3), cerebral cortex, cerebellum and 
hippocampus (RFRP-1) (Fukusumi et al., 2001; Yoshida et al., 2003), detecting by 
radioimmunoassay in rat tissues. 
The distribution of different peptides from pro-NPFFB is substantially equivalent 
to that of the mRNA of the precursor. In contrast, the different distribution pattern 
of NPFF and RFRP-1 immunoreactive neurons suggested a same pattern of the 
peptide distribution according to their precursors (Yano et al., 2003). 
 
1.2.  The neuropeptide FF receptors 
1.2.1.  G protein-coupled receptors 
G protein-coupled receptors (GPCRs) are also called seven transmembrane 
receptors, which are the most common membrane-bound receptors. They are 
involved in the recognition and transduction of messages as diverse as light, Ca2+, 
odorants, small molecules including amino-acid residues, nucleotides and peptides, 
as well as proteins. In addition, they control the activity of enzymes, ion channels 
and transport of vesicles via the catalysis of the GDP–GTP exchange on 
heterotrimeric G proteins. 
 
1.2.1.1. Different families of G protein-coupled receptors in humans 
Results of sequence comparison revealed the existence of different receptor 
families sharing no sequence similarity. However, all these receptors have in 
common a central core domain constituted of seven transmembrane helices (TM-I to 
VII) connected by three intracellular (i1, i2 and i3) and three extracellular (e1, e2 
and e3) loops (Baldwin, 1993). 
The Rhodopsin family (also known as Class A) has the largest number of 
receptors and several characteristics such as NSxxNPxxY motif in TMVII and the 
DRY motif or D(E)-R-Y(F) at the border between TMIII and IL2. 
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The Rhodopsin family could be divided into 4 sub-groups according to the size 
and the ligand binding site of the receptor. 
The α-Group contains receptors for small ligands like retinal, odorants or small 
peptides, and the binding site is localized within the seven TMs; 
The β-Group contains receptors for peptides whose binding site includes the 
N-terminal, the extracellular loops and the superior parts of TMs. Both NPFF1 and 
NPFF2 receptor belong to this group; 
The γ-Group contains receptors responding to peptides and lipid ligands, and in 
humans by far there are 59 receptors identified including opioid receptors and 
certain RF-amides receptors; 
The δ-Group contains receptors for glycoprotein hormones, and it is 
characterized by a large extracellular domain and a binding site which is mostly 
extracellular but at least with contact with extracellular loops e1 and e3. 
 
 
 
 
Figure 4: Conserved residues and functional 
microdomains in GPCRs. (a) Rhodopsin (PDB 
accession 1GZM) with bound inverse agonist 
11-cis-retinal is shown as a representative 
GPCR. The basic GPCR architecture consists of 
7TM helices, linked by cytoplasmic (C1–C3, 
top) and extracellular (E1–E3, bottom) loops. 
The cytoplasmic helix H8 follows directly after 
TM7 and is frequently terminated by one or 
two palmitoylated Cys residues (Cys322 and 
Cys323 in rhodopsin). Oligosaccharide chains 
are often attached at the N terminus (Asn2 
and Asn15 in rhodopsin). A conserved disulfide 
bridge constrains the extracellular end of TM3 
and themiddle of loop E2 (Cys1103.25 and 
Cys187 in rhodopsin). The most conserved 
residue in each TMhelix is shown in blue. (b) 
Rhodopsin-specific microdomains. These 
include the TM3–TM5 network (blue shading) 
with Glu1223.37 ,Trp1263.41 on TM3 and 
His2115.46 on TM5, and the Schiff base 
network (purple shading) with the protonated 
Schiff base (PSB) linkage between Lys2967.43 
on TM7 and the inverse agonist 11-cis-retinal. 
From (Hofmann et al., 2009) 
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The Secretin and Adhesion receptor family are also known as Class B GPCRs. 
The Secretin family has a similar morphology to class A, but they do not share any 
sequence homology, and ligands for receptors of this family include high molecular 
weight hormones such as glucagon, secretine, VIP-PACAP and α-latrotoxin 
(Krasnoperov et al., 1997; Davletov et al., 1998). The relatively long N-terminal 
domain played a role in the binding of the ligand (Pantaloni et al., 1996). 
The name ―adhesion‖ relates to these long N termini, which contains motifs that 
are likely to participate in cell adhesion. It‘s also found that receptors of this family 
are involved in immunological functions in the central nervous system. 
 
Receptors of the glutamate receptor family (also known as Class C) all possess a 
very large N-terminal extracellular domain, where two lobes separated by a hinge 
region formed. Several studies including X-ray crystallography indicated that these 
two lobes closed like a Venus‘ flytrap upon binding of the ligand. This receptor 
family represents by metabotropic glutamate receptors (mGluRs), GABA-B receptors, 
Ca2+ sensing receptors (Pin and Bockaert, 1995) and a group of putative pheromone 
receptors (Bargmann, 1997). 
 
The Frizzled/Taste2 receptor family contains small number of GPCRs. The 
―frizzled‖ and the ―smoothened‖ (Smo) receptor are involved in embryonic 
development and in particular in cell polarity and segmentation. The Taste2 
receptor is found expressed in the tongue and the epithelium of the roof of the 
mouth probably playing a role in the perception of bitter taste. 
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Figure 5: Dendrogram of the human GPCR superfamily with the crystal structures solved. The tree is drawn based 
on sequence similarity in the seven-transmembrane domain. Human GPCRs include Class A (Rhodpsin family), 
Class B (Secreting and Adhesion families), Class C (Glutamate family) and Frizzled/TAS2 Family. The Rhodopsin 
family is divided into Groups (α-γ). From (Katritch et al., 2013) 
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Figure 6: Diversity of ligand binding pockets in GPCRs. Pockets are shown as molecular surfaces for available 
inactive-state GPCR structures in complex with corresponding antagonists. Receptor orientations and the surface 
clipping planes are the same for all receptors. Pairs of closely related GPCR subtypes with similar pockets are 
highlighted by colored frames. From (Katritch et al., 2013) 
 
1.2.1.2. Heterotrimeric G proteins 
As with the G-protein-coupled receptors (GPCRs), heterotrimeric guanine 
nucleotide-binding proteins (G-proteins) represent an ancient protein family that 
has been highly conserved over evolution. A number of bacterial exotoxins, having 
the capacity to regulate the function of the α-subunit of many heterotrimeric 
G-proteins, are good tools in the discovery and studying of G-protein functions. 
By using an exotoxin produced by Vibrio cholerae (cholera toxin, CTX), a 45 kDa 
polypeptide was firstly purified and identified (Northup et al., 1980), which is known 
as the α-subunit of the adenylyl cyclase stimulatory G-protein (Gs) now. However, 
despite efforts employing a range of chromatographic steps, the 45 kDa polypeptide 
was copurified with a 35 kDa and an 8–10 kDa polypeptide. The corresponding 35 
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kDa and the 8–10 kDa polypeptide are the β- and γ- subunit, respectively, which 
make up the functional G-protein heterotrimer. In addition, by using an exotoxin 
produced by Bordetella pertussis (pertussis toxin, PTX), a 41 kDa polypeptide as the 
α-subunit of adenylyl cyclase inhibitory G-protein (Gi), along with a 35 kDa and an 
8–10 kDa polypeptide that appeared identical to the β- and γ- subunit of Gs protein, 
respectively, was identified (Bokoch et al., 1984). Thereafter, a series of G-proteins 
were discovered with different tissue distribution and effectors (Milligan and 
Kostenis, 2006). 
Thirty five genes in humans encode G-proteins, 16 encoding α-subunits, 5 β and 
14 γ (Downes and Gautam, 1999). The α-subunit can be classified in four families 
according to their similarity of sequence: 1) Gαs, 2) Gαi/o, 3) Gαq/11 and 4) Gα12/13 
(Table 1) (Milligan and Kostenis, 2006). 
 
Table 1: Diversity and function of different G-protein subunits 
Family Subty
pe 
Effectors Distribution Toxin 
Gαs αs 
αolf 
AC↑, Src tyrosine kinases↑ 
AC↑ 
Ubiquitous 
Olfactory neurons, certain CNS 
ganglia; digestive and urogenital 
tract 
CTX 
CTX 
Gαi/o 
 
 
αo1-2 
 
αi1-3 
 
αz 
 
αt1/2 
AC↓, Ca2+ channels↓, K+ channels↑ 
 
AC↓, Ca2+ channels↓, K+ channels↑, 
Src tyrosine kinases↑, MAPK↑ 
AC↓, Ca2+ channels↓, K+ channels↑, 
Rap1GAP↑ 
cGMP-PDE↑ 
Neurons, astrocyte, neuroendocrine 
cells, heart 
Neurons and many others 
 
Platelets, neurons, adrenal 
chromaffin cells, neurosecretory 
cells 
Rod and cone outer segments, taste 
buds 
PTX 
PTX 
 
? 
PTX 
Gαq/11 
 
αq/11 
α14,15,1
6 
Isoformes PLCβ (β1, β3) ↑ 
Isoformes PLCβ (β1, β3) ↑ 
Ubiquitous 
Hematopoietic cells 
YM-25489
0 
? 
Gα12/13 α12/13 Phospholipase D/ Cε↑, RhoGEF↑, 
Na+/H+ exchanger↑ 
Ubiquitous ? 
Gβ/γ β1-5 
γ1-12 
PLCβ↑, PLA2↑, K+ channels 
(GIRK1,2,4) ↑, Ca2+ channels (N-, 
P/Q-, R-type) ↓, AC type I↓, AC type 
II, IV, VII↑, PI-3 kinases↑, c-Src 
kinases↑, GRK↑, JNK↑ 
β1γ1: retinal rod cells 
β3γ8: retinal cone cells 
β5: neurons and neuroendocrine 
organs 
β5(L): retina 
Other subtypes are Ubiquitous 
 
Modified from (Milligan and Kostenis, 2006) 
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Figure 7: Structure of the G protein. From (Milligan and Kostenis, 2006; McCudden et al., 2004)   
 
Although the effectors are different and so does the downstream signaling, G 
proteins of different families exhibit a common mechanism of being activation and 
inactivation (Figure 8). 
Before activation, the GDP is bound to the Gα subunit of G proteins. When the G 
protein-coupled receptor is activated by a ligand, there is a conformational change 
in the receptor that allows the receptor to function as a guanine nucleotide 
exchange factor (GEF) and exchanges GTP for GDP, thus turning the GPCR "on". 
This exchange triggers the dissociation of the Gα subunit (which is bound to GTP) 
from the Gβγ dimer and the receptor as a whole (Figure 8). 
The Gα subunit will eventually hydrolyze the attached GTP to GDP by its 
inherent enzymatic activity, allowing it to re-associate with Gβγ and starting a new 
cycle. A group of proteins called regulator of G protein signallings (RGSs), act as 
GTPase-activating proteins (GAPs), are specific for Gα subunits. These proteins 
accelerate the hydrolysis of GTP to GDP, thus terminating the transduced signal. 
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1.2.2.  Cloning of NPFF1 and NPFF2 receptors 
In 2000, two G protein-coupled receptors, NPFF1 (also called OT7T022/GPR147) 
and NPFF2 (also called HLWAR77/GPR74), were isolated from human and rat  
central nervous system tissues (Bonini et al., 2000; Elshourbagy et al., 2000; 
Hinuma et al., 2000; Kotani et al., 2001). 
The hNPFFR1 and hNPFFR2 exhibit 59% sequence identity (Bonini et al., 2000; 
Elshourbagy et al., 2000; Hinuma et al., 2000; Kotani et al., 2001) (Figure 9). The 
sequence of both receptors predicts two cysteine residues positioned on the 
extracellular loops I and II forming a constraint within the receptor. Furthermore, 
the existence of a sequence D / ERF at the end of transmembrane domain III and a 
cysteine at the C-terminus (putative palmitoylation site) suggests that NPFF 
receptors belong to the rhodopsin family (Figure 9). 
In addition, they have about 40% sequence homology with Neuropeptide Y and 
Orexin receptors (Bonini et al., 2000). 
 
 
 
 
 
 
Figure 8: Summary of the G Protein Signaling Cycle. In State 1, 
activated receptor binds to the GDP-bound heterotrimeric G protein and 
promotes release of GDP from the Gα subunit. Binding of GTP to the Gα 
subunit results in dissociation of this high-aff inity complex into 
GTP-bound Gα, and Gβγ (State 2), each of which are now able to bind 
to downstream effectors (State 3) and elicit downstream responses. 
The Gα subunit has intrinsic GTPase activity which is enhanced by 
Regulators of G protein Signaling (RGS). Following hydrolysis of GTP, 
GDP-bound Gα subunits reassociate with Gβγ subunits (State 4) and 
traff ic to the membrane, where they can interact with receptors in the 
next signaling cycle (State 5). From (Thaker et al., 2012) 
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hNPFF1      MEGEPSQPPNSSWP--LSQNGTNTEATPATNLTFSSYYQHTSPVAAMFIVAYALIFLLCM    58 
hNPFF2      MNEKWDTNSSENWHPIWNVNDTKHHLYSDINITYVNYYLHQPQVAAIFIISYFLIFFLCM    60 
 
59        VGNTLVCFIVLKNRHMHTVTNMFILNLAVSDLLVGIFCMPTTLVDNLITGWPFDNATCKM     118 
61        MGNTVVCFIVMRNKHMHTVTNLFILNLAISDLLVGIFCMPITLLDNIIAGWPFGNTMCKI     120 
 
119       SGLVQGMSVSASVFTLVAIAVERFRCIVHPFREKLTLRKALVTIAVIWALALLIMCPSAV     178 
121       SGLVQGISVAASVFTLVAIAVDRFQCVVYPFKPKLTIKTAFVIIMIIWVLAITIMSPSAV     180 
 
179       TLTVTREEHH-FMVDARNRSYPLYSCWEAWPEKGMRRVYTTVLFSHIYLAPLALIVVMYA     237 
181       MLHVQEEKYYRVRLNSQNKTSPVYWCREDWPNQEMRKIYTTVLFANIYLAPLSLIVIMYG     240 
 
238       RIARKLCQAPGPAPGGE-EAADPRASRRRARVVHMLVMVALFFTLSWLPLWALLLLIDYG     296 
241       RIGISLFRAAVPHTGRKNQEQWHVVSRKKQKIIKMLLIVALLFILSWLPLWTLMMLSDYA     300 
 
297       QLSAPQLHLVTVYAFPFAHWLAFFNSSANPIIYGYFNENFRRGFQAAFRARLCPRPSGSH     356 
301       DLSPNELQIINIYIYPFAHWLAFGNSSVNPIIYGFFNENFRRGFQEAFQLQLCQKR-AKP     359 
 
357       KEAYSERPGGLLHRRVFVVVRPSDSGLPSESGPSSGAPRPGRLPLRNGRVAHHGLPREGP     416 
400       MEAYA------LKAKSHVLINTSN-QLVQES--TFQNPHGETLLYR--KSAEK--PQQEL     406 
 
417       GCSHLPLTIPAWDI          430 
407       VMEELKETTNSSEI          420 
 
Figure 9: Comparison of sequences of hNPFF1 and hNPFF2 receptors. Seven putative transmembrane domains are 
indicated above the corresponding sequence. Modified from (Bonini et al., 2000) 
 
It is showed that both receptors were preferentially Gi/o protein-coupled when 
expressed in Chinese hamster ovary cells, human embryonic kidney 293 cells or 
human neuroblastoma SH-SY5Y cells by measuring the inhibition effect produced 
by agonists of both receptors on cAMP accumulation induced by forskolin 
(Elshourbagy et al., 2000; Hinuma et al., 2000; Kotani et al., 2001; Mollereau et al., 
2002; Mollereau et al., 2005). 
Furthermore, the application of competitor peptides of different Gα subunits 
helps us refine the knowledge about the G protein coupling of NPFF1 and NPFF2 
receptors. These peptides correspond to the C-terminal part of Gα subunits which 
TM1 
TM2 
TM3 TM4 
TM5 
TM6 
TM7 
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represents a large interaction site with the receptor. Thus they compete with native 
G proteins to the receptor coupling. [35S]GTPγS binding assay results then showed, 
in CHO cells transfected with hNPFF1 or hNPFF2 receptors, a preferential coupling of 
Gi3 and Gs type proteins to hNPFF1 receptors, while hNPFF2 receptors preferred to 
coupling with Go, Gi2, Gi3 and Gs type proteins (Gouarderes et al., 2007). In addition, 
in SH-SY5Y cells transfected with hNPFF2 receptors, blocker peptides corresponding 
to Gαi1/2, Gαo and Gαs proteins decreased the affinity of [125I] EYF (radiolabeled 
specific agonist of the NPFF2 receptor with iodine 125) for hNPFF2 receptors as well 
as the ability of 1DMe reactivate the signal path way of PLCβ (Mollereau et al., 2005). 
Studies of mouse olfactory bulb membranes suggested NPFF2 receptors coupled 
to Gs proteins (Gherardi and Zajac, 1997). Furthermore, it has been shown that 
although the treatment of cholera toxin did not affected the in vivo NPFF anti-opioid 
effect in the tail-flick test, the hypothermic effect produced by NPFF could be 
inhibited (Francés et al., 2001). 
 
1.2.3.  Distribution of NPFF1 and NPFF2 receptors 
Before the cloning of both receptors, several studies showed the presence of 
NPFF binding sites in the central nervous system (Roumy and Zajac, 1998). 
Following the cloning of precursors and receptors, and the establishment of 
their pharmacological profiles, a more accurate NPFF receptor mapping was 
performed by using specific agonists of each receptor [125I] -YVP (modified NPVF, 
selective agonist of NPFF1 receptors) and [125I]-EYF (modified EFW-NPSF, selective 
agonist of NPFF2 receptors) (Gouardères et al., 2001; Gouardères et al., 2002). It has 
been shown that the NPFF2 receptor predominated in rat brain (Gouardères et al., 
2002). In contrast, the NPFF1 receptor was only detected in the septum, thalamus, 
hypothalamus and nucleus of the solitary tract (Gouardères et al., 2002). At the 
spinal cord level, only NPFF2 receptor binding sites were found in outer layers of the 
dorsal horn (Gouardères et al., 2002). 
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Region Bmax NPFF1 
pCi / mg tissue 
Bmax NPFF2 
pCi / mg tissue 
Telencephalon 
Nucleus Accumbens 
Caudate Putamen 
Lateral Globus Pallidus 
Medial Globus Pallidus 
Nucleus of the Vertical limb of the Diagonal Band 
Lateral Septal nucleus, Dorsal part 
Lateral Septal nucleus, Intermediate part 
Bed nucleus of the Stria Terminalis 
Anterior Amygdaloid nucleus 
Presubiculum 
Medial Preoptic Area 
 
Diencephalon 
Thalamus 
Anterodorsal thalamic nucleus 
Paraventricular thalamic nucleus, Anterior part 
Central medial thalamic nucleus 
Ventromedial thalamic nucleus 
Parafascicular thalamic nucleus 
Laterodorsal thalamic nucleus 
Paratenial thalamic nucleus 
Zona Incerta 
Hypothalamus 
Ventromedial Hypothalamic nucleus 
Anterior Hypothalamic area 
Lateral Hypothalamic area 
Mammillary nucleus 
Suprachiasmatic nucleus 
Periventricular hypothalamic nucleus 
Paraventricular hypothalamic nucleus 
 
Midbrain 
Anterior Pretectal nucleus, Dorsal part 
Medial Geniculate nucleus 
Interpeduncular nucleus 
Superficial gray layer of the superior colliculus 
Dorsal Raphe nucleus 
Central Gray 
Ventral Tegmental nucleus 
 
Hindbrain 
Lateral Parabrachial nucleus 
Parabigeminal nucleus 
Spinal Trigeminal nucleus 
Nucleus of the Solitary Tract 
Spinal Trigeminal Tract 
 
Spinal cord 
Lamina I-II 
 
- 
- 
39 
45 
- 
39 
62 
22 
22 
- 
25 
 
 
 
25 
17 
- 
31 
34 
- 
- 
- 
 
42 
34 
34 
- 
- 
39 
53 
 
 
- 
- 
- 
- 
- 
- 
- 
 
 
- 
- 
- 
28 
- 
 
 
- 
 
277 
970 
 
 
748 
464 
1496 
200 
 
1639 
636 
 
 
 
713 
662 
796 
961 
3808 
2253 
862 
1322 
 
1027 
- 
1518 
1912 
1603 
- 
- 
 
 
2730 
504 
1080 
521 
1432 
970 
1481 
 
 
1617 
1522 
669 
1643 
2277 
 
 
2411 
 
Table 2: Quantitative autoradiographic distribution of NPFF1 and NPFF2 receptors in rat brain. The distribution of 
NPFF1 and NPFF2 receptors was determined by specific agonists [125I]-YVP and [125I]-EYF, respectively. The Bmax 
corresponded to the density of receptors in corresponding region. (-): non-detectable. Modified from (Gouardères et 
al., 2002) 
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1.2.4.  Pharmacological profile of NPFF1 and NPFF2 receptors 
Data from binding studies and the inhibition effect of NPFF receptors on cAMP 
accumulation indicated each NPFF receptor recognizes peptides from both 
precursors with nanomolar affinities (Mollereau et al., 2002). However, there is a 
slight preference of peptides from pro-NPFFA for NPFF2 receptors and from 
pro-NPFFB for NPFF1 receptors (Mollereau et al., 2002). Meanwhile, 1DMe, an 
analogue of NPFF which is less easily degradable by aminopeptidases (Gicquel et al., 
1992), has a low selectivity towards NPFF2 receptors. 
 
BIBP3226, a selective Neuropeptide Y (NPY) Y1 receptor antagonist (Rudolf et al., 
1994), displayed relatively high affinities for NPFF receptors and exhibited 
antagonist properties towards hNPFF1 receptors (Bonini et al., 2000; Mollereau et 
al., 2001; Mollereau et al., 2002; Fang et al., 2006). 
 
RF9 is an RFamide dipeptide having an adamantine group at the N-terminal 
part. This peptide binds with NPFF1 and NPFF2 receptors with relatively good 
affinities (Ki = 58 nM and Ki = 75 nM, respectively) while having very low affinities for 
nearby receptors, such as NPY receptors and other RFamide type peptides receptors 
(receptors GPR10, GPR54 and GPR103) (Simonin et al., 2006). In vitro, RF9 
prevented the inhibition effect of NPVF on adenylyl cyclase and the activation of G 
proteins by NPFF in cells expressed NPFF1 or NPFF2 receptors (Simonin et al., 2006). 
In vivo, RF9 inhibited the hypothermic effect induced by NPFF in mice although 
there was no activity by itself (Fang et al., 2008). 
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CHO hNPFF1 
  
CHO hNPFF2 
  
S1/2 
 
Ki (nM) EC50 (nM) R Ki (nM) EC50 (nM) R 
 Pro-NPFFA-derived peptides 
       NPFF (FLFQPQRFa) 2.82 ± 0.06 236 ± 43 84 0.21 ± 0.03 2.3 ± 0.5 15 13 
1DMe (dYL(NMe)FQPQRFa) 1.09 ± 0.03 71 ± 14 65 0.18 ± 0.04 2.7 ± 0.5 15 6 
3D (dYdL(NMe)FQPQRFa) 4.2 ± 0.7 231 ± 58 55 1.02 ± 0.12 10 ± 2 10 4 
SQA-NPFF (h) 4.16 ± 0.31 153 ± 27 37 0.16 ± 0.02 0.56 ± 0.05 3.5 26 
SPA-NPFF (b,m) 
   
0.047 ± 0.003 0.84 ± 0.25 18 
 NPA-NPFF (r)  3.4 ± 0.2 166 ± 40 49 0.033 ± 0.003 0.64 ± 0.05 19 103 
NPAF (h) 13 ± 2 324 ± 30 25 0.14 ± 0.01 0.53 ± 0.03 3.8 93 
NPAF (b) 
   
0.16 ± 0.02 1.5 ± 0.5 9.4 
 NPSF (SLAAPQRFa) 32 ± 6 876 ± 10 27 20 ± 2 222 ± 26 11 1.6 
QFW-NPSF (m) 
   
0.19 ± 0.01 1.5 ± 0.4 7.9 
 EFW-NPSF (r) 20.8 ± 0.8 n.d. 
 
0.21 ± 0.01 2.2 ± 0.3 10.5 94 
EYW-NPSF 18 ± 3 n.d. 
 
0.24 ± 0.03 n.d. 
 
75 
NPFF-OH >10000 
  
>1000 >1000 
  1DMe-ol 80 ± 11 >1000 >12 17.6 ± 0.5 397 ± 88 22 4 
NPFY (FLFQPQRYa) 102 ± 26 >10000 >100  39 ± 7  361 ± 75  9 3 
        Pro-NPFFB-derived peptides 
       hRFRP1 (MPHSFANLPLRFa) 1.27 ± 0.08 9.6 ± 0.7 7.5 3.9 ± 0.6 21 ± 4 5.4 0.3 
NPVF (VPNLPQRFa) 0.6 ± 0.1 12 ± 2 20 17.4 ± 1.7 133 ± 11 7.6 0.03 
YVPNLPQRFa 0.69 ± 0.09 8.2 ± 1.1 12 8.9 ± 1.5 n.d. 
 
0.08 
        Others 
       FMRFa 1.8 ± 0.2 391 ± 113 217 6.6 ± 1.1 517 ± 91 78 0.3 
PQRFa 8.7 ± 0.2 2372 ± 100 272 6.8 ± 1.2 309 ± 27 45 1.3 
PLRFa 0.83 ± 0.02 116 ± 16 140 0.51 ± 0.05 6.5 ± 0.9 12.7 1.6 
LPLRFa 1.7 ± 0.1 84 ± 18 49 10.6 ± 0.5 129 ± 23 12 0.16 
        NPY-related peptides 
       NPY (p) >1000 n.d. 
 
>1000 n.d. 
  fPP  >1000 n.d. 
 
7 ± 2 115 ± 5 16 >150 
BIBP3226 12 ± 1 >10000 antag 84 ± 12 >10000 antag 0.14 
BIBO3304 57 ± 7 >10000 antag 288 ± 69 >10000 
 
0.2 
GR231118 96 ± 26 >10000 
 
47 ± 5 3024 ± 370 64 2 
 
Table 3: Apparent affinities (K i) and potency (EC50) of diverse peptides of the NPFF and neuropeptide Y (NPY) 
families on human NPFF1 and NPFF2 receptors expressed in CHO cells. 
NPFF1 receptors were labelled with 0.05 nM [125I]-YVP and NPFF2 receptors were labelled with 0.05 nM [125I]-EYF. 
Concentration of the forskolin is 2 µM. A full inhibition of the forskolin-induced cAMP production was observed for 
all agonists. R = EC50/Ki for the activity index of the ligand, S1/2 = Ki NPFF1/Ki NPFF2 for the selectivity index of the 
ligand. n.d.: not determined; (b): bovine, (h): human, (m): mouse, (p): porcine. (Mollereau et al., 2002) 
 
1.3.  Pharmacological effects of NPFF system in vivo 
1.3.1.  Pain modulation 
NPFF has been described as having two different effects on pain perception, 
which depends on the site of administration. 
When administrated at the supra-spinal level via intracerebroventricular (i.c.v.) 
injection, both in mice and rats, NPFF had a pro-nociceptive effect characterized by 
a reversal of morphine analgesia in the tail flick test, indicating that it displays an 
anti-opioid property (Gicquel et al., 1992, Oberling et al., 1993). In addition, i.c.v. 
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injection of SQA-neuropeptide FF, a peptide sequence contained in human 
neuropeptide FF, dose-dependently inhibited the anti-nociceptive effect of i.c.v. 
injection of morphine in the tail flick test of mice (Gelot et al., 1998b). Furthermore, 
in rats, pre-treatment of NPFF in ventral tegmental area (VTA) blocked the analgesia 
induced by either intra-VTA morphine or exposure to footshock stress in the 
formalin test for tonic pain (Altier and Stewart, 1997), and dorsal raphe nucleus 
(DRN) microinfusion of NPFF reversed the analgesia produced by morphine after 
either i.c.v. or DR infusion (Dupouy and Zajac, 1995). Moreover, Neuropeptide FF 
injected into the periaqueductal gray may produce a selective attenuation of tactile 
allodynia in neuropathic rats, since the dose of Neuropeptide FF producing a 
significant antiallodynic effect was not anti-nociceptive in a test of mechanical or 
thermal nociception (Wei et al., 1998). 
RF9, a selective NPFF receptor antagonist, reversed the inhibition effect of NPFF 
on morphine analgesia in mice, which further confirms that the anti-morphine 
action of NPFF is mediated directly by the activation of NPFF receptors (Fang et al., 
2008). 
Although, in most reports, NPFF alone had no effect on basal nociceptive 
threshold but efficiently reversed morphine analgesia, it is noteworthy that in few 
studies NPFF administered alone by i.c.v. lowered the nociceptive threshold 
measured by the tail flick test in rats, which is consistent with the anti-opioid 
property of this peptide (Yang et al., 1985; Oberling et al., 1993). 
 
When administrated by intrathecal (i.t.) injection, NPFF showed an 
anti-nociceptive effect or potentiated the analgesia produced by morphine. For 
instance, intrathecal injection of NPFF induced a dose-dependent and long-term (24 
- 48h) analgesia by using noxious thermal (tail flick) and mechanical (paw pressure) 
tests in rats (Gouardères et al., 1993), and the same results were observed in 
carrageenan inflammation and neuropathic pain models of rats (Xu et al., 1999). 
Furthermore, intrathecal injection of NPFF enhanced morphine analgesia in all 
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animal models above, and naloxone attenuated this anti-nociception effect 
produced by NPFF after either intrathecal or subcutaneous injection (Gouardères et 
al., 1993; Xu et al., 1999). Thereafter, it has been demonstrated that µ-and δ-opioid 
receptors play a role in this anti-nociception effect produced by NPFF (Gouardères et 
al., 1996; Xu et al., 2001). 
At the molecular level, it has been demonstrated that 1DMe intrathecal infusion 
into anesthetized rats induced a concentration-dependent increase in the release of 
Met-enkephalin and decrease in the release of dynorphin, both of which could 
persist for at least 90 min (Ballet et al., 1999, 2002). In addition, on superfused rat 
spinal cord slices, 1DMe blocked the reduction of the release of Met-enkephalin due 
to the stimulation of δ-opioid receptors by deltorphin (Mauborgne et al., 2001). All 
these data indicated that activation of NPFF receptors blocked presynaptic δ-opioid 
(DOP) autoreceptors which acted as feedback inhibitor of the release of 
Met-enkephalin. Therefore, the Met-enkephalin released by the indirect action of 
NPFF could bind to postsynaptic MOP receptors to produce analgesia. Meanwhile, 
the long lasting decrease of dynorphin release, which has pronociceptive property, 
also could explain the long duration of anti-nociceptive action of NPFF. 
It was also shown that injection of a sub-effective dose of NPFF potentiated the 
spinal analgesia induced by morphine intrathecal adminstration (Gouardères et al., 
1993; Gouardères et al., 1996). This effect was blocked by antagonists of DOP 
receptors showing the same mechanism of the inhibition of DOP autoreceptors. 
 
1.3.2.  Opioids tolerance and dependence 
Tolerance is a state of adaptation in which exposure to a drug produces changes 
resulting in progressive attenuation of one or more effects of the drug. In terms of 
dependence, it could be divided into two espects: physical dependence and 
psychological dependence (or addiction). Physical dependence is a state of 
adaptation that is manifested by specific withdrawal syndromes to a class of drugs 
that can be produced by abrupt cessation, rapid dose reduction, reduction of drug 
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levels in the blood and / or administration of an antagonist. Psychological 
dependence is characterized by an uncontrollable urge to obtain drugs and 
contributes to the risk of relapse after a long period of withdrawal. 
In the case of opioids tolerance and dependence, according to the anti-opioid 
model defined by Gillman and Lichtigfeld (Gillman and Lichtigfeld, 1981) and 
developed by Rothman (Rothman, 1992), there is a constant homeostatic balance 
between opioid and anti-opioid systems. 
 
Many studies suggest the involvement of NPFF system in opioids tolerance and 
dependence. For instance, on rat spinal cord slices, morphine might stimulate the 
release of NPFF (Devillers et al., 1995). In addition, chronic administration of 
morphine could induce an increase in the NPFF like immunoreactivity in the 
cerebrospinal fluid and CNS of rats (Malin et al., 1990b; Stinus et al., 1995). 
Moreover, chronic treatment of NPFF for 13 days produced a decrease in the 
number of MOP receptors in rat CNS (Rothman et al., 1993; Goodman et al., 1996), 
whereas chronic treatment of NPFF antibodies increased the MOP receptor binding 
sites and decreased the amount of DOP receptors in various CNS regions (Goodman 
et al., 1998, 1999). 
Chronic administration of 1DMe increased the intensity of morphine tolerance, 
while suppression NPFF system by using antisense sequence of the precursor 
Pro-NPFFA significantly attenuated the development of opioids tolerance (Gelot et al., 
1998a). In addition, in rats, hyperalgesia (due to a decrease in nociceptive threshold) 
induced by chronic treatment of heroin was diminished by co-treatment of the NPFF 
receptor antagonist RF9 systemically (Simonin et al., 2006). Moreover, a delayed 
development of tolerance, induced by systemically injection of morphine, also could 
be observed after chronically RF9 administration (Elhabazi et al., 2012). 
 
Concerning physical dependence, signs of opioid-withdrawal syndromes 
precipitated by naloxone in morphine-dependent mice decreased upon the third 
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ventricle administration of antibodies against NPFF or anti-sense nucleotides 
directly against precursor Pro-NPFFA (Malin et al., 1990b; Gelot et al., 1998a). While, 
i.c.v. injection of NPFF elicited an opioid-withdrawal syndrome in morphine 
dependent rats without any effects in naive rats (Malin et al., 1990a). Similarly, in 
mice, co-administration of NPFF and morphine caused a stronger opioid-withdrawal 
syndrome than that of in the absence of NPFF (Tan et al., 1999). 
 
Along with the physical dependence, chronic using of opiates also leads to the 
development of psychological dependence, while an acute pre-injection of NPFF 
reduced the hyperlocomotion induced by acute morphine injection in naive mice 
(Kotlinska et al., 2007a). 
A classical test named conditioned place preference (CPP) is usually used to 
assess the motivational properties of a drug in animals, of which the principle is to 
involve a particular environment to drug taking. In the CPP test for mice, i.c.v. 
injection of 1DMe blocked the acquisition of the reinforcing property of morphine 
without showing effect by itself (Marchand et al., 2006). Similarly, in rats, a single 
dose of NPFF, two minutes before the confrontation of animals to both environments, 
blocked the expression of CPP induced by morphine (Kotlinska et al., 2007b). In 
addition, injection of RF9 enhanced the CPP induced by morphine without having 
effect by itself (Elhabazi et al., 2012). 
Besides, the protocol of CPP also could be used to measure conditioned place 
aversion (CPA) with an identical procedure involving aversive stimuli instead. In this 
test, i.c.v. injection of NPFF dose-dependently reversed the acquisition of CPA 
induced by endomorphin-2 (also i.c.v. injection) (Han et al., 2013). Similarly, the 
expression of endomorphin-2-induced CPA also could be reduced by NPFF, and the 
effects of NPFF on the acquisition and expression of endomorphin-2-induced CPA 
were completely blocked by NPFF receptors antagonist RF9 (i.c.v. injection) (Han et 
al., 2013). 
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Furthermore, the role of NPFF in addiction to other drugs was also studied. For 
instance, i.c.v. injection of 1DMe reduced the expression of CPP induced by cocaine 
(5 mg / kg) in rats and sensitization to the hyperlocomotor effect of cocaine in mice, 
although it had no specific effect in both tests (Kotlinska et al., 2008). Besides, 
co-injection of NPFF in lateral ventricles of rats potentiated the behavioral 
sensitization to amphetamine in amphetamine-sensitized rats, which accompanied 
by a decrease in serotonin levels and an increase in glutamate and GABA levels in 
the medial prefrontal cortex (Chen et al., 1999). 
 
1.3.3.  Cardiovascular and neuroendocrine regulation 
Experimental evidence supporting the key role of NPFF in cardiovascular 
regulation first became apparent in the mid-1980s, when Roth and colleagues (Roth 
et al., 1987) reported that two NPFF analogs produced significant pressor effect after 
systemically administration. Subsequently, local injection of NPFF into the 
brainstem nucleus of the solitary tract, the first terminus for cardiovascular inputs 
originating from the periphery, resulted in an increase in blood pressure and 
bradycardia. This effect could be attenuated by adrenergic antagonists (Laguzzi et 
al., 1996). In addition, NPFF-synthesizing neurons in the same nucleus were 
activated in response to hemorrhage and morphine withdrawal induced 
hypertension (Jhamandas etal., 1998). Furthermore, Intrathecal and i.c.v. 
administration of NPFF has been demonstrated to evoke dose-dependent elevations 
in arterial blood pressure and heart rate (Jhamandas and MacTavish, 2002, 2003; 
Fang et al., 2010), and these effects could be prevented by conjunction application 
of RF9 (Simonin et al., 2006). 
Identity of neural circuits that participate in centrally generated NPFF 
responses have been best studied in the hypothalamus, where i.c.v. injection of 
NPFF evoked the activation of chemically indefined paraventricular nucleus (PVN) 
neurons that project to the brainstem nucleus of the solitary tract, which controls 
CNS humoral and autonomic outflow to the periphery (Jhamandas and MacTavish, 
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2003). 
 
1.3.4.  Role in hypertension 
Immunohistochemical data indicated a significant number of NPFF fibers, 
NPFF1 and NPFF2 receptors in human parvocellular PVN (Goncharuk and 
Jhamandas, 2004, 2008; Goncharuk et al., 2006). In addition, the relative 
preponderance of NPFF (and its receptors) and its intimate anatomical relationship 
to important cardiovascular regulatory peptides, such as corticotropin releasing 
hormone (CRH) in human hypothalamus, suggest an important role of this peptide 
in hypertension. 
Recent immunohistochemical observations from post-mortem brain tissue of 
hypertensives showed a marked reduction of NPFF in discrete cardiovascular  
brainstem and hypothalamic nuclei compared to age-matched controls (Goncharuk 
et al., 2011, 2014). In these studies, NPFF immunoreactivity severely reduced in a 
subnuclear zone adjacent to the hypothalamic PVN and supraoptic nucleus, a site 
where dense networks of GABAergic neurons reside. These GABAergic neurons have 
been identified to mediate arterial baroreceptor inputs that control the release of 
pressor hormone vasopressin from the neurohypophysis (Jhamandas and 
Goncharuk, 2013). Thus, the loss of NPFF input to GABAergic cells has the potential 
to dysregulate cardiovascular reflexes and the control of arterial blood pressure. 
 
1.3.5.  Thermoregulation 
The effect of NPFF system on thermoregulation has been studied in mice by 
using selective agonists of NPFF receptors (Moulédous et al., 2010a). 
The dNPA, a selective NPFF2 receptor agonist, administered into the third 
ventricle evoked an increase in body temperature. In contrast, the NPVF, a selective 
NPFF1 receptor agonist, significantly decreased body temperature after 
administered into the third ventricle. Both effects could be completely antagonized 
by RF9 (Moulédous et al., 2010a). Similarly, third ventricle administration of RF9 
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inhibited the hypothermia induced by morphine or nociceptin/orphanin FQ (Wang 
et al., 2008). 
In addition, in one neuroinflammation model, RF9 decreased the fever induced 
by lipopolysaccharide (LPS) after the third ventricle injection (Wang et al., 2011). 
 
These results suggest NPFF-induced hypothermia or hyperthermia are mainly 
mediated by its own receptors, in contrast, the activation of NPFF receptors is 
required for opiates and LPS to produce hypothermia and fever, respectively. 
 
1.3.6.  Role in locomotor activities 
Generally, i.c.v. injection of NPFF induced a delayed hyperlocomotion (Betourne 
et al., 2010), and could inhibit morphine-induced hyperlocomotion in rodents 
(Marco et al., 1995; Cador et al., 2002; Marchand et al., 2006; Kotlinska et al., 
2007a). 
Studies showed that in rodents, central activation of NPFF receptors did not 
affect the locomotion in a standard automated apparatus for activity assessment 
during a 30 min period (Kotlinska et al., 2007a; Betourne et al., 2010). Nonetheless, 
Betourne and colleagues found an unsuspected rebound of horizontal activity in 
high concentration (5 or 10 mM) 1DMe injected animals which started 45 min after 
injection and lasted for at least 45 min (Betourne et al., 2010). 
 
The hyperlocomotion induced by opiates involves dopamine reward circuitry 
and results from the increase of dopamine release in ventral tegmental area (VTA). 
After VTA injection, dNPA, a stable NPFF2 receptor agonist, decreased the 
hyperlocomotion induced by morphine and the elevation of dopamine and serotonin 
metabolites within the nucleus accumbens (NAc) (Kersanté et al., 2011). This 
neurochemical and behavioural anti-opioid effect mediated by NPFF2 receptors at 
the level of VTA suggests the involvement of NPFF in rewarding effects of opiates in 
mesolimbic dopamine system. 
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1.3.7.  Effects on feeding behavior 
Intracerebroventricular injection of NPFF caused a decrease in food intake in 
rats. This effect was comparable to that observed following treatment with naloxone, 
but both effects were not additive (Murase et al., 1996). NPFF could therefore oppose 
the orexigenic effect of endogenous opioid system. 
However, it has been shown that the reduction in food intake could be resulted 
from a rapid increase of fluid intake induced by NPFF (Sunter et al., 2001). Indeed, 
in rats, NPFF caused a drinking behavior almost immediately after injection, which 
continued up to 8 hours post-injection (Sunter et al., 2001). The decrease in food 
intake in these rats was only observed in the first 30 minutes after i.c.v. injection of 
NPFF. So, it is conceivable that the outlet of mass water observed shortly after 
injection prevents the food intake of animals compared to rats injected with saline 
(Sunter et al., 2001). 
 
The effect of NPFF on feeding behavior has been studied in more discrete regions 
of CNS such as the lateral parabrachial nucleus (L-PBN), which plays a central role 
in the integration of informations controlling food intake. Infusion of DAMGO into 
L-PBN caused hyperphagic effects in rats, which could be inhibited by naloxone as 
well as by low dose of NPFF injected into the same core (Nicklous and Simansky, 
2003). However, the same study showed that high dose of NPFF injected into L-PBN 
caused hyperphagic effects, which could be inhibited by naloxone. In contrast, 
whatever the dose was, NPFF didn‘t alter the fluid intake of rats (Nicklous and 
Simansky, 2003). The effect of NPFF in food intake, in lateral parabrachial nucleus, 
therefore depends on the dose used. 
 
1.3.8.  Role in learning and memory 
One pioneering data showed that a pre-training i.c.v. injection of IgG from NPFF 
antiserum reduced the spatial learning of mice, while i.c.v. administration of 1 µg 
and 10 µg of NPFF marginally improved and significantly reduced the spatial 
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acquisition of mice in Morris water maze, respectively (Kavaliers and Colwell, 1993). 
Recently, a study investigated consequences of 1DMe injection in several 
paradigms of short-term and long-term memory (Betourne et al., 2010). The object 
location task was chosen for short-term memory assessment, while the distributed 
Morris water maze was chosen for long-term retention of spatial memory 
assessment. The data showed that i.c.v. injection of 1DMe induced mildly 
impairment in both short-term memory and long-term retention of spatial memory 
(Betourne et al., 2010). However, 1DMe central injection failed to alter long-term 
retention of contextual memory as well as tone-shock association (Betourne et al., 
2010). 
 
1.3.9.  Role in gastrointestinal system 
Raffa and Jacoby (Raffa and Jacoby, 1989) showed a delayed expulsion of balls 
in mice colon after i.c.v. injection of NPFF, and like the effect induced by morphine, 
it could be inhibited by naloxone. In rats, i.c.v. injection of NPFF or DALAD 
(D-Ala-Met-Enképhalinamide) inhibited the contraction of intestine caused by the 
ingestion of food, of which both effects could be inhibited by naloxone (Million et al., 
1993). NPFF therefore presents pro-opioid activity on intestinal motility. 
An acute, but not a chronic, morphine treatment could inhibit the motility of the 
colon, which means the happening of animal tolerance. In tolerant animals, the 
diarrhea caused by naloxone induced colonic contraction is typically observed 
during an opioid withdrawal syndrome. Similarly, i.c.v. injection of NPFF also 
produced the same effect as naloxone in morphine tolerant rats (Gelot et al., 1995). 
Diarrhea is one of opioid-withdrawal symptoms in animals, so the results can be 
correlated with the ability of NPFF to induce withdrawal symptoms in opioid tolerant 
animals (Malin et al., 1990a; Tan et al., 1999). In addition, i.c.v. injection of NPFF 
was also able to reduce the duration of myoelectric activity disturbances induced by 
endotoxin of Escherichia coli, which depends on the activation of endogenous opioid 
system, on the big intestine of rats (Million et al., 1997). Furthermore, this effect was 
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also found on guinea pig ileum and mediated by the modulation effect of morphine 
on the inhibition of acetylcholine release induced by morphine (Demichel et al., 
1993). NPFF therefore produces anti-opioid effects in these cases. 
 
Furthermore, NPFF also modulates the gastrointestinal motility through opioid 
system independent mechanisms. This was well illustrated by a study of intestinal 
transit in mice measured by the ingestion of milk labeled with 51 Cr (sodium 
chromate). In this study, authors demonstrated that both morphine and NPFF could 
inhibit the intestinal transit in mice, but only the morphine effect was abolished by 
naloxone treatment (Gicquel et al., 1993). 
 
NPFF may also increase the myoelectric activity of pig intestine and mouse colon 
(Decker et al., 1997; Fang et al., 2005). These two studies showed an action of NPFF 
on the inhibition of nitric oxide production (NO, responsible for the dilation of 
smooth muscle cells), while the activation of L-type voltage-dependent calcium 
channels was only shown in pigs (Decker et al., 1997). Although the effect produced 
by NPFF on endotoxin was opioid-dependent, in the same study, Million and 
colleagues showed that NPFF, but not naloxone, reduced the duration of myoelectric 
activity disturbances induced by platelet activating factor (PAF) in wholesale rat 
intestine (Million et al., 1997). 
 
1.4.  Pharmacological effects of NPFF system at cellular level 
1.4.1.  Modulation of ion channels 
1.4.1.1. Modulation of N-, P/Q-type voltage-dependent calcium channels 
Voltage gated calcium channels (Ca2+ channels) are key mediators of calcium 
influx, into excitable cells, induced by depolarization. After influx, calcium in turn 
mediates a wide array of physiological responses including activation of calcium 
dependent enzymes, smooth muscle contraction, pacemaker activity and 
neurotransmitter release (Wheeler et al., 1994; Turner and Dunlap, 1995; 
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Goonasekera et al., 2005; Cooper et al., 2010; Zhao et al., 2011; Braun, 2011; 
Marger et al., 2011a, 2011b). Ca2+ channels also associate with a wide range of 
pathological processes, including pain, epilepsy, migraine, cardiac arrhythmias and 
autism (Splawski et al., 2004; Tottene et al., 2011; Pietrobon and Striessnig, 2003; 
Iftinca and Zamponi, 2009; Khosravani and Zamponi, 2006). Ten members of 
voltage-gated calcium channels have been identified in mammals based on their 
electrophysiological and pharmacological profiles (Table 4) (Catterall, 2011). 
In neurons, certain L-type Ca2+ channel isoforms are expressed at cell bodies 
and dendrites, and one of their key functions is the initiation of calcium dependent 
gene transcription events (Hell et al., 1993; Westenbroek et al., 1998; Wheeler et al., 
2008; Dolmetsch et al., 2001; Brittain et al., 2012). Other L-type channel subtypes 
are expressed in cochlear hair cells and photoreceptor nerve terminals where they 
regulate neurotransmitter release at ribbon synapses (Baig et al., 2011; Doering et 
al., 2008). 
T-type calcium channels are expressed in cell bodies as well as dendrites, and 
one of their key functions is to regulate cellular excitability and neuronal firing 
properties (McKay et al., 2006; Molineux et al., 2006; Perez-Reyes, 2003), in 
addition to participate in secretion (Giancippoli et al., 2006; Weiss et al., 2012; 
Carbone et al., 2006). 
N-type and P/Q-type calcium channels are expressed at synaptic nerve 
terminals where their opening results in the release of neurotransmitters (Wheeler 
et al., 1994; Westenbroek et al., 1992, 1995, 1998; Khanna et al., 2007; Reid et al., 
2003). It should be noted that N-type channels are especially involved in the 
transmission of nociceptive messages with the induction of the release of 
neuropeptides such as substance P, and thereby represent an important target in 
the pharmacological treatment of pain. 
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Ca2+ 
current 
type 
α1 
Subunits 
Specific 
blocker 
Principal physiological 
functions 
Inherited diseases 
L Cav1.1 DHPs Excitation-contraction 
coupling in skeletal muscle, 
regulation of transcription 
Hypokalemic periodic 
paralysis 
 Cav1.2 DHPs Excitation-contraction 
coupling in 
cardiac and smooth muscle, 
endocrine secretion, neuronal 
Ca2+ transients in cell bodies 
and 
dendrites, regulation of 
enzyme 
activity, regulation of 
transcription 
Timothy syndrome: 
cardiac arrhythmia with 
developmental 
abnormalites and autism 
spectrum disorders 
 Cav1.3 DHPs Endocrine secretion, cardiac 
pacemaking, neuronal Ca2+ 
transients in cell bodies and 
dendrites, auditory 
transduction 
 
 Cav1.4 DHPs Visual transduction Stationary night 
blindness 
N Cav2.1 ω-CTx-GVIA Neurotransmitter release, 
Dendritic Ca2+ transients 
 
P/Q Cav2.2 ω-Agatoxin Neurotransmitter release, 
Dendritic Ca2+ transients 
Familial hemiplegic 
migraine, 
cerebellar ataxia 
R Cav2.3 SNX-482 Neurotransmitter release, 
Dendritic Ca2+ transients 
 
T Cav3.1 None Pacemaking and repetitive 
firing 
 
 Cav3.2  Pacemaking and repetitive 
firing 
Absence seizures 
 Cav3.3    
 
Table 4: Subunit composition and function of Ca2+ channel types. Abbreviations: DHP, dihydropyridine;  
ω-CTx-GVIA, ω-conotoxin GVIA from the cone snail Conus geographus; SNX-482, a synthetic version of a peptide 
toxin from the tarantula Hysterocrates gigas. From (Catterall, 2011) 
 
Voltage-gated calcium channels are composed of five subunits: α1, α2, β, γ and δ 
(Figure 10). Analysis of the biochemical properties, glycosylation, and 
hydrophobicity of these five subunits led to a model comprising a principal 
transmembrane α1 subunit of 190 kDa in association with a disulfide-linked α2-δ 
dimer of 170 kDa, an intracellular phosphorylated β subunit of 55 kDa and a 
transmembrane γ subunit of 33 kDa (Takahashi et al., 1987). Different types of Ca2+ 
channels are primarily defined by different α1 subunits, and ten different ones have 
been characterized by cDNA cloning and functional expression in mammalian cells 
or Xenopus oocytes. These subunits can be divided into three structurally and 
functionally related families (CaV1, CaV2 and CaV3) (Snutch and Reiner 1992; Ertel 
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et al., 2000). 
 
 
 
Figure 10: Subunit structures of Ca2+ channels. The structures of Ca2+ channel subunits are illustrated as 
transmembrane folding models; predicted α helices are depicted as cylinders; the lengths of lines correlate 
approximately to the lengths of the polypeptide segments represented; and the zigzag line on the d subunit 
illustrates its glycophosphatidylinositol anchor. From (Catterall, 2011) 
 
The α1 subunit consists of 4 homologous domains (denoted I to IV), 3 
cytoplasmic connecting loops (linker I-II, II-III and III-IV) and the intracellular C- 
and N-termini. Each domain of the four contains six transmembrane helices (S1–S6) 
and a membrane-associated P-loop between transmembrane helices S5 and S6 
which structure forms the pore lining of voltage-gated ion channels. The presence of 
glutamate residues on each P-loop gives the channel selectivity of Ca2+ (Heinemann 
et al., 1992). It should be noted that the helix S4, which is positively charged by 
highly rich in lysine and arginine residues segment, acts as the voltage sensor for 
activation, moving outward and rotating under the influence of electric field, and 
initiates a conformational change that opens the pore (Catterall, 2000). 
The β subunit is encoded by four genes in vertebrates, and this protein locates 
in cytoplasmic except the palmitoylated splice variant β2α and therefore anchored 
on the membrane. This subunit includes two highly conserved domains, guanylate 
SH3 and kinase, which were interacted by less conserved domains. In addition, the 
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β subunit interacts with the α1 subunit via the BID domain (β-interaction_domain) 
that binds the AID domain (α-interaction domain) on the I-II linker (Tedford and 
Zamponi, 2006). 
The α2 and δ subunit are encoded by the same gene, and the mature forms of 
these two subunits are produced by posttranslational proteolytic processing and 
disulfide linkage (De Jongh et al., 1990). The α2 subunit locates in extracellular but 
connects to the membrane through disulfide linkage to the δ subunit. Although 
initially the δ subunit was assumed anchoring to the membrane via a single 
membrane segment, recent work argued persuasively that further posttranslational 
processing actually cleaved the predicted transmembrane segment and replaced it 
with a glycophosphatidylinositol membrane anchor (Davies et al., 2010). 
There are eight isoforms of the γ subunit (γ1 to γ8), and each of them consists of 
four transmembrane helices with the intracellular N- and C-termini. At present, the 
presence of this subunit is very controversial since it seems only the L-type 
voltage-gated calcium channel could be co-purified with the γ subunit (Dolphin, 
2006). 
 
Expression of the α1 subunit is sufficient to produce a functional skeletal 
muscle Ca2+ channel, but with low expression level and abnormal kinetics and 
voltage dependence of Ca2+ currents (Perez-Reyes et al., 1989). Co-expression of α2-δ 
dimer and (or) especially the β subunit with the α1 subunit enhanced the level of 
expression, conferred more normal gating properties and exhibited more channel 
specificity (Lacerda et al., 1991; Singer et al., 1991; Hofmann et al., 1994; Arikkath 
and Campbell, 2003; Davies et al., 2007). In general, γ subunits have smaller 
effects. 
 
Nowadays, the inhibition of CaV2 channels by G protein coupled receptors is 
widely and intensively studied. Indeed, there are mainly two mechanisms 
underlying this process: voltage-dependent and voltage-independent inhibition. 
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In terms of voltage-dependent inhibition of G protein coupled receptors, there 
are several characteristic hallmarks: in whole cell recordings, the inhibition of 
peakⅠCa amplitude is diminished at depolarized membrane potentials; activation 
kinetics are slowed; the voltage-dependence of activation is shifted to more 
depolarized potentials; a conditioning prepulse to depolarized potentials relieves 
most of the inhibition and normalizes channel kinetics (termed prepulse relief or 
prepulse facilitation). Generally, this process involves direct binding of the Gβγ to 
the α1 subunit of CaV2 channels. In addition, the β and γ (specifically protein 
stargazin) subunit of Ca2+ channels, protein kinase C and synaptic proteins (such as 
syntaxin 1A, rab3 interacting molecules and cysteine string protein) also play 
important roles in the integration of the inhibition effect (Zamponi and Currie, 
2013). 
In contrast, mechanisms leading to voltage-independent inhibition of G protein 
coupled receptors are less well understood and perhaps less widespread. These 
include direct interaction with GPCRs, inhibition through lipid signaling pathways, 
and channel phosphorylation (Zamponi and Currie, 2013). 
 
There are few experimental data concerning the action of NPFF receptors on 
Ca2+ channels. Roumy and Zajac first observed the inhibition effect of NPFF on Ca2+ 
influx induced by depolarization in mouse spinal ganglion neurons (DRG) (Roumy 
and Zajac, 1996). In this study, a short perfusion (5-10 s) with 30 mM K+ induced 
the entry of Ca2+ ions, in particular through L- and N-type voltage dependent Ca2+ 
channels opened during action potentials that triggered by depolarization. This 
effect could account, at least partly, for the analgesia induced by intrathecal 
injection of NPFF. In SH-SY5Y human neuroblastoma cells, stably transfected with 
hNPFF1 receptors, Kersanté and colleagues showed a dose-dependent inhibition 
effect of NPVF (specific agonist of the NPFF1 receptor) on N-type Ca2+ channels, and 
the EC50 was 10.4 nM (Kersanté et al., 2006). However, it should be noted that in 
acutely dissociated rat dorsal raphe nucleus (DRN) neurons, the inhibition effect of 
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NPFF on Ca2+ influx induced by depolarization was not observed (Roumy and Zajac, 
1999). Therefore, firstly, in the thesis work, we compared the mouse model with 
previously used rat model for direct activities of NPFF receptors on Ca2+ transient 
induced by depolarization and analysed the relationship between the direct and 
anti-opioid activity of NPFF receptors. 
 
1.4.1.2. Modulation of Acid-Sensing Ion Channels 
ASICs (Acid-Sensing Ion Channels) are neuronal voltage-insensitive cationic 
channels which could be activated by extracellular protons (i.e decrease in 
extracellular pH). To data, four genes have been isolated, and these genes encode 
seven different subunits: ASIC 1a, 1b, 1b2, ASIC 2a, 2b, ASIC 3 and ASIC 4. ASICs 
are characterized by transiently rapid opening followed by rapid inactivation, and 
low input current residual was observed in the case of ASIC 3 (Lingueglia et al., 
2006). In addition, ASICs are Na+ permeable with ASIC 1a showing low Ca2+ 
permeability. 
An ASIC is composed of an assembly of four homo- or heterotrimeric subunits. 
Each subunit consists of two transmembrane domains connected by a large 
extracellular loop, which probably forms the passage pore of Na+ ions. The assembly 
of different subunits gives the ASIC properties of its own in terms of pH sensitivity 
and kinetics of activation and deactivation. 
 
 
 
Figure 11: Overview of the 
acid-sensing ion channel 1 
(ASIC1) crystal structure. 
A: surface view of trimeric 
chicken ASIC1 (cASIC1a). 
B: one subunit of cASIC1 in 
ribbon format. From 
(Sherwood et al., 2012) 
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ASICs are found in most of central neurons as well as sensory fibers, 
particularly on nociceptive fibers such as dorsal root ganglia (Lingueglia et al., 2006). 
ASICs play roles, at the central level, in long-term potentiation and synaptic 
transmission, while have a role, at the peripheral level, in the perception of pain 
during inflammation or ischemia. Indeed, inflammation could cause a decrease in 
extracellular pH (acidosis) at the inflamed area, which induces the opening of ASICs. 
Then, the opening of these channels makes an entry of Na+ into the intracellular 
medium resulting in low depolarization of the plasma membrane. Finally, the 
excitability threshold of neurons becomes lower and the fibers are much easier to be 
excited by a noxious stimulus, thus favoring the transmission of nociceptive 
information. 
 
Several studies showed a direct modulatory effect of NPFF and mollusk FMRFa 
peptide on ASICs. Although the FMRFa like peptides and NPFF didn‘t generate an 
incoming sodium current, they slowed down the opening of channels at acidic pH. 
Furthermore, in the case of ASIC 3, Askwith and colleagues observed an increase in 
the amplitude and the duration of incoming residual current (Askwith et al., 2000). 
Moreover, it was well illustrated that, in rat dorsal root ganglion neurons, 
application of NPFF increased the action potential trains induced by application of 
an acid solution at the pH to open ASIC 3 (Deval et al., 2003). It is also interesting to 
note that chronic inflammation increased the expression of NPFF and ASICs at 
spinal cord level, suggesting a role of this modulation in the nociceptive stimuli 
involved in inflammation (Lingueglia et al., 2006). 
 
Besides, the effect of NPFF is dependent on the structure of the channel. For 
instance, at a concentration of 50 µM, the FMRFa like peptide has a greater activity 
on ASIC 1, while NPFF prefers to activate ASIC 3. In addition, similar sensitivity 
increasing was observed by NPFF stimulation for heterotetramer ASIC 2a-ASIC 3 
(Askwith et al., 2000; Catarsi et al., 2001). Moreover, the potentiation of ASICs is 
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specific to RFamides peptides, because of the RF sequence, as other nociception 
neuromodulators (CCK, substance P or nociceptin) have no effect on these channels 
(Catarsi et al., 2001). Furthermore, the FMRFa like peptides modulated ASICs via a 
direct interaction with them, which was independent to G proteins coupled with 
their own receptors and the opioid system (Lingueglia et al., 2006). For instance, the 
FMRFa like peptides can bind directly to ASIC 1 in physiological pH conditions 
(Askwith et al., 2000). 
 
1.4.2.  Modulation of hypothalamic paraventricular nucleus (PVN) neurons 
The PVN is considered as a key site for homeostasis and a model nucleus for 
understanding the central regulation of autonomic and neuroendocrine function in 
brain (Cunningham and Sawchenko, 1991). The magnocellular neurosecretory cells 
of the PVN synthesize either vasopressin or oxytocin and release these hormones 
from their axonal projections to the posterior pituitary into the systemic circulation 
following stimulation (Sawchenko and Swanson, 1982). On the other hand, the 
parvocellular component of the PVN is more complex and consists of two broad 
categories, neurosecretory and non-neurosecretory (autonomic) cells. 
Neurosecretory parvocellular neurons are located within the dorsal medial and 
periventricular PVN and their axons terminate on median eminence portal 
capillaries to facilitate the release of ―factors‖ regulating anterior pituitary secretion. 
Neurons of this type for example express corticotrophin-releasing hormone or 
thyrotrophin-releasing hormone. Parvocellular non-neurosecretory (autonomic) 
neurons are located within the dorsal cap and ventral medial PVN and project their 
axons to the brainstem and the spinal cord. Some of the chemical messengers 
expressed in these types of cells include tyrosine hydroxylase, oxytocin and 
somatostatin (Roland and Sawchenko, 1993; Dawson et al., 1998). 
 
Central administration of NPFF resulted in a preferential activation of 
oxytocin-synthesizing parvocellular PVN neurons that project to the brainstem. In 
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contrast, i.c.v. injection of NPFF did not activate vasopressin-secreting 
magnocellular PVN neurons as measured by c-Fos immunohistochemistry, 
suggesting that the effect of NPFF on these subsets of PVN neurons are inhibitory 
(Jhamandas et al., 2006). 
In addition, on one hand, electrophysiological recordings from hypothalamic 
brain slices revealed that NPFF increased the inhibitory synaptic drive to 
magnocellular PVN neurons through a GABA-synthesizing network of interneurons 
located within the sub-PVN region (Roland and Sawchenko, 1993; Jhamandas et al., 
2006). On the other hand, NPFF presynaptically disinhibited the GABAergic input to 
the parvocellular PVN, thereby increasing the net excitability of these neurons. 
Moreover, NPFF also exerted a distinct depolarizing [tetrodotoxin (TTX)-independent] 
postsynaptic effect on parvocellular PVN neurons (Jhamandas et al., 2007). 
NPFF-induced excitation of parvocellular PVN neurons would be expected to result 
in an increase in autonomic outflow and sympathetic activation which is precisely 
what is observed with acute infusions of i.c.v. NPFF in conscious animals. 
 
 
 
1.4.3.  Interactions with opioids 
Many studies showed both functional and physical interactions between NPFF 
and opioid receptors at the cellular level, which is characterized by an inhibition of 
Figure 12: Schematic depicting 
parvocellular and magnocellular 
components of the hypothalamic 
paraventricular nucleus (PVN) and 
their projection sites. NPFF 
differentially modulates GABAergic 
input (originating from the adjacent 
subPVN region) to parvocellular and 
magnocellular neurons of the PVN. 
NPFF inhibits activity of GABAergic 
terminals that project to the 
parvocellular PVN neurons 
resulting in a disinhibition of these 
neurons. On the other hand, NPFF 
augments GABA synaptic input to 
magnocellular PVN neurons. From 
(Jhamandas and Goncharuk, 2013)  
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opioid effects. 
Indeed, in rat periventricular hypothalamic and dorsal raphe neurons, where 
NPFF1 and NPFF2 receptors were expressed respectively, the NPFF analogues were 
capable of reducing the inhibition effect of nociceptin/orphanin FQ on calcium 
conductance (Roumy and Zajac, 1999; Roumy et al., 2003). In contrast, 1DMe did 
not reduce the inhibitory effect of serotonin on calcium conductance in rat dorsal 
raphe neurons (Roumy and Zajac, 1999), which means the anti-opioid effect of NPFF 
is specific. In addition, the anti-opioid effect of NPFF was also observed in rat 
pyramidal neurons of the hippocampal CA1 area and at the myenteric plexus level of 
guinea pig ileum (Miller and Lupica, 1997; Takeuchi et al., 2001). 
 
 
 
 
 
 
 
 
 
In SH-SY5Y human neuroblastoma cells, it has been demonstrated that both 
NPFF1 and NPFF2 receptors could functionally inhibit the opioid effect on Ca2+ 
transient induced by depolarization (Mollereau et al., 2005; Kersanté et al., 2006), 
and there was a physical interaction between NPFF2 and mu-opioid receptors 
(Roumy et al., 2007). Furthermore, data from our labrotory showed, in SH-SY5Y 
neuroblastoma cells, after the activation of NPFF2 receptors, MOP receptors could be 
heterologously phosphorylated by GRK2 (G-protein coupled receptor kinases 2). 
Although the β-arrestin 2 was recruited to MOP receptors during the heterologous 
phosphorylation induced by activation of NPFF2 receptors, the internalization of 
MOP receptors was undetectable (Moulédous et al., 2012), suggesting the 
 
Figure 13: Schematic of the 
trans-phosphorylation of 
MOR receptors by NPFF2 
receptor activation. GRK2 
(G-protein coupled receptor 
kinases2). Modified from 
(Moulédous et al., 2012) 
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phosphorylation pattern or extent was different from the homologous 
phosphorylation induced by MOP receptors agonists. 
 
2. The nociceptin/orphanin FQ (NOP) receptor 
2.1.  Opioid receptors 
The endogenous opioid system consists of four distinct neuronal systems (table 
5) which are widely distributed throughout the CNS and peripheral organs, and is 
involved in many different physiological functions (Bodnar, 2014). Particularly, 
opioid receptors are the target of opiates, which are the most powerful analgesic 
molecules used in clinic. 
Opioid-binding sites were first shown in isolated mammalian brain tissues by 
using radioligand-binding assay in 1970s (Pert and Snyder, 1973; Simon et al., 
1973; Terenius, 1973), followed by the characterization of endogenous opioid 
peptides (Hughes et al., 1975; Cox et al., 1976; Guillemin et al., 1977; Goldstein et 
al., 1981). 
To date, all four opioid receptors, the mu (MOR), kappa (KOR), delta (DOR) and 
nociceptin/orphanin FQ (NOP) receptor, have been cloned (Evans et al., 1992; 
Kieffer et al., 1994; Chen et al., 1993a, b; Meng et al., 1993; Thompson et al., 1993; 
Fukuda et al., 1994; Mollereau et al., 1994), and they all belong to the class A or 
rhodopsin family of G protein coupled receptors. The endogenous opioid peptides 
are generated from four precursors: proopiomelanocortin, proenkephalin, 
prodynorphin, and pronociceptin/orphanin FQ (Nakanishi et al., 1979; Kakidani et 
al., 1982; Noda et al., 1982; Meunier et al., 1995; Reinscheid et al., 1995). The final 
active peptides are released at synaptic terminals of opioidergic neurons. These 
peptides exert their physiological actions by interacting with various classes of 
opioid receptors present on both pre- and post-synaptic membranes of opioid and 
opioid target neurons (Besse et al., 1990). 
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Table 5: Opioid receptor classification (International Union of Pharmacology) 
 Classical   Non Classical 
     
 µ δ κ NOP 
Other names  MOP DOP KOP ORL-1 
 MOR DOR KOR LC132 
 OP3 OP1 OP2 OP4 
Endogenous ligand β-Endorphin Enkephalin Dynorphin N/OFQ 
 Endomorphin    
Preferred G-protein Gi/o Gi/o Gi/o Gi/o 
     
Main transduction pathway     
K+ channel ↑ ↑ ↑ ↑ 
Ca2+ channel ↓ ↓ ↓ ↓ 
Adenylyl cyclase ↓ ↓ ↓ ↓ 
MAPKinase ↑ ↑ ↑ ↑ 
Naloxone sensitive Yes Yes Yes No 
 
2.2.  Cloning of the Nociceptin/orphanin FQ (NOP) receptor 
and the Nociceptin/Orphanin FQ (N/OFQ) peptide 
The nociceptin/orphanin FQ (NOP) receptor was identified by using molecular 
screening methods based on the classical opioid receptor gene sequences (Mollereau 
et al., 1994). In 1995, two groups simultaneously described the 
nociceptin/orphanin FQ peptide (N/OFQ) as the endogenous ligand for the NOP 
receptor by monitoring adenylate cyclase inhibition in NOP receptor-transfected 
cells (Meunier et al., 1995; Reinscheid et al., 1995). Their work was the first 
example of reverse pharmacology. 
 
However, despite the NOP receptor displays sequence homology with other three 
opioid receptors, it poorly binds peptides and alkaloid opioid ligands (Mollereau et 
al., 1994; Reinscheid et al., 1995). Moreover, the Nociceptin/Orphanin FQ (N/OFQ) 
peptide has high affinities for NOP receptors but interacts poorly with other opioid 
receptors, suggesting unique pharmacological effects of NOP receptors (Meunier et 
al., 1995; Reinscheid et al., 1995). 
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Figure 14: Structure overview of the NOP receptor. (a) Structural overview of NOP colored gray and ECL2 colored 
red. The bound ligand C-24 is depicted as green sticks, and transparent disks highlight the EC and IC membrane 
boundaries (colored blue and red, respectively). (b) Structural superposition of NOP molecules ‘A’ and ‘B’, κ–OR, 
and CXCR4, colored gray, yellow, blue and orange, respectively. From (Thompson et al., 2012) 
 
2.3.  Distribution of NOP receptors in central nervous system 
Before the cloning of the endogenous ligands for NOP receptors, the distribution 
of N/OFQ transcripts in murine tissues was investigated by in situ hybridization 
studies (Bunzow et al., 1994; Fukuda et al., 1994; Lachowicz et al., 1995; Mollereau 
et al., 1994; Wick et al., 1994), Northern (Chen et al., 1994) and RT-PCR (Wang et al., 
1994) analyses. 
Immunolocalization of the receptor, using a monoclonal antibody raised against 
the N-terminal extracellular domain of rat NOP receptor, provided a detailed 
mapping of the rat brain (Anton et al., 1996) and spinal cord (Monteillet et al., 1998). 
Following the identification of N/OFQ, the NOP receptor distribution was 
confirmed by autoradiographic study based, either on agonist-stimulated 
[35S]GTPγS binding assay (Shimohira et al., 1997, Sim et al., 1996, 1997) or routine 
binding procedures using [125I][Tyr14]N/OFQ (Foddi et al., 1997; Gouardères et al., 
1999) or [3H]N/OFQ (Florin et al., 1997; Jia et al., 1998). 
The NOP receptor is widely expressed in the central nervous system, in 
particular in the forebrain (cortical areas, olfactory regions, limbic structures, 
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thalamus), throughout the brainstem (central periaqueductal gray, substantia nigra, 
several sensory and motor nuclei) and in both dorsal and ventral horns of the spinal 
cord. Regions almost devoid of NOP receptors are the caudate-putamen and the 
cerebellum (Mollereau and Mouledous, 2000). 
NOP mRNA and binding sites exhibit approximately the same distribution 
pattern, indicating that the NOP receptor is located on local neuronal circuits. 
 
Brain region nCi/mg (means ± SEM) 
1 µM N/OFQ 10 µM  Ro64-6198 
Accessory olfactory nucleus (AON) 264.4 ± 25.7 242.6 ± 14.2 
Amygdala   
   Medial (MeA) 806.0 ± 65.9 579.8 ± 27.9 
   Basomedial (BM) 954.2 ± 54.7 556.7 ± 29.2 
   Basolateral (BLA) 756.7 ± 62.7 512.4 ± 37.9 
Anterior cingulate cortex (ACC) 800.0 ± 85.7 519.5 ± 60.3 
Bed nucleus of the stria terminalis (BST) 270.5 ± 40.5 232.5 ± 22.3 
Caudate–putamen (CPu) 69.6 ± 12.1 83.7 ± 29.0 
Central gray (CG) 307.2 ± 26.9 105.6 ± 36.6 
Claustrum (Cl) 647.3 ± 67.0 371.4 ± 44.3 
Dorsal endopiriform nucleus (DEN) 761.4 ± 69.1 334.3 ± 40.2 
Hippocampus   
   CA1-oriens (CA1or) 283.5 ± 47.4 282.2 ± 30.8 
   CA1-radiatum 306.3 ± 199.2 352.7 ± 33.9 
   CA2-oriens (CA2or) 285.0 ± 30.9 244.6 ± 17.0 
   CA2-radiatum 321.0 ± 180.1 284.6 ± 24.4 
   CA3-oriens (CA3or) 363.4 ± 41.2 257.9 ± 23.7 
   CA3-radiatum 321.5 ± 39.6 300.6 ± 27.0 
Hypothalamus   
   Ventromedial nucleus (VMH) 1081.0 ± 98.4 624.9 ± 51.6 
Interpeduncular nucleus (IP) 119.0 ± 20.8 65.4 ± 29.8 
Lateral septum (LS) 313.8 ± 35.1 137.7 ± 21.7 
Median preoptic area (MPA) 253.4 ± 71.7 122.9 ± 21.8 
Nucleus of the solitary tract (NTS) 288.6 ± 48.0 179.5 ± 32.8 
Olfactory bulb   
   External plexiform layer (EPL) 109.5 ± 19.0 97.9 ± 14.5 
   Granule cell layer (Gr) 67.4 ± 16.2 86.2 ± 13.1 
Parietal cerebral cortex   
   Laminae 1–3 128.7 ± 26.2 144.1 ± 21.8 
   Lamina 4 (L4) 315.9 ± 31.5 202.0 ± 29.1 
   Laminae 5–6 225.8 ± 21.9 154.0 ± 73.4 
Piriform cortex (Pir) 689.0 ± 60.1 389.6 ± 37.2 
Spinal trigeminal nucleus (sp5) 129.1 ± 26.8 391.6 ± 77.8 
Superior colliculus – superficial gray (SuG) 383.2 ± 41.3 309.0 ± 35.7 
Thalamus   
   Nucleus reuniens (Re) 808.0 ± 51.9 715.5 ± 52.1 
   Paraventricular nucleus (PV) 780.0 ± 78.5 585.7 ± 43.3 
   Intermediodorsal nucleus (IMD) 603.8 ± 44.1 481.0 ± 16.6 
 
Table 6: Agonist-induced [35S]-GTP gamma S binding in the rat brain. Binding values were determined by exposing 
14C-plastic standards to the imaging plates along with the radiolabled slides. Values were determined using an 
image density versus nCi/mg plastic calibration curve. From (Gehlert et al., 2006) 
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2.4.  Pharmacological effects of N/OFQ system in central 
nervous system 
2.4.1.  Pain modulation 
The effect of N/OFQ peptide in pain modulation is complex. Indeed, N/OFQ 
administered supraspinally reversed the effect of exogenous opioids, which is an 
anti-opioid effect (Pan et al., 2000). In contrast, spinal administration of N/OFQ 
produced a classical antinociceptive effect (King et al., 1997; Ko et al., 2006). 
The neuroanatomical site underlying the anti-opioid action of N/OFQ is the 
rostral ventromedial medulla where two types of cell exist: the ―On‖ and the ―Off‖ cell 
(Zeilhofer et al., 2003; Pan et al., 2000). ―On‖ cells inhibit the action of ―Off‖ cells and 
are inhibited by morphine acting on MORs. The ―Off‖ cell projects back to the spinal 
dorsal horn to reduce the ascending nociceptive information that reaching 
third-order neurons via the ascending spinothalamic tract. The inhibition of the 
―On‖ cell by morphine disinhibits the ―Off‖ cell leading to an antinociceptive effect. 
N/OFQ inhibits both the ―On‖ and ―Off‖ cell with direct inhibition of ―Off‖ cells 
producing an increase in nociceptive traffic. Clearly, this inhibition of ―Off‖ cells 
would reverse any actions of opioids in ―On‖ cells producing an anti-opioid action. 
However, the consensus view is that spinal administration of N/OFQ produces a 
classical (opioid-like) antinociceptive response by inhibiting transmitter release 
such as glutamate at primary nociceptive afferent terminals (Faber et al., 1996; 
Zeilhofer et al., 2003; Ko et al., 2006; Inoue et al., 2003). Interestingly, one study 
reported an increase in the release of the pro-nociceptive transmitter substance P 
(Inoue et al., 1999). 
 
At the spinal level, N/OFQ produces classical opioid analgesia by inhibiting 
nociceptive afferent inflow, which can occur in peripheral tissues such as skin and 
bladder, and possibly via an interaction with the neuroimmune axis (Figure 15). 
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Figure 15: Schematic to describe the interrelationship between the anatomical s ite(s) underlying the actions of 
N/OFQ in pain modulation. PBMC, peripheral blood mononuclear cells. From (Lambert, 2008) 
 
2.4.2.  Tolerance and dependence 
N/OFQ has been found to act in the brain with functional anti-opioid 
mechanisms. Thus, some studies have investigated the role of N/OFQ in the 
development of tolerance to the analgesic effect of morphine. 
Repeated treatments with morphine increased N/OFQ levels in different brain 
areas (Yuan et al., 1999). Accordingly, treatment with selective NOP receptor 
antagonists prevented the development and expression of tolerance following 
chronic treatment with morphine (Scoto et al., 2010). Moreover, NOP receptor 
knockout mice showed a 50 % reduction in tolerance to the analgesic effect of 
morphine (Ueda et al., 1997). 
As mentioned above, dependence could be divided into two expects: physical 
dependence and psychological dependence. 
Concerning morphine-induced physical dependence, the role of N/OFQ and its 
receptor is less clear. Malin and colleagues reported that supraspinal 
administration of N/OFQ produced a dose-dependent withdrawal symptom in 
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non-tolerant rats (Malin et al., 2000). However, in morphine-tolerant and 
-dependent mice, N/OFQ did not induce any withdrawal symptoms (Tian et al., 
1997; Kotlinska et al., 2000). Most puzzling, although, is the reported ability of both 
N/OFQ and J-113397, the NOP receptor antagonist, to attenuate withdrawal 
symptoms in morphine-dependent animals after supraspinal administration 
(Kotlinska et al., 2000; Ueda et al., 2000). 
For NOP receptor knockout mice, the withdrawal symptoms (jumping, paw 
tremor, backward locomotion, sniffing and defecation) are reduced or absent (Ueda 
et al., 2000). 
Furthermore, N/OFQ and NOP receptors also play important role in the 
happening of alcohol withdrawal syndromes. Economidou and colleagues showed 
that N/OFQ reduced the expression of somatic withdrawal signs by activating NOP 
receptors in ethanol-dependent Wister rats which, to a large extent, are dependent 
upon glutamatergic hyperactivity, and it reversed anxiety-like behaviors associated 
with both chronic and acute alcohol intoxication as they are regulated by 
extrahypothalamic CRF transmission (Economidou et al., 2011). 
Paradoxically, in another study using Sprague–Dawley rats, it has been found 
that acute ethanol intoxication (1 day binge exposure), ethanol dependence (5 day 
binge exposure) and ethanol withdrawal (1 day after 5 day binge exposure) were 
associated with significant increase of pronociceptin mRNA levels in amygdala 
(D'Addario et al., 2013). Perhaps, in that study, the increase in pronociceptin 
transcript reflects an allostatic process, or the body attempts to adapt to and 
counter the administration of high level ethanol. Overall, the data suggests that 
activation of NOP receptors might have beneficial effects not only in ethanol drinking 
and relapse but also in treating withdrawal. 
 
In terms of psychological dependence, N/OFQ blocked morphine-reward in CPP 
test (Murphy et al., 1999; Ciccocioppo et al., 2000). A key neurochemical correlation 
to the behavioral finding was offered by microdialysis data, which showed that 
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N/OFQ reduced morphine-induced dopamine (DA) release in NAc of conscious rats 
(Di Giannuario and Pieretti, 2000). Importantly, the same dose of N/OFQ did not 
modify the basal extracellular level of DA, in keeping with the finding that N/OFQ 
per se produced neither preference nor aversion in the place conditioning paradigm. 
Further support for this potential mechanism came from results of 
immunohistochemistry experiments, which indicated that N/OFQ blocked the 
expression of c-fos, a marker of neuronal activation, induced by morphine in the 
shell portion of NAc (Ciccocioppo et al., 2000). In fact, evidence suggested that 
rewarding stimuli, including morphine, potently increased c-fos expression in this 
area, reflecting the activation of DA receptor-containing neurons (Barrot et al., 
1999). 
In addition, it has been shown that N/OFQ prevented the expression of CPP 
engendered by either cocaine or methamphetamine (Kotlinska et al., 2002; Zhao et 
al., 2003), and microdialysis experiments revealed that intracranial injection of 
N/OFQ prevented cocaine from stimulating mesoaccumbal DA efflux (Lutfy et al., 
2001). 
For the NOP receptor knockout mice, cocaine produced the place conditioning 
effect in a more sensitive way (Sakoori and Murphy, 2009), replicating previous 
findings with both morphine and nicotine (Marquez et al., 2008; Rutten et al., 2011). 
Although results are negative, it‘s also worth to be noted that one study evaluated 
the activity of N/OFQ on stress-induced reinstatement of cocaine seeking behaviors 
(Martin-Fardon et al., 2000). 
 
Effects of N/OFQ on ethanol-related behaviors have been largely explored in 
genetically selected Marchigian Sardinian Alcohol-Preferring (msP) rats. This rat line 
is particularly sensitive to the suppression of ethanol drinking and the relapse 
induced by N/OFQ and analogs (Ciccocioppo et al., 1999; Ciccocioppo et al., 2004; 
Economidou et al., 2008). Furthermore, it has been shown that complex adaptive 
changes in the N/OFQ system may occur following protracted exposure to 
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intoxicating dose of ethanol, which may potentially limit the therapeutic efficacy of 
NOP receptor agonists in alcoholism. In fact, Wistar rats made dependent on 
ethanol, tested by ethanol self-administration 1 week following withdrawal, were 
sensitive to the suppressant and anxiolytic-like action of N/OFQ, whereas 
non-dependent control rats remained less sensitive (Aujla et al., 2013; 
Martin-Fardon et al., 2010; Economidou et al., 2011). However, after 3 weeks 
post-intoxication, N/OFQ engendered anxiogenic-like actions in ethanol-dependent 
rats but continued to exert anxiolytic-like actions in non-dependent controls. 
 
2.4.3.  Stress, anxiety and depression 
Data from many scientific literatures suggest a modulatory role of N/OFQ in the 
control of physiological systems regulating stress and stress reactivity. The findings 
that lead to this current understanding come from diverse sources including the 
impact of stress on NOP receptors and the impact of N/OFQ on biochemical, 
neurochemical and behavioral changes relevant to stress processing. 
Devine and colleagues showed that restraint stress decreased the level of 
N/OFQ in the basal forebrain of rats (Devine et al., 2003). Thus, the hypothesis is 
that restraint stress produced peptide release that further engaged in synthetic 
machinery. Indeed, direct measurements of N/OFQ by immunohistochemical 
localization studies have confirmed this hypothesis in rat brain, and glucocorticoids 
might function as mediators in this process as suggested by studies in 
adrenalectomized rats supplemented with corticosterone (Nativio et al., 2012). The 
released N/OFQ could then act upon its receptors to engender downstream 
biochemical changes. Since the biochemical effect observed with N/OFQ are 
comparable to those engendered by stressors, the peptide system is likely engaged 
in the transduction of stress signals to HPA axis and central nervous system as 
discussed further below. 
 
Central administration of N/OFQ increased the activation of HPA axis, 
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specifically the plasma level of corticosterone and adrenocorticotropic hormones 
(ACTH). However, if N/OFQ was given after more extreme stress conditions such as 
restraint, the increase of stress hormones was not observed (Devine et al., 2001). In 
contrast, increased expression of N/OFQ peptide was observed in hippocampus and 
dentate gyrus of rats after immobilization stress (Nativio et al., 2012). Thus, these 
data supported the physiological role of N/OFQ in stress reactivity and suggested 
that the regulation effect of N/OFQ might be dependent upon the basal state of the 
system. 
Effects observed after central administration of N/OFQ were similar to the 
biological changes observed after acute stress (Harbuz and Lightman, 1989). In 
addition, central administration of UFP-101, an antagonist of NOP receptors, had no 
effect on either plasma markers or central increase of CRF or POMC expression level 
(Leggett et al., 2006). However, UFP-101 blocked N/OFQ-induced HPA axis 
activation, as measured by plasma corticosterone and central CRF/POMC 
expression level (Leggett et al., 2006). While the evidence clearly demonstrates that 
the N/OFQ system is involved in stress modulation, and the lack of suppression by 
UFP-101 alone suggests that the N/OFQ system is not tonically active. 
 
Furthermore, N/OFQ inhibits the release of central monoamines, both in vitro 
and in vivo, that are critical to stress and the processing of stress input (anxiety, 
mood). For example, in synaptosomes prepared from rat neocortex, the K+-induced 
release of serotonin and norepinephrine was inhibited by N/OFQ, an effect that 
could be attenuated by NOC receptor antagonists (Mela et al., 2004). On-target 
activity of the peptide was confirmed by showing that the inhibition of serotonin 
overflow was lost in NOP−/− mice (Mela et al., 2004). Both in vitro and in vivo data 
indicate that the neurotransmitter release induced by N/OFQ occurs at multiple 
levels. Thus, cell bodies located in DRN that regulate the serotonin release have 
been shown to be inhibited by N/OFQ, and N/OFQ potently increased the inwardly 
rectifying K+ current in dorsal raphe neurons in brain slices, however, all effects 
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were not sensitive to naloxone (Vaughan and Christie, 1996). In addition, 
N/OFQ-induced suppression of serotonin neurons in DRN was later verified via 
both in vitro and in vivo electrophysiological studies, which might involve an 
increase in inwardly rectifying K+ currents (Nazzaro et al., 2010). Similarly, N/OFQ 
has been reported to decrease the release of NE from neocortical cells of rat brain in 
vitro, an effect could be blocked by an N/OFQ antagonist (Okawa et al., 2001; 
Siniscalchi et al., 2002). 
However, there are ample data that contradict the hypothesis that N/OFQ 
produces stress-like biological responses (Jenck et al., 1997; Köster et al., 1999; 
Jenck et al., 2000; Dautzenberg et al., 2001; Gavioli et al., 2002; Ouagazzal et al., 
2003; Kamei et al., 2004; Varty et al., 2005; Gavioli et al., 2007; Leggett et al., 2007; 
Varty et al., 2008; Lu et al., 2011a; Rizzi et al., 2011). Indeed, findings reported in 
literatures also indicate that, at extrahypothalamic level, activation of N/OFQ 
receptors leads to anti-stress and anxiolytic-like effects. 
In fact, either central administration of N/OFQ or systemic injection of brain 
penetrant selective NOP agonists could lead to marked anxiolytic-like effects in 
rodents (Jenck et al., 1997; Varty et al., 2005; Gavioli and Calo, 2006; Goeldner et 
al., 2012). These effects appear to be particularly robust under stressful conditions, 
for instance, alcohol withdrawal following intoxication or after exposure to restraint 
stress (Economidou et al., 2008). This may depend upon the ability of N/OFQ to act 
as a functional antagonist for the extrahypothalamic CRF1 receptor. It has been 
reported that N/OFQ blocked the anxiogenic-like effect of CRF and abolished the 
anorectic effect of restraint stress and CRF within BNST and CeA, where both 
systems interect (Rodi et al., 2008; Uchiyama et al., 2008). Of note, ex vivo 
electrophysiological recordings from brain slices containing CeA revealed that 
N/OFQ treatment completely prevented the ability of CRF to stimulate GABAergic 
neurotransmission in this area (Cruz et al., 2012). The anxiolytic-like effect of NOP 
receptor agonists was not due to a non-N/OFQ-related pharmacology, and has also 
been demonstrated by showing attenuation of agonist-induced anxiolytic-like effect 
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with an antagonist (Varty et al., 2005, 2008). 
 
To reconcile the apparently opposite effect of N/OFQ on HPA axis where it 
mimics a stress-like response and on extrahypothalamic sites where it shows 
anti-stress and anxiolytic-like effects, it is possible to hypothesize that this 
peptidergic system is part of the stress-coping mechanisms associated with 
physiological responses to stress. After exposure to an acute stimulus, the N/OFQ 
system is recruited to facilitate the adaptation of the organism to new environmental 
conditions by recruiting the hormonal stress system. However, following protracted 
exposure to a stressful condition, stimulation by N/OFQ at extrahypothalamic sites 
may serve to attenuate the pathological consequences associated with chronic 
stress. This hypothesis might be helpful to reconcile the discordant data in 
experimental literatures where both agonism and antagonism of NOP receptors have 
been suggested to counter or facilitate stress-related disorders such as anxiety and 
possibly post-traumatic stress. 
 
In contrast to behavioral findings that detect anxiolytic and anti-stress drug 
effects, uniform findings have been reported in the antidepressant-like effect of 
N/OFQ ligands. 
Intracerebroventricular administration of N/OFQ did not affect the behavior of 
rodents in forced-swim or tail-suspension test. However, antagonists of the NOP 
receptor have positive effect in these assays. Additional data that support the idea 
that the blockade of NOP receptors might have antidepressant effects comes from 
studies reporting increased N/OFQ plasma level in patients with depression 
including post-partum depression, major depressive disorder (MDD) and bipolar 
disorder (Gu et al., 2003; Wang et al., 2009; Zhang et al., 2009). Confirmation of 
these findings and extension to central measures of N/OFQ (e.g., cerebral spinal 
fluid and central NOP receptor occupancy) would be important data to link to the 
preclinical findings that have generated the stress/depression hypothesis. 
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Figure 16: Interplay of NOP receptors with stress pathways, and neuropeptide and non-peptide neurotransmitters. 
From (Witkin et al., 2014) 
 
2.4.4.  Locomotor activities 
The effect of N/OFQ on morphine-induced locomotor sensitization was studied 
with negative results (Ciccocioppo et al., 2000). Another negative finding came from 
the study in which NOP receptor agonism was tested against opioid 
self-administration. In this study, acute treatment with N/OFQ was unable to 
prevent the intravenous infusion rate of heroin (Walker et al., 1998). In contrast, 
N/OFQ blocked cocaine- and amphetamine-induced locomotor sensitization (Lutfy 
et al., 2002; Kotlinska et al., 2003; Bebawy et al., 2010), an effect that was absent in 
NOP receptor KO mice (Bebawy et al., 2010). 
 
2.4.5.  Learning and memory 
Initial studies showed an impairment of memory of rats after intrahippocampal 
infusion of N/OFQ in Morris water maze task (Sandin et al., 1997), and this effect 
could be rescued by NOP receptor antagonists (Sandin et al., 2004; Redrobe et al., 
2000; Hiramatsu et al., 2008). Concordantly, electrophysiological data suggested 
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N/OFQ could also impair the long-term potentiation (LTP) in the CA1 in rats (Yu et 
al., 1997). 
Moreover, NOP receptor agonism with N/OFQ or the NOP receptor agonist 
Ro64-6198 has consistently been shown to impair memory consolidation in 
contextual fear and passive avoidance paradigms (Fornari et al., 2008; Goeldner et 
al., 2009; Higgins et al., 2002; Hiramatsu and Inoue, 1999; Mamiya et al., 2003; 
Roozendaal et al., 2007). These two tasks are highly dependent on hippocampal 
functions. Experiments in mice showed that neither subcutaneous injection of 
Ro64-6198 nor i.c.v. injection of N/OFQ at low doses (0.1 to 1 nmol) affected 
cued-fear memory consolidation (Goeldner et al., 2009; Mamiya et al., 2003). In 
contrast, i.c.v. injection of N/OFQ at higher doses (2.5 to 5 nmol) and i.p. or 
intra-CeA injection of the recently discovered NOP receptor agonist SR-8993 after 
fear acquisition impaired cued-fear memory consolidation (Andero et al., 2013; 
Fornari et al., 2008). These results from cued-fear conditioning tests primarily reflex 
the role of amygdala in these processes. It is not possible to draw conclusions about 
these data because different drugs were administered through different routes. 
Therefore, more experiments about contextual and cue-dependent fear are needed 
to further understand the role of N/OFQ-NOP receptor in learning and memory. 
Furthermore, more and more evidence indicated that the modulation effect of 
NOP receptor in learning and memory works through its interaction with other 
systems. For instance, atenolol, the β1-adrenoceptor antagonist, within the 
basolateral amygdala (BLA) potentiated the effect of N/OFQ, thereby impairing the 
consolidation of inhibitory avoidance (Roozendaal et al., 2007). Moreover, the 
enhanced memory consolidation elicited by the NOP receptor antagonist 
[Nphe(1)]nociceptin(1–13)NH(2) could be blocked by atenolol (Roozendaal et al., 
2007). Conversely, a systemic dose of the NOP receptor antagonist J-113397 was 
shown to increase the noradrenaline level within the BLA, and a local infusion of 
N/OFQ inhibited this release (Kawahara et al., 2004). In addition, the interaction 
between NMDA and NOP receptors also may be critical for the consolidation of 
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contextual fear memories (Goeldner et al., 2009). In contrast, NOP receptors may 
interact with acetylcholine in learning and memory with a much more complex 
situation (Cavallini et al., 2003; Uezu et al., 2005; Hiramatsu et al., 2008). 
 
2.5.  NOP Receptor Signalings 
2.5.1.  Cellular effects of NOP receptors 
The NOP receptor, like other opioid receptors, is a prototypical G 
protein–coupled receptor (GPCR) that couples with pertussis toxin–sensitive (Ma et 
al., 1997) and –insensitive (Chan et al., 1998) G proteins. 
After agonist activation, the NOP receptor triggers intracellular signaling events 
including inhibition of adenylyl cyclase (Ma et al., 1997) and activation of protein 
kinase C (PKC) (Lou et al., 1997), phospholipase A (Fukuda et al., 1998) and C (Lou 
et al., 1997), extracellular signal-regulated kinases 1 and 2 (ERK1/2) (Fukuda et al., 
1997; Lou et al., 1997), p38 mitogen-activated protein kinase (Zhang et al., 1999), 
c-Jun N-terminal kinase (JNK) (Chan and Wong, 2000), nuclear factor kB(NFkB) 
(Donica et al., 2011), and modulation of calcium (Connor et al., 1996b) and 
potassium channel conductance (Connor et al., 1996a). The inhibition of 
presynaptic voltage-gated calcium channels mediated by N/OFQ has been 
demonstrated both in vitro (Connor et al., 1996b) and in vivo (Knoflach et al., 1996). 
Furthermore, activation of the NOP receptor opened inwardly rectifying potassium 
channels, and produced a postsynaptic hyperpolarization preventing excitation or 
propagation of action potentials (Vaughan et al., 1997). 
The significance of kinase activation and channel modulation by N/OFQ directly 
relates to the ability of N/OFQ in modulating neurotransmitter release, immune 
function and transcriptional activation. 
 
2.5.2.  Termination of NOP receptor signalings 
2.5.2.1. Phosphorylation 
The NOP receptor contains several serine and threonine residues in its 
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intracellular loops and carboxyl terminus that serve as potential phosphorylation 
sites for intracellular serine/threonine protein kinases. 
Indeed, GRK2 and GRK3 play important roles in mediating NOP receptor 
desensitization. Studies using two different human neuroblastoma cell lines that 
endogenously express the NOP receptor demonstrated that prolonged activation of 
NOP receptors increased GRK2 and GRK3 level by 2.2–2.5-fold (Thakker and 
Standifer, 2002). Blockade of GRK2/3 up-regulation by ERK inhibition or GRK 
anti-sense DNA treatment prevented the desensitization of NOP receptors. Of 
interest, homologous NOP receptor desensitization in BE(2)-C cells was mediated by 
GRK3, while knocking down of GRK2 had no effect (Thakker and Standifer, 2002). 
 
Furthermore, PKC also plays an important role in mediating NOP receptor 
desensitization. Binding of N/OFQ to the NOP receptor activates PKC, as 
demonstrated by translocation of cytosolic PKC to the plasma membrane and 
increased phosphorylation of proteins by PKC in cell lines that endogenously 
express or stably transfected with NOP receptors (Lou et al., 1997; Pei et al., 1997; 
Pu et al., 1999; Mandyam et al., 2002; Ozsoy et al., 2005). Indeed, N/OFQ-induced 
translocation of PKC involved only the conventional PKC isoform (Lou et al., 1997; 
Mandyam et al., 2002). Despite having an important role in mediating NOP receptor 
desensitization, direct phosphorylation of NOP receptors by PKC has yet to be 
demonstrated. However, N/OFQ-induced activation of PKCα promoted its 
membrane translocation (Mandyam et al., 2000) and phosphorylation of GRK2/3 
(Ozsoy et al., 2005), resulting in GRK2/3-mediated desensitization of NOP receptors 
(Mandyam et al., 2002). GRKs phosphorylate serine residues 334 and 335 on the 
C-terminal tail of the rat NOP receptor (corresponding to Ser337 in the human NOP 
receptor), such that a single mutation at each site reduced receptor desensitization. 
A double S334A/S335A mutation almost abolished the homologous desensitization 
and significantly impaired the phosphorylation of NOP receptors (Wang et al., 2006). 
 
 54 
Introduction 
2.5.2.2. Internalization 
Receptor internalization can occur through clathrin-dependent and/or 
-independent (e.g., caveolae/lipid rafts) processes. To date, there is no report that 
the internalization of NOP receptors occurs by clathrin-independent endocytosis. 
Phosphorylated GPCRs serve as target for adaptor proteins, such as β-arrestins, 
which further disrupt the G protein–mediated actions of the receptor (Krupnick and 
Benovic, 1998) and trigger the formation of clathrin-coated pits to transport surface 
receptors to intracellular compartments through clathrin-mediated endocytosis. 
Clathrin-coated vesicles are trafficked to early endosomal compartments, where the 
receptor is completely internalized. Agonist-induced receptor internalization is the 
intermediate phase of GPCR desensitization, where the receptor is now inaccessible 
for activation by the extracellular agonist, thereby inhibiting further 
agonist-mediated cellular responses. 
Many studies reported different results concerning NOP receptor internalization, 
which may be attributable to the variability of experimental conditions like the 
cellular components of the cell lines, the level of NOP receptor expression and the 
efficacy of peptide versus nonpeptide agonists. In generally, these studies all 
confirmed the temperature- and ATP-dependent of NOP receptor internalization via 
clathrin-mediated endocytosis (Dautzenberg et al., 2001; Spampinato et al., 2001, 
2002; Corbani et al., 2004). In addition, β-arrestin2 and GRK3 play an important 
role in mediating NOP receptor internalization (Spampinato et al., 2001, Zhang et al., 
2012), and When Ser363, a putative GRK phosphorylation site on the NOP receptor, 
was mutated to an alanine, cytosolic β-arrestin2 could not be recruited to the cell 
surface after N/OFQ treatment following significantly reduced NOP receptor 
internalization (Zhang et al., 2012). 
 
2.5.2.3. Down-Regulation 
Long-term treatment with agonists often causes internalized receptors to be 
transported from endosomes to either proteosomes or lysosomes for degradation. 
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The consequent decrease in total receptor number is referred to as receptor 
down-regulation, which generally ensues after chronic (hours or days) activation by 
an agonist. Down-regulation is the last phase of desensitization, where the total 
number of receptors in the cell is reduced, and therefore, responsiveness to the 
agonist is reduced until new receptors are synthesized and targeted to the cell 
surface. 
 
Compared with the non-peptide (Ro 64-6198) agonist, it is possible that peptide 
NOP receptor agonists, such as N/OFQ, differentially induce the down-regulation of 
NOP receptors in a time-dependent manner. For instance, an acute (≤ 1 hour) but 
not chronic (24–48 hours) Ro 64-6198 treatment produced NOP receptor 
down-regulation (Dautzenberg et al., 2001; Mandyam et al., 2002), whereas the 
reverse was true with N/OFQ treatment (Hashimoto et al., 2002). Furthermore, Ro 
64-6198 also differently modulated NOP receptor functions from that the N/OFQ 
did in the vas deferens, ileum and ventrolateral PAG (Calò et al., 1996; Chiou et al., 
2004). For instance, Ro 64-6198 regulated only 60 % of N/OFQ-sensitive receptors 
in rat PAG slices, suggesting Ro 64-6198 may only regulate a specific subset of NOP 
receptors (Chiou et al., 2004). Whether this can be attributed to the expression of 
NOP receptor splice variants (Pan et al., 1995, 1998; Xie et al., 1999), spare 
receptors or receptor dimerization (Pan et al., 2002) is not clear. Differences in 
neuronal (rat brain) versus non-neuronal cell phenotype expression (CHO and HEK 
cells), backgrounds (native versus recombinant) and the level of NOP receptor 
expression all may account for some of these differences in data. 
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Figure 17: Regulation of G protein–coupled receptor (GPCR) trafficking by G protein–coupled receptor kinases 
(GRKs) and arrestins. 1. Agonist (asterisk) binding to GPCRs leads to receptor activation, G protein coupling, and 
signal transduction. 2. GRKs then phosphorylate the agonist-activated GPCR on intracellular domains, initiating 
arrestin recruitment. Arrestin binding to the receptor inhibits G protein coupling and terminates signaling, a 
process termed desensitization. 3. Receptor/arrestin complexes are then targeted to clathrin-coated pits, where 
arrestin forms a multicomponent complex with clathrin, adapter protein-2 (AP-2), and phosphoinositides, resulting 
in receptor internalization. 4. Internalized GPCRs are sorted to either degradation (5a) or recycling (5b) 
compartments. From (Moore et al., 2007) 
 
3. The membrane/lipid rafts (MLRs) 
Historically, Singer and Nicolson described the plasma membrane (PM) as 
having a ―fluid mosaic‖ environment that randomly partitions proteins and lipids so 
as to achieve the lowest free energy (Singer et al., 1972). Thereafter, the concept of 
lipid domains was formalized by Karnovsky et al. (Karnovsky et al., 1982). According 
to substantial evidences, Simon and colleagues proposed a model for membrane 
structure that described the organization of lipid microdomains and presented 
evidence that proteins could selectively be included or excluded from these 
microdomains (Simon et al., 1997). They concluded that the function of these 
microdomains was to serve as rafts for the transport of selected membranes or as 
relay stations in intracellular signaling (Simon et al., 1997). 
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However, the very existence of lipid rafts has been questioned (Munro, 2003). 
This controversy has stemmed mainly from the technical challenges of studying 
these submicroscopic, dynamic structures in the membranes of living cells. At the 
Keystone symposium on lipid rafts and cell function, lipid rafts were defined as 
small (10–200 nm), heterogeneous, highly dynamic, sterol- and 
sphingolipid-enriched domains that compartmentalize cellular process (Pike, 2006). 
 
There are two major types of membrane/lipid rafts (MLRs): those that contain 
the cholesterol binding protein caveolin (Cav) and those that do not. Cav containing 
MLRs form morphologically distinct entities, caveolae (―little caves‖), the flask-like 
invaginations of the plasma membrane (PM) (detectable at the resolution of electron 
microscopy), while MLRs that lack Cav are flat and not identifiable by electron 
microscopy. However, some cells, such as neurons and lymphocytes, that express 
Cav containing MLRs do not have morphologically identifiable invaginated 
structures (Head and Insel, 2007), of which the mechanisms are still unclear. 
 
 
 
Figure 18: Membrane/lipid raft microdomains (yellow area) and membrane organization of signalling molecules. 
There are two common raft domains in mammalian cells: planar lipid rafts and caveolae. Both possess a similar 
lipid composition. Planar rafts are essentially continuous with the plane of the plasma membrane and lack 
distinguishing morphological features. By contrast, caveolae are small, flask-shaped membrane invaginations of 
the plasma membrane that contain caveolins. IR, Ionotropic receptor; E, effector. 
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3.1.  MLRs lipid constituents: sphingolipids and cholesterol 
MLRs are highly enriched in sterols and sphingolipids. Sphingolipids are 
derived from ceramide, a lipid involved in numerous cellular responses including 
differentiation, adherence, migration and cell death (Zheng et al., 2006; 
Morales-Serna et al., 2007; Young et al., 2013). Ceramide within the ER is 
synthesized into sphingolipids or shuttled to the Golgi complex to become 
gangliosides (in particular, GM1 and GM3). GM, which connotes ganglioside plus 
one (mono) sialic acid, or GD, wherein the D stands for disialic acid, are complex 
glycolipids with strong amphiphilic properties due to the saccharidic headgroup and 
a double-tailed hydrophobic moiety (Sonnino et al., 2007). The number 1, 2, and 3 
(e.g., GM1, GM2, or GM3) denotes the migration of the gangliosides on thin-layer 
chromatography. The presence of sialic acid distinguishes gangliosides from neutral 
glycosphingolipds and sulfatides. 
Although non-Cav-containing MLRs exist in planar form that cannot be readily 
identified morphologically, they could be labeled with fluorescent cholera toxin (CTX) 
β subunits, which binds to ganglioside GM1 (Merritt et al., 1994; Blank et al., 2007). 
Sphingolipids contain acyl chains that are longer than the width of a single leaflet of 
the PM (Simons and Vaz, 2004) and thus, may help facilitate transmembrane events 
in the absence of transmembrane proteins. 
Cholesterol is another major membrane component of MLRs. Following its 
synthesis in ER, cholesterol is trafficked to the Golgi complex where it binds 
sphingolipids or proteins such as Cav (Glenney and Soppet, 1992; Rothberg et al., 
1992; Kurzchalia et al., 1992; Dupree et al., 1993; Murata et al., 1995). These 
sphingolipid- and cholesterol-enriched structures self-aggregate in Golgi complex 
and generate vesicles that are transported to the PM and form MLRs. 
In the formation of MLRs, sphingolipids associate via their head groups and 
cholesterol interdigitates among them (Rietveld and Simons, 1998; Zocher et al., 
2012). Sphingolipids and cholesterol, as well as GPI-anchored proteins, are 
predominantly found in the outer leaflet (exofacial domains) of PM, while Cav and 
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associated proteins are found in the inner leaflet (cytofacial domains). Cav and other 
inner leaflet proteins interact with membrane lipids via myristic and/or palmitic 
acid, which are present on a number of MLR-localized proteins. Cholesterol binds 
certain membrane proteins, such as G-protein-coupled receptors (GPCRs), and can 
influence properties of GPCRs and presumably other membrane proteins (Zocher et 
al., 2012). 
 
3.2.  MLRs Scaffolds: Caveolin, Cavin, Flotillin/Reggie 
Caveolin (Cav), an integral membrane protein that exists in 3 isoforms (Cav-1, 
-2, and -3), was first discovered as a tyrosine-phosphorylated substrate of Src in 
transformed chick fibroblasts (Glenney, 1989). This phosphorylation can be 
mediated by Src, Fyn, Yes, c-Abl, certain growth factors and integrin activation 
(Salanueva et al., 2007). Cav-1 could also be phosphorylated on serine 80, an event 
implicated in the trafficking of cholesterol (Schlegel et al., 2001; Fielding et al., 
2004). 
Cav-1 contains the α-helical hairpin intramembrane domain (IMD; residues 
102–134) and palmitoylated cysteines 133, 143, and 156, which are not required for 
membrane insertion but facilitating the binding of cholesterol and its transportation 
to the membrane (Mundy et al., 2002). A cholesterol recognition/interaction amino 
acid consensus (CRAC) motif (residues 94–101, VTKYWFYR) within Cav-1 appears 
to mediate its binding to cholesterol (Epand et al., 2005). 
Cav-1 also scaffolds and organizes a wide variety of signaling components via a 
β-stranded Cav scaffolding domain (CSD) (Hoop et al., 2012; Couet et al., 1997). It 
has been proposed that this 20 amino acid (amino acid residues 82–101 for Cav-1) 
CSD was critical for the binding (via a Cav binding domain [CBD]) and regulation of 
the activity of signaling components (Head and Insel, 2007; Insel et al., 2005), 
although this proposal has been questioned (Fuhs and Insel, 2011; Byrne et al., 
2012). 
Originally thought to be a negative regulator of signal transduction components 
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(Couet et al., 1997; Pike, 2003), Cavs may also activate cellular events, including 
various signaling proteins. Examples include responses mediated by insulin, Ras 
and neurotrophin (Yamamoto et al., 1998; Wary et al., 1998; Head et al., 2011). All 
three isoforms of Cav contain a conserved structural motif (FEDVIAEP) that allows 
for their oligomerization within a caveolae coat (Pelkmans et al., 2005), which 
typically consists of 12–18 monomers of Cav-1/Cav-2 (Sargiacomo et al., 1995; 
Monier et al., 1995) forming a heteroligomer-filamentous structure (Fernandez et al., 
2002). Recent data suggested that 9 monomers can form a homoligomer-toroidal 
shape for Cav-3 (Whiteley et al., 2012) and for the CSD. 
 
Since Cav also exists in cells that lack morphological caveolae (Head and Insel, 
2007; Stern and Mermelstein, 2010), this raises the question: what causes these 
unique plasmalemmal invaginations? Recent evidence has shown that caveolae 
formation appears to depend upon the protein cavin (also known as polymerase I 
and transcript release factor, PTRF) (Liu and Pilch, 2008). 
There are 4 isoforms of cavin: cavin-1 (PTRF), cavin-2 (aka serum deprivation 
protein response [SDPR]), cavin-3 (aka sdr-related gene product that binds C-kinase 
[SRBC]) and cavin-4 (aka muscle restricted coiled-coil protein [MURC]) (Hansen and 
Nichols, 2010). Cavin is a peripheral membrane protein that binds to 
phosphatidylserine within caveolae (Aboulaich et al., 2004) and exists with Cav in a 
1:1 stoichiometric ratio in close proximity with each other (Chadda and Mayor, 
2008). Furthermore, Cavin could be phosphorylated, possibly by the 
serine/threonine kinase ARAF1 (Pelkmans et al., 2005), on serine residues 36, 40, 
365, and 366 (Aboulaich et al., 2004). 
 
Another family of proteins that has been described in MLRs is 
flotillin-1/reggie-2 and flotillin-2/reggie-1, which were originally discovered as 
neuronal proteins in retinal ganglion cells during regeneration after injury (Schulte 
et al., 1997; Lang et al., 1998). Flotillins/reggies oligomerized via their C-terminal 
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tail domains (Solis et al., 2007) and have been implicated in the endocytosis of 
GPI-anchored proteins. 
 
3.3.  Methods for MLRs study 
A typical method to determine the protein association with MLRs is to assess 
whether the membrane localization of the target protein could be affected by MLRs 
disruption induced by cholesterol depletion. This can be achieved by different 
approaches such as (1) depletion and removal of cell cholesterol by cyclodextrins; (2) 
use of microbial cholesterol oxidases that catalyze cholesterol to 4-cholesten-3-one; 
(3) cholesterol sequestration by polyene macrolide antibiotics, namely, filipin, 
nystatin or amphotericin; (4) treatment with statins, which could inhibit HMG-CoA 
reductase activity, thus blocking cholesterol biosynthesis (Allen et al., 2007). Due to 
their relatively easy implementation and short incubation time, cyclodextrins and 
cholesterol oxidase treatment are the most widely used methods to disrupt MLRs. 
However, uncritical use of these methods to study complex cellular processes 
caused an inflation of claims that were difficult to interpret and reconcile. For 
instance, cyclodextrins treatment could lead to serious side effects such as lateral 
protein immobilization (Kenworthy, 2008). As plasma membranes can contain up to 
40 mol % cholesterol (Kalvodova et al., 2009), it is perhaps not surprising that many 
cellular functions can be perturbed by cholesterol depletion (Zidovetzki and Levitan, 
2007). So in this thesis work, we used a relatively low concentration of methyl-β- 
cyclodextrin (2 mg/ml) in order to reduce side effects as far as possible. 
 
In addition, there are two classical approaches for MLRs isolation. First, MLRs 
are defined as being insoluble in cold non-ionic detergents such as Triton X-100. 
Detergent-resistant membrane (DRM) fractions float into the buoyant fractions of 
sucrose gradients during ultracentrifugation and are distinguished as two or three 
opaque bands in the lighter density sucrose (Brown and Rose, 1992). There is also a 
non-detergent protocol for the isolation of MLRs based on pH and carbonate 
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resistance (Song et al., 1996). Sodium carbonate, at high pH, separates proteins 
that are firmly attached to the membrane from those more peripherally associated. 
Then, rafts are isolated by ultracentrifugation and fractions are harvested as for the 
preparation with detergent. 
However, these two biochemical protocols for the isolation of MLRs are not 
without pitfalls. As detergent solubilization is an inherently artificial method giving 
different results depending on the concentration and type of the detergent, duration 
of extraction and temperature (Lingwood and Simons, 2007), and the high pH-based 
method requires cell disruption, in this case by sonication, which alters the often 
delicate relationship between the membrane, proteins and cytoskeletal components 
that normally exists in cells. 
 
Furthermore, several kinds of new microscopy techniques, such as hetero- and 
homo-FRET and fluorescence polarization anisotropy (Sharma et al., 2004; Vyas et 
al., 2008), single-particle tracking (Kusumi et al., 2004), dual-colour total internal 
reflection fluorescence (TIRF) microscopy, single quantum dot tracking (Pinaud et 
al., 2009), fluorescence correlation spectroscopy (FCS) analysis, stimulated 
emission depletion (STED) microscopy (Eggeling et al., 2009) and Super-resolution 
near-field scanning optical microscopy (NSOM) (van Zanten et al., 2010) have been 
using to visualize MLRs. Despite data gained recently are valuable, all techniques 
mentioned above have their inherent disadvantages. FCS is diffraction-limited and 
therefore must be extrapolated (Lenne et al., 2006; Lasserre et al., 2008; 
Wawrezinieck et al., 2005) or combined with a super-resolution technique like STED 
(Eggeling et al., 2009) to reach the nanoscopic world. NSOM requires nanometre 
proximity to a tip or surface, which may influence the system under study (Wenger 
et al., 2007). A further issue is the use of labels, usually fluorescent tags, beads or 
quantum dots, which are bulky or chemically foreign to the cell. Although there are 
attempts to tackle the bulkiness of these tags (Sahl et al., 2010), it remains to be 
seen whether these tagged (often overexpressed) constructs faithfully mimic the 
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behaviour of unmodified native membrane components. 
Despite these limitations, data from all these methods above conclusively 
support the existence of nanoscale, cholesterol-assisted, dynamic and selective 
assemblies. But the problems still required the development of high temporal and 
spatial resolution technique to compare the location of different molecular 
constituents on the membrane. 
 
3.4.  Roles of MLRs in cellular functions 
3.4.1.  MLRs and T cell activation 
T cells are activated by conjugation with cognate antigen-presenting cells (APCs). 
T cell receptors (TCRs) interact with the antigenic peptide bound to the major 
histocompatibility complex (pMHC) on APCs, and this leads to the phosphorylation 
of immunoreceptor Tyr-based activation motifs in the TCR multisubunit complex by 
lymphocyte cell-specific protein Tyr kinase (LCK; a Src family kinase) and 
subsequent recruitment and activation of the Tyr kinase 70 kDa zeta-associated 
protein (ZAP70) (Figure. 19). In turn, activated ZAP70 phosphorylates linker for T 
cell activation (LAT), a transmembrane adaptor protein that recruits several 
signalling molecules to initiate downstream events such as actin polymerization, 
Ca2+ influx, Ras activation and transcriptional changes. This cascade of events 
results in the formation of an ‗immunological synapse‘ between the contacting  cells. 
In this process, peripheral MLRs cluster towards a central MLRs region to 
become a supramolecular activation cluster (cSMAC), and this clustering and the 
activation of TCRs was cholesterol-, sphingomyelin- and Cav-1-dependent (Molnar 
et al., 2012; Tomassian et al., 2011). The interaction between MLRs and cytoskeletal 
was essential for T cell activation (Lim et al., 2011; Chichili et al., 2010; Lin et al., 
2010). The lateral membrane mobility and clustering of MLRs are thought to 
enhance signal transduction at immunologic synapses. This clustering depended 
upon Rho-mediated actin rearrangement, and disruption of rafts prevented the 
formation of immunologic synapses (Gonnord et al., 2012). Within MLRs, Cav-1 
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contributed to membrane polarity and TCRs-induced actin polymerization of CD8 
(Tomassian et al., 2011). In addition, CD26 bound Cav-1 in APCs to induce T cell 
proliferation in a TCRs/CD3-dependent manner (Ohnuma et al., 2009). 
 
In addition to Cav, MLRs-associated proteins, such as Flots and TSPNs, also 
play a role in T cell activation. Flots in polarized regions of T cells formed a ―cap‖ 
where TCRs complexes organized following stimulation (Stuermer, 2010). This ―cap‖ 
is necessary for T cell activation in which it localizes TCRs and initiates 
communication with actin through Fyn, Lck, Src and Rho GTPases. Similar to 
subcellular actions exhibited in neurons, Flots interact with the GPI-anchored 
protein PrP to form PrP clusters and subsequent recruitment of CD3. TSPNs 
facilitate similar clustering events and regulate the lateral movement of SMAC, 
leading to the formation of cSMAC in an actin-dependent manner following TCR 
activation and CD3 chain phosphorylation by Lck (Fooksman et al., 2010; Huse et 
al., 2007). 
 
 
 
Figure 19: The T cell receptor activation. Abbreviations: TCR, T cell receptor; pMHC, peptide-bound major 
histocompatibility complex; APC, antigen-presenting cell; LCK, lymphocyte cell -specific protein Tyr kinase; LAT, 
linker for T cell activation; cSMAC, supramolecular activation cluster. From (Simons and Gerl, 2010) 
 
3.4.2.  Entry of pathogens and toxins 
Endocytosis plays an important role in the communication between eukaryotic 
cells and their outside environment by regulating cell dynamics and homeostasis. 
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Cytoskeletal rearrangement allows (and is required for) cellular entry via MLRs of 
many types of cargo, including nutrients, receptor-ligand complexes, lipid, antigens, 
DNA nanoparticles and infectious agents that include fungal, bacterial and viral 
pathogens (Chen et al., 2011; Wang et al., 2012; Huang et al., 2011; Thaa et al., 
2010; Ewers and Helenius, 2011; Goldston et al., 2012). Of note, especially with 
respect to disease are roles of MLRs and interaction with cytoskeletal components in 
the endocytosis of microbial-derived toxins and pathogens. One example is the 
neurotropic fungal pathogen Cryptococcus neoformans, which crossed the blood 
brain barrier of brain microvascular endothelial cells via a MLRs-mediated 
endocytotic pathway (Huang et al., 2011). This occured in GM1-enriched regions 
and was regulated by dual specificity tyrosine-phosphorylation-regulated kinase 3 
(Dyrk3) (Huang et al., 2011). Pore-forming toxins such as equinatoxin II invaded 
cells by binding to MLRs, and subsquently re-organize of the actin cytoskeleton 
facilitated the toxin entry which leads to cell death (Garcia-Saez et al., 2011). As part 
of their invasion of cells, bacterial toxins such as the exotoxin of Vibrio cholera (CTX) 
and Shigella dysenteriae Shiga (STX) bind to the MLRs glycosphingolipids GM1 and 
globotriosylceramide Gb3, respectively (Ewers and Helenius, 2011). Such toxins 
(which also include Shiga-like toxin, Escherichia coli Heat labile enterotoxin 1 and 
Heat labile toxin IIb) are composed of a catalytic A subunit and a pentameric B 
subunit, and the latter flat-like ring structure binds to the carbohydrate moiety of 
glycosphingolipids to achieve internalization. Clostridial neurotoxins, such as 
Tetanus and Botulinium, possessed a single binding subunit and invaded cells by 
binding to gangliosides GT1b, GD1b, GQ1b and GD1a (Binz et al., 2009; Brunger 
and Rummel, 2009). 
 
3.4.3.  Virus budding 
Many viruses acquire a membrane envelope when budding off from the host cell 
plasma membrane. Some viruses, including HIV (Waheed and Freed, 2009) and 
influenza (Scheiffele et al., 1999), seem to do this by organizing a MLR domain 
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around their nucleocapsid that includes viral glycoproteins and excludes most host 
cell surface proteins from the budding viral envelope. The matrix domain of the Gag 
protein of HIV assembles with the Env glycoprotein in the plasma membrane, and 
these assemblies become detergent-resistant while driving the budding process 
(Figure 20). 
 
 
 
 
 
 
 
 
 
 
 
Furthermore, the budding process is cholesterol-and sphingolipid-dependent. 
By application of labelled cholera toxin to HIV-expressing cells, it has been shown 
that Gag, GM1 and virus proteins were co-patched in distinct clusters that 
segregated away from clusters of non-raft transferrin receptors (Waheed and Freed, 
2009). These data suggest that assemblies of the virus envelope at the host cell 
plasma membrane involve the clustering of MLRs. In support of this hypothesis, the 
lipidome of purified HIV particles showed that sphingolipids, cholesterol, plasmenyl 
phosphatidylethanolamine (PtdEtn), PtdSer and saturated PtdChos were enriched 
in the HIV membrane relative to total host cell membranes (Brugger et al., 2006). 
Comparison of the HIV lipidome with that of the host cell plasma membrane found 
that only cholesterol, the ganglioside GM3 and ceramide (Grassmé et al., 2007) were 
highly enriched in the virus envelope (Chan et al., 2008). Consistent with the 
enrichment of MLRs, the viral membrane was shown to have an ordered lipid 
 
Figure 20: HIV assembly and release. 
Gag binding induces the formation of 
raft platforms at the plasma membrane 
of the host cell and Gag multimerization 
drives the assembly of the virus particle. 
The viral Env protein is incorporated 
during the budding process and the 
virus detaches from the plasma 
membrane. From (Simons and Gerl, 
2010) 
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packing by spectroscopy using the fluorescent probe laurdan (Lorizate et al., 2009). 
 
3.4.4.  Cancer cell metastasis 
Migration of metastatic cells and their invasion of tissues depend upon many 
cellular events, including detachment from adhesion molecules (Hanahan and 
Weinberg, 2011). MLRs-resident proteins at focal adhesion sites play a central role 
in initiating detachment from the ECM (Grider et al., 2009). For example, prostate 
cancer cells appeared to require Cav-1, cavin-1, Src, FAK and the actin cytoskeleton 
to achieve adherence to or detachment from extracellular components (Su et al., 
2013; Thompson et al., 2010; Tahir et al., 2009). In some cases MLRs proteins (e.g., 
Cav-1) were released by these cells, an event that altered the recruitment of the actin 
cytoskeleton to the PM (Inder et al., 2012). MLRs also contributed to the regulation 
of polarized cell adhesion through growth factor receptor activation, in a 
ligand-independent manner (Lu and Chen, 2011), via CD24-integrin-mediated 
transmission of contractile forces (Mierke et al., 2011) or as a platform for 
association of the KCl cotransporter with a myosin-actin motor protein (Fu et al., 
2009). Neuroblastoma/glioma cell migration might occur, at least in part, through 
the action of MLRs-localized P2Y2 receptor-Gq/11-PLC signaling (Ando et al., 2010). 
 
3.4.5.  Neurodegenerative diseases 
MLRs play contrasting roles (preventive or exacerbating) in certain 
neurodegenerative diseases, such as Alzheimer's disease (AD). Altered MLRs 
homeostasis or ―lipid raft aging‖ has been suggested to be a factor in the processing 
of amyloid precursor protein (APP) to the toxic amyloid beta (Aβ) peptide (Evangelisti 
et al., 2013; Fabelo et al., 2012; Marin, 2011; Kapoor et al., 2010). Enhanced 
phospholipid/cholesterol ratio was found in brain membranes of AD mice compared 
to those of wild-type animals, suggesting that ―lipid raft aging‖ resulted from the 
alterations in structure and physicochemical properties of raft microdomains 
(Fabelo et al., 2012; Hicks et al., 2012; Vetrivel and Thinakaran, 2010). Within 
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MLRs, both Cav-1 and Flot have been implicated in AD, in particular with regards to 
γ-secretase-mediated APP processing (Kapoor et al., 2010) and estrogen 
receptor-voltage-dependent anion channel (VDAC) neuroprotection (Marin, 2011). 
However, it is unclear whether these raft proteins enhanced or dampened the 
production of neurotoxic peptides (Kapoor et al., 2010; Schneider et al., 2008). 
Thathiah and colleagues have demonstrated that a GPCR-β-arrestin 2 interaction in 
MLRs enhanced γ–secretase activity and subsequent generation of Aβ peptide 
(Thathiah et al., 2013). The production of Aβ peptide could alter membrane 
mechanical properties, such as membrane fluidity and molecular order (Yang et al., 
2010), suggesting that the alterations in physiochemical properties of the PM may 
be the result of Aβ peptide aggregates rather than the cause of such alterations. 
 
 
 
  
Objective 
 
The aim of my thesis work is to study the regulation of opioid activities by 
Neuropeptide FF receptors at cellular and molecular levels and to investigate the 
potential role of NPFF in anti-depressant response. 
    We chose acutely dissociated neurons of mice (dorsal raphe nucleus and 
periaqueductal gray neurons) and a neuronal cell line (SH-SY5Y) stablely expressed 
hNPFF2 receptors as models characterized the cellular and molecular mechanisms 
responsible for the anti-opioid effect of Neuropeptide FF. 
    By using mouse depression models (Tail suspension test and Splash test), we 
investigated the potential role of NPFF in the anti-depressant response. This work 
was done in the collaboration with Dr Bruno Guiard (UPS, Paris XI).
  
 
 
 
 
 
Results & Discussion 
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Results & Discussion 
 
Part 1: Neuropeptide FF receptors and mechanisms of their anti-opioid 
effect, in vitro study at cellular level 
 
Study direct and anti-N/OFQ activities of NPFF receptors 
Neuropeptide FF (FLFQPQRFa) was first isolated from bovine brain and 
characterized as a modulator of morphine action by tail-flick test in rats (Yang et al., 
1985). Thereafter, the using of other animal behavioural tests for inflammatory or 
neuropathic pain and opioid tolerance, dependence, reward and locomotor activity 
further confirmed that NPFF and related peptides possess anti-opioid properties 
(Moulédous et al., 2010b). 
At the cellular and molecular level, NPFF attenuated the opioid-mediated 
inhibition of C-fiber evoked firing on in vivo rat spinal cord preparations (Magnuson 
et al., 1990) and presynaptic morphine-induced decrease in GABAergic inhibitory 
post synaptic currents in rat brain slices (Miller and Lupica, 1997). In addition, 
NPFF was shown to inhibit morphine-induced reduction of acetylcholine release 
from myenteric plexus of guinea pig ileum (Takeuchi et al., 2001). 
Results from animal behavioural tests and tissue preparations described above 
could be explained by an indirect anti-opioid effect due to neuronal circuitry or by a 
direct anti-opioid effect mediated by a cross-talk between receptors in the same 
neuron. Several observations are in favor of the second hypothesis. 
Data from our laboratory showed that 1DMe reversed the inhibitory effect of 
DAMGO on Ca2+ conductance in acutely dissociated rat dorsal root ganglion (DRG) 
neurons (Rebeyrolles et al., 1996) or that of N/OFQ and DAMGO in rat dorsal raphe 
nucleus (DRN) neurons, and the reversion was specific for opioid receptors as no 
anti-serotonin effect of NPFF was observed (Roumy and Zajac, 1999). In addition, 
heterologous expression of physiological amounts of hNPPF2 (Mollereau et al., 2005) 
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or hNPFF1 (Kersanté et al., 2006) receptors in SH-SY5Y human neuroblastoma cells 
produced model cell lines in which NPFF ligands displayed anti-opioid activities 
against the negative regulation of N-type voltage gated calcium channels by both 
endogenous mu (MOP) and delta (DOP) receptors. Results from acutely dissociated 
neurons and cultured cells indicated that the cellular anti-opioid effect of NPFF may 
explain most of these pharmacological modulation effects at animal behavioural and 
tissue level. 
It should be noted that, in rat dorsal raphe nucleus (DRN) neurons, although 
1DMe produced a selective anti-opioid effect, the direct activity of NPFF receptors on 
Ca2+ transients induced by depolarization was not observed (Roumy and Zajac, 
1999). Moreover, NPFF receptors expressed on rat DRN neurons have been 
suggested to couple with stimulatory G-proteins (Gs) (Roumy and Zajac, 2001). 
In the present study, we investigated and compared a mice model to results 
previously obtained in rats. By using DRN neurons acutely dissociated from 
C57BI/6J mice, we tested direct and anti-opioid effects of NPFF receptors, 
stimulated by 1DMe, on Ca2+ transients triggered by depolarization. In addition, the 
type of G proteins which NPFF receptors prefer to associate in mice DRN neurons 
was also identified. 
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a b s t r a c t
By using acutely dissociated dorsal raphe nucleus neurons (DRN) from young mice, direct and anti-opioid
effects of Neuropeptide FF (NPFF) receptors were measured. The NPFF analog 1DMe (10 mM) had no effect
on resting Ca2þ channels but reduced the magnitude of Ca2þ transients induced by depolarization in
83.3% neurons tested, of which the inhibition rate is 45.472.9%. Pertussis toxin treatment reduced to
18.9% the number of responding neurons and attenuated by 47% the response of 1DMe. In contrast, cholera
toxin treatment had no significant effect. Eighteen minute perfusion with 1DMe at a very low 10 nM
concentration, that did not directly inhibit Ca2þ transients triggered by depolarization in every neuron,
attenuated by 78% the inhibitory effect of Nociceptin/orphanin FQ (N/OFQ) on Ca2þ transients, but not that
of by serotonin. These results demonstrated for the first time that NPFF receptors on mice DRN inhibit
Ca2þ transients induced by depolarization via Gi/o protein and also exhibit a specific anti-opioid activity on
nociceptin receptors, and that their specific anti-opioid activity is not a direct consequence of their activity
on Ca2þ transients.
& 2014 Elsevier B.V. All rights reserved.
1. Introduction
Neuropeptide FF (NPFF, FLFQPQRF-NH2), first isolated from
bovine brain (Yang et al., 1985), is an important opioid modulating
peptide. Two G protein-coupled receptors, NPFF1 and NPFF2, have
been cloned (Bonini et al., 2000). Both receptors are Gi/o protein-
coupled when expressed in Chinese hamster ovary (CHO) cells
(Hinuma et al., 2000) and human embryonic kidney (HEK) 293
cells (Elshourbagy et al., 2000). In contrast, NPFF receptors
expressed on rat dorsal raphe nucleus (DRN) and mouse olfactory
bulb neurons have been suggested to couple with stimulatory
G-proteins (Gs) (Roumy and Zajac, 2001; Gherardi and Zajac, 1997).
When expressed in SH-SY5Y cells, NPFF2 receptors are mainly
coupled with Gi but interactions with Gs proteins have also been
proposed (Mollereau et al., 2005). It is now widely accepted that
receptors can couple to several G-proteins, such as Gs and Gi/o, which
can transduce divergent signaling pathways (Hermans, 2003).
The nociceptin receptor, which belongs to the opioid system, has
50–60% sequence homology with mu delta and kappa opioid
receptors but does not bind opioid classical ligands. The endogenous
ligand Nociceptin/orphanin FQ (N/OFQ), resembles opioid peptides,
especially dynorphin, but has little or no affinity for classical opioid
receptors. Like the classical opioid receptors, nociceptin receptor
is coupled to Gi/o protein and inhibits Ca2þ channels in neurons
(Gavioli and Calo, 2013).
Although Neuropeptide FF analogs do not interact with opioid
receptors, close relationships between NPFF and opioid system,
especially in pain perception, have been clearly demonstrated.
Injection sites will determine whether NPFF plays anti-opioid or
pro-opioid role (Moulédous et al., 2010b) since intracerebroventri-
cular (i.c.v) injection of 1DMe, a stable NPFF analog, in mice, inhibits
morphine induced analgesia, but after intrathecal administration
1DMe induces long-lasting analgesia (Roumy and Zajac, 1998). Thus,
the NPFF system is considered to be an opioid-modulating system
involved in homeostasis that counteracts the action of opioids.
At the cellular level, NPFF agonists also exert anti-opioid actions.
In acutely dissociated neurons from dorsal root ganglion (DRG) and
DRN of rats, 1DMe attenuates the inhibitory effect of both m-opioid
receptors and nociceptin receptors on Ca2þ transients triggered by
depolarization (Roumy and Zajac, 1999; Rebeyrolles et al., 1996),
and in SH-SY5Y neuroblastoma cells transfected with NPFF recep-
tors 1DMe also exhibits functional anti-opioid effect (Mollereau
et al., 2005; Kersanté et al., 2006).
The DRN is a serotoninergic nucleus involved, among other
things, in the descending inhibitory control of pain (Fardin et al.,
1984). Autoradiography experiments with high affinity peptides to
NPFF receptor subtypes showed that NPFF receptors are localized in
a restricted number of regions of rat and mouse brain and spinal
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cord (Gouardères et al., 2004). Comparatively, NPFF2 receptors are
the predominant one, and in DRN only NPFF2 receptors binding
sites are detected (Gouardères et al., 2004).
In the present study, we have investigated and compared
a mouse model to results previously obtained in rat. By using
neurons acutely dissociated from C57BI/6J mice, we tested the
direct and anti-opioid effects of NPFF receptors, stimulated by
1DMe, on Ca2þ transients triggered by depolarization.
2. Materials and methods
2.1. Solutions and chemicals
BSA (fraction V) was from Euromedex (France). Trysin type XIII,
soybean trysin inhibitor, pertussis toxin (PTX), cholera toxin (CTX),
nifedipine and 5-hydroxytryptamine creatine sulfate (5-HT) were
obtained from sigma (France). Fluo4-AM (Molecular Probes, The
Netherlands) was dissolved (0.5 mM) in dry dimethylsulfoxide and
stored at 20 1C. 1DMe, ([D-Tyr1, (N–Me) Phe3] NPFF) and N/OFQ
were synthesized using solid phase techniques (Gicquel et al.,
1992; Meunier et al., 1995), dissolved (1 mM) in methanol (20%)
and stored at 20 1C. A fresh solution of 5-hydroxytryptamine
creatine sulfate (50 mM) in 0.1 N HCl was prepared for the
experiment. The antagonist RF9 was synthesized as previously
described (Simonin et al., 2006).
2.2. Neuron preparation
The DRN neurons were obtained from young C57BI/6J mice
(45–60 days) as previously described (Roumy and Zajac, 1999).
Experiments were performed in accordance with the European
Communities Council Directive 86/609/EEC and approved by the
local ethical committee. Briefly, the mice were kindly killed and
their brains quickly removed and placed in ice-cold dissection
buffer (in mM: NaCl, 150; KCl, 5; MgCl2, 2; glucose, 10; HEPES, 10;
pH¼7.3). Three 200 mM slices were cut corresponding to the
region from 4.84 to 4.36 mm from Bregma of the mice brain
(Paxinos and Franklin, 2001). The area of the dorsal raphe was
dissected and dissociated in 1 ml of dissociation buffer (in mM:
NaCl, 150; KCl, 5; MgCl2, 1; CaCl2, 2; glucose, 10; HEPES, 10;
pH¼7.3) containing 0.25 mg trpsin (type XIII) for 25 min at room
temperature (RT). The pieces of tissue were further incubated at
RT for 3 min in the presence of soybean trypsin inhibitor (1 mg/
ml) and BSA (0.1%) and washed three times in 1 ml of dissociation
buffer plus 0.1% BSA. Neurons were resuspended and 50 ml aliquot
was deposited in the middle of a 30 mm dish for 15 min to let the
neurons attach.
2.3. Measurement of intracellular calcium concentration
Ca2þ transients triggered by depolarization were monitored in
living, perfused neurons by quantitative photometry using the
fluorescent Ca2þ indicator Fluo4-AM as previously described
(Mollereau et al., 2005). Neurons were incubated with Fluo4-AM
(3.5 mM, 60 min, RT) and further incubated for 20 min with
perfusion buffer (RT) to allow for complete intracellular de-
esterification of Fluo4-AM.
Neurons were perfused at 1.8 ml/min with a perfusion buffer
containing (in mM): NaCl, 150; KCl, 2.5; CaCl2,2; MgCl2,1; Glu-
cose,10; HEPES,10. The pH was adjusted to 7.3, BSA (0.1%) and
nifedipine (3 mM) was added. Neurons were depolarized during
10 s with a perfusion medium in which KCl concentration was
raised to 50 mM and NaCl reduced accordingly to maintain
osmotic pressure. All ligands were diluted in perfusion buffer just
before use. Neurons were viewed with 40/0.65 objective,
illuminated at 488 nm (10-nm bandwidth interference filter),
and imaged with a cooled charge-coupled device camera (Micro-
Max 782 Y; Princeton Instruments, Evry, France) driven by Meta-
View software (Universal Imaging Corporation, Downingtown, PA).
Quantification of the fluorescence was made on random allocated
round neurons for each experiment. The fluorescence intensity
was expressed as F/F0, where F and F0 are the fluorescence
intensity at any time and the mean resting fluorescence intensity
preceding the first stimulation, respectively.
2.4. Data analysis
Data are presented as mean7S.E.M, and only the neurons that
responded to agonists are included into the mean. The level of
significance was chosen as 0.05 in all analysis performed using
GraphPad Prism software.
3. Results
The responses of 227 dorsal raphe neurons were recorded.
3.1. Responses to 1DMe
35/42 (83.3%) neurons perfused with 1DMe (10 mM, 3 min)
responded with a reduction (by 45.472.9%) of the magnitude of
Ca2þ transients induced by depolarization. The effect of 1DMe was
fully reversible and repeatable (Fig. 1A). Perfusion with 1DMe
(10 mM, 3 min) alone without depolarization did not induce any
change in intracellular Ca2þ concentration (data not shown).
For all 10 neurons tested, RF9 (a specific antagonist of NPFF
receptor, 10 mM) (Simonin et al., 2006) alone did not change the
magnitude of Ca2þ transients induced by depolarization (Fig. 1B),
but decreased both the proportion of responding neurons from
83.3% to 45.2% (14/31 neurons) and the 1DMe effect (Fig. 1C) from
43.774.6% to 17.473.2% (Fig. 1D). As nifedipine was present in
the perfusion medium to block L-type Ca2þ channel, these results
suggest that direct activation of NPFF receptors in mouse DRN
neurons inhibit N-type or P/Q-type Ca2þ channels.
In all 9 neurons tested, there was no evidence of desensitization
after 10 or 20 min perfusion with 1DMe (10 mM) (Fig. 1E and F).
When 1DMe concentration was decreased or after the short-
ening of perfusion time, the inhibition rate decreased significantly
(Fig. 1G). The proportion of neurons responded for 10 mM with
1 min perfusion, 1 mM with 5 min perfusion and 10 nM with 5 min
perfusion was 7/15 (46.7%) neurons, 6/17 (35.3%) neurons and
5/33 (15.2%) neurons, respectively, and the inhibition rate was
16.473.2%, 16.672.9% and 21.672.9%, respectively.
3.2. Effect of pertussis toxin and cholera toxin on the responses
to 1DMe
Treatment with PTX or CTX both did not induce any change in
Ca2þ transients induced by depolarization. A 10 mM concentration
of 1DMe was tested for a perfusion time of 3 min after pretreat-
ment with 200 ng/ml pertussis toxin (PTX) for 90 min. Only 7/37
(18.9%) neurons responded to 1DMe stimulation and inhibition of
Ca2þ transients was reduced to 23.873.1% (Fig. 2A).
Similarly, 10 mM concentration of 1DMe was tested for a
perfusion time of 3 min after pretreatment with 500 ng/ml cholera
toxin (CTX) for 90 min. For all 12 neurons tested, the direct effect
of 1DMe on Ca2þ transients induced by depolarization was
56.573.5%, which was not significantly different from control
(Fig. 2B).
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3.3. Responses to N/OFQ
Neurons were perfused with 300 nM N/OFQ for 1 min. 40/46
(86.9%) neurons tested responded with a reduction (by 45.172.6%)
of the magnitude of Ca2þ transients induced by depolarization.
The effect of N/OFQ was fully reversible and repeatable (Fig. 3).
3.4. Effects of 1DMe on the neuronal responses to N/OFQ
According to previous data (Roumy and Zajac, 1999), 10 nM
1DMe is enough to produce a maximal anti-opioid effect. So this
dose was chosen to study the effect of 1DMe on the neuronal
response to 300 nM N/OFQ.
Fig. 1. Responses of DRN neurons to 1DMe (10 mM). Neurons were depolarized with 50 mM KCl (10 s, arrowheads). Ordinate: normalized changes of the average intensity of
fluorescence, abscissa: time (in seconds) from the beginning of recording. Numbers on bars represent neurons tested. (A) 1DMe was applied for 3 min (horizontal lines).
(B) RF9 (10 mM) was applied for 3 min (horizontal lines). (C) 1DMe was applied for 3 min (horizontal lines) and 1DMe plus RF9 (both at 10 mM) were applied for 3 min (open
rectangle). (D) Inhibition of 1DMe effect by RF9. Control refers to 1DMe alone. Significantly different from control (nnnn, Po0.0001). (E) 1DMe was applied for 3 min (short
horizontal lines) and 10 min (long horizontal lines). (F) 1DMe was applied for 20 min (horizontal lines). (G) Inhibitory effect of various 1DMe applications. Control refers to
10 mM, 3 min. Significantly different from control (n, Po0.05; nn, Po0.01).
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Among 12 neurons tested, only six of them exhibited direct
activity of NPFF receptors on Ca2þ transients triggered by depo-
larization (Fig. 4A), whereas the others did not (Fig. 4B). However,
whether 1DMe (10 nM) inhibited Ca2þ transients triggered by
depolarization or not, 1DMe perfusion for 18 min could inhibit the
effect of N/OFQ on Ca2þ transients triggered by depolarization
(Fig. 4C).
Of nine neurons tested, the anti-nociceptin effect of 10 nM
1DMe was abolished in the presence of the NPFF antagonist RF9
(100 nM) (23.573.2% reduction of the magnitude of Ca2þ tran-
sients for N/OFQ, 23.774.2% in the presence of 1DMe plus RF9).
3.5. Effects of 1DMe on the neuronal responses to 5-HT
Using the same experimental protocol, for all 9 neurons tested,
the inhibitory effect of 5-HT (50 mM) on Ca2þ transients induced
by depolarization was 5075.4%. Contrary to N/OFQ, 5-HT effect
was not affected by 1DMe (10 nM) treatment (Fig. 5).
4. Discussion
In this study, we have observed, for the first time, the direct
activity of NPFF receptors on Ca2þ transients induced by depolar-
ization on acutely dissociated DRN neurons of mice with 10 mM
1DMe and 3 min perfusion. There was no evidence of desensitiza-
tion after 20 min perfusion. When 1DMe concentration decreased
the proportion of responding neurons and inhibition rate was
significantly decreased, so it did after shortening of perfusion time.
It is not surprising since even belonging to the same nucleus some
neurons are different from the others in terms of receptor
distribution, density and activity. In a previous paper by using
a low number of neurons of rat DRN (Roumy and Zajac, 1999),
1DMe at 1 mM exhibited no direct effect, suggesting a different
sensitivity of rat neurons but a higher dose of agonist on a greater
number of neurons should be used before conclusion.
In order to identify the type of G proteins involved in NPFF
direct effect, pertussis toxin and cholera toxin were used (Elmslie,
2003; Hille, 1994). After treatment with PTX, both responding
percentage of neurons and inhibition rate produced by 1DMe
stimulation were attenuated by 77.3% and 47.6%, respectively. In
contrast, CTX treatment group showed no significant difference
with control group for NPFF receptors activity on Ca2þ transients
induced by depolarization. Besides, perfusion with 1DMe alone
produced no intracellular calcium release that could reflect Gq
coupling. So NPFF receptors on mice DRN prefer to associate with
Gi/o proteins, with no or very limited proportion of Gq protein
coupling. Gs protein coupling could only be ruled out after cAMP
assay but, if it exists, it does not affect the direct effect produced by
1DMe stimulation on Ca2þ transients triggered by depolarization.
Unsurprisingly, on mice DRN, Ca2þ transients induced by
depolarization could be inhibited by 45.172.6% after 300 nM
N/OFQ stimulation, and by 5075.4% after 50 mM 5-HT stimulation.
Similar to that previously observed in rat (Roumy and Zajac, 1999),
10 nM 1DMe could specifically inhibit the inhibitory effect pro-
duced by N/OFQ, but not the inhibitory effect produced by 5-HT,
on Ca2þ transients. Furthermore, we demonstrated that this anti-
opioid activity was not a consequence of the direct activity of NPFF
receptors on Ca2þ transients since it occurred at 1DMe dose for
which the direct inhibitory effect is minimal. It has been pre-
viously demonstrated that GRK2 mediated heterologous phos-
phorylation, induced by 1DMe stimulation, in SH-SY5Y cells, could
contribute to the loss of function of mu-opioid receptors
(Moulédous et al., 2012), and 10 nM 1DMe treatment is enough
to phosphorylate the mu-opioid receptors in this model. Further-
more, in SH-SY5Y cells, 4.2 nM EC50 value for 1DMe anti-opioid
effect on Ca2þ transient induced by depolarization has been
determined (Mollereau et al., 2005) at similar concentrations
and we observed an anti-opioid affect on neurons of rat DRN.
Thus, a possible explanation of our data could be that, in mouse
DRN, NPFF receptor stimulation at nanomolar concentration, could
be sufficient to induce a heterologous desensitization of nociceptin
receptors. The putative involvement of heterologous phosphoryla-
tion by GRK or other kinases and heterodimerization, similar to
NPFF2/mu-opioid interactions (Roumy et al., 2007), remains to be
determined.
Alternatively, it was proposed that NPFF receptors of rat DRN
couple to Gs proteins rather than Gi/o and that this coupling could
lead to a reduction of the effect of N/OFQ on Ca2þ transients
triggered by depolarization (Roumy and Zajac, 2001). The demon-
stration of a direct effect of 1DMe in the mouse DRN involving Gi
proteins could thus indicate that the anti-opioid and the direct
actions of 1DMe are mediated by a different G-protein coupling.
Fig. 2. Influence of PTX and CTX on 1DMe effect on Ca2þ transients induced by depolarization. Neurons were incubated for 90 min with 200 ng/ml PTX (A), or for 90 min
with 500 ng/ml CTX (B). Bars represent mean7S.E.M., nn, Po0.01, significantly different from control; CTX treatment group is not significantly different from control.
Fig. 3. Responses of DRN neurons to N/OFQ (300 nM). N/OFQ was applied for 1 min
period (horizontal lines) at 10 min intervals.
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But CTX treatment could induce a complex downstream kinases
signal transduction, so the possibility that different G-protein
coupling mediates different effect remains to be determined by
some other assays.
A growing body of evidence suggests that blockade of noci-
ceptin receptors evokes antidepressant-like actions. Among all the
possible mechanisms, the role played by monoaminergic systems,
particularly serotoninergic, in the dorsal raphe, in mediating the
antidepressant properties of nociceptin receptor antagonists, is
very important (Gavioli and Calo, 2013). On the other hand, NPFF
receptor agonist (1DMe) exerts a complex influence in terms of
central locomotor and cognitive effects after i.c.v. injection in
C57Bl/6J mouse (Betourne et al., 2010). As a potent opioid system
modulating peptide, 1DMe also blocks the acquisition of condi-
tioned place preference to morphine after i.c.v. injection in C57Bl/
6J mouse (Marchand et al., 2006) and inhibits morphine effects in
dopaminergic pathways (Moulédous et al., 2010a). However, the
potential effect of NPFF receptor agonists on depression has never
been studied, and would be interesting to test.
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The potential role of membrane/lipid rafts in NPFF anti-N/OFQ effect 
The construction of recombinant cellular model, SH-SY5Y human 
neuroblatoma cells stably transfected with hNPFF2 receptors, gives us a good 
opportunity to explore the cellular and molecular mechanisms underlying NPFF 
anti-opioid effect. 
Consistent with data obtained from acutely dissociated neurons (Roumy and 
Zajac, 1999), NPFF functionally inhibited the negative regulation of N-type voltage 
gated calcium channels by both endogenous mu (MOP) and delta (DOP) receptors in 
recombinant SH-SY5Y cells (Mollereau et al., 2005; Kersanté et al., 2006). By using 
the same cellular model, our laboratory proposed a heterologous phosphorylation 
model of mu-opioid receptors, mediated by GRK2 protein, after activation of NPFF2 
receptors stimulated by NPFF analogue 1DMe (Moulédous et al., 2012). 
Moreover, the physical interaction between CFP-tagged NPFF2 and YFP-tagged 
MOP receptors in SH-SY5Y cells has been demonstrated using fluorescence 
resonance energy transfer (FRET) and co-immunoprecipitation (Roumy et al., 2007). 
Fluorescence recovery after photobleaching (FRAP) experiment also showed that, 
stimulation of NPFF2 receptors could influence the lateral diffusion and 
compartmentalization (association with membrane/lipid rafts) of MOP receptors in 
the plasma membrane (Roumy et al., 2007). In addition, a role of membrane 
compartmentalization in the cross-talk process of both receptors is also supported 
by the fact that cellular differentiation affected the specificity of the interaction 
between NPFF2 and other Gi-coupled GPCR (Mollereau et al., 2007). However, the 
distribution of MOP receptors in membrane/lipid rafts was highly dependent upon 
the method of purification, and the NPFF analogue 1DMe did not modify the 
distribution profile of MOP receptors (Moulédous et al., 2008), which suggested it‘s 
not possible to reconcile the membrane fractionation data of MOP receptors and the 
direct measurement data of receptor compartmentation in living cells. Although 
more and more new technologies are involved in the study of membrane protein 
compartmentation, they are still all with pitfalls. The problems still required the 
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development of high temporal and spatial resolution techniques to compare the 
location of different molecular constituents in the membrane. 
Nevertheless, for the NOP receptor, except one study showed that the inhibitory 
neuronal activity of N/OFQ could be inhibited by 1DMe treatment (Roumy and Zajac, 
1999), little is known about the detailed mechanisms underlying the NPFF 
anti-N/OFQ effect. As the fourth and non-classical member of the opioid system, the 
NOP receptor was first identified by molecular screening methods based on opioid 
receptor gene sequences, and N/OFQ, the endogenous ligand of the NOP receptor, 
was found by monitoring adenylate cyclase inhibition in NOP receptor-transfected 
cells. Despite the NOP receptor displayed sequence homology with the first three 
opioid receptors, it poorly bound peptide and alkaloid opioid ligands (Mollereau et 
al., 1994; Reinscheid et al., 1995). Moreover, the Nociceptin/Orphanin FQ (N/OFQ) 
peptide had a high affinity for NOP receptors but interacted poorly with other opioid 
receptors, suggesting that the NOP receptor was pharmacologically unique from the 
other opioid receptors (Meunier et al., 1995; Reinscheid et al., 1995). Indeed, 
N/OFQ produced a bidirectional modulatory effect on morphine-induced analgesia: 
antagonism in brain and potentiation in spinal cord of rats (Tian et al., 1997). In 
addition, at the cellular level, the heterodimerization of NOP/MOP receptors has 
been reported (Pan et al., 2002; Wang et al., 2005; Evans et al., 2010), as well as a 
reciprocal regulation of both receptors (Hawes et al., 1998; Mandyam et al., 2000, 
2002; Thakker and Standifer, 2002; Ozsoy et al., 2005; Wang et al., 2005; Evans et 
al., 2010). 
In the present study, we chose acutely dissociated mice DRN neurons and 
SH-SY5Y cells, which endogenously express NOP receptors, as models. By using 
calcium imaging technology and [35S]GTPγS binding assay combined with cell 
transfection, siRNA interference and western-blot, we studied the mechanisms 
underlying NPFF anti-opioid effect by focusing on the anti-N/OFQ effect of NPFF. 
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Abstract 
The participation of a signaling platform to the anti-Nociceptin/Orphanin FQ (N/OFQ) effect 
of Neuropeptide FF (NPFF) receptors was investigated in both acutely dissociated neurons 
and SH-SY5Y human neuroblastoma cells. The NPFF anti-N/OFQ, not anti-μ opioid effect, 
on the Ca2+ transient triggered by depolarization was reversed by methyl-β-cyclodextrin 
which depletes cholesterol from cell membranes. While the inactive α-cyclodextrin had no 
effect. By using [35S]GTPγS binding assay, a significant 20 % decrease of the activity of 
Nociceptin/Orphanin FQ peptide (NOP) receptors induced by the NPFF analogue 1DMe was 
observed in detergent resistant membranes (DRMs) but not in total membranes of SH-SY5Y 
cells. Moreover, siRNA knock-down of GRK2 indicated that GRK2, but not PKC, acted as the 
mediator in the NPFF anti-N/OFQ process. These data indicate that cholesterol-rich lipid 
rafts play an important role in the anti-N/OFQ effect of NPFF receptors. 
 
Key words Neuropeptide FF, anti-N/OFQ, Methyl-β-cyclodextrin, Membrane/lipid rafts, 
GRK2 
 
1. Introduction 
Neuropeptide FF (NPFF, FLFQPQRF-NH2) is a mammalian peptide first isolated from 
bovine brain with anti-opioid activity on morphine-induced analgesia in the rat (Yang et al., 
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1985). 1DMe ([D-Tyr1, (N–Me) Phe3] NPFF) is a commonly used stable NPFF analog. NPFF 
acts on two G protein coupled receptors NPFF1 and NPFF2 to produce its effect. Both NPFF 
receptors are preferentially coupled to Gi/o proteins (Mollereau et al., 2005) but their 
interactions with Gs proteins have also been proposed (Gherardi and Zajac, 1997; Roumy 
and Zajac, 2001; Mollereau et al., 2005). Numerous studies showed that NPFF and related 
peptides possess anti-opioid properties at in vivo pharmacological and in vitro cellular and 
molecular levels (Moulédous et al., 2010). Moreover, recently, our laboratory proposed one 
NPFF anti-opioid cellular model: the loss of function of μ-opioid recepors (MOR) was due to 
their heterologous phosphorylation, which was mediated by GRK2 proteins after the 
activation of NPFF2 receptors stimulated by 1DMe (Moulédous et al., 2012). However, the 
detailed mechanisms underlying NPFF anti-opioid effect is still unclear. 
The nociceptin/orphanin FQ (N/OFQ) peptide (NOP) receptor is the fourth and 
non-classical member of the opioid receptor superfamily that also includes μ (MOR), δ (DOR) 
and κ (KOR) opioid receptor subtypes. N/OFQ binds NOP receptors with high affinity 
(Kd≈0.1nM) but poorly interacts with other opioid receptors and, opioid peptides and 
alkaloid do not bind to the NOP receptor neither. The binding property of ligands and 
receptors suggested the unique pharmacological activities of the NOP receptor. Indeed, 
N/OFQ produced a bidirectional modulatory effect on morphine-induced analgesia: 
antagonism in brain and potentiation in spinal cord of the rat (Tian et al., 1997). In addition, 
at the cellular level, NOP receptors were also reported to regulate the activities of classical 
opioid receptors (Donica et al., 2013). In terms of the G protein coupling and signaling 
transduction, like the classical opioid receptors, NOP receptors were coupled to Gi/o protein 
mediated transduction pathway: inhibition of adenylate cyclase  (Ma et al., 1997), activation 
of an inwardly rectifying K+ conductance (Vaughan et al., 1997) and inhibition of 
voltage-dependent Ca2+ channels (Connor et al., 1996; Knoflach et al., 1996). However, for 
the NOP receptor, except one study showed that the inhibitory neuronal activity of N/OFQ 
could be inhibited by 1DMe treatment (Roumy and Zajac, 1999), little is known about the 
detailed mechanisms underlying the NPFF anti-N/OFQ effect. 
Membrane/lipid rafts (MLRs) were defined as small (10–200 nm), heterogeneous, highly 
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dynamic, sterol- and sphingolipid-enriched domains that compartmentalize cellular 
processes (Pike, 2006). Indeed, numerous data conclusively support the existence of 
nanoscale, cholesterol-assisted, dynamic and selective assemblies (Simons and Gerl, 2010). 
As putative dynamic cellular signaling ―platform‖, MLRs are involved in several aspects of 
cellular function, including lymphocyte activation, cell migration, polarity of endothelial 
and epithelial cells, neuronal growth and signaling (Head et al., 2014). 
The Dorsal raphe nucleus (DRN), one of the main serotoninergic nuclei, plays important 
role in the descending inhibitory control of pain. Periaqueductal gray (PAG) is the primary 
control center for descending pain modulation. In addition, autoradiography experiments 
detected many binding sites of NPFF receptors on both nuclei (Gouardères et al., 2002). As 
both nuclei are important for pain modulation and several observations support the 
hypothesis that the anti-opioid effect of NPFF is more likely a direct cross-talk between 
receptors in the same neuron (Roumy and Zajac, 1999, 2001), the acutely dissociated DRN 
and PAG neurons provide us good models to study the anti-opioid effect of NPFF receptors. 
Moreover, we used SH-SY5Y human neuroblastoma cells transfected with hNPFF2 receptors, 
named SH2D9 (Mollereau et al., 2005), as another model to explore the cellular and 
molecular mechanisms underlying NPFF anti-opioid effect. 
 
2. Materials and methods 
2.1 Solutions and chemicals 
BSA (fractionV) was from Euromedex (France). Trysin type XIII, soybean trysin inhibitor, 
Methyl-β-cyclodextrin and α-cyclodextrin were obtained from Sigma (France). Fluo4-AM 
(Molecular Probes, Netherlands) was dissolved (0.5 mM) in dry dimethylsulfoxide and stored 
at -20 °C. 1DMe, ([D-Tyr1, (N–Me) Phe3] NPFF) and N/OFQ were synthesized using solid 
phase techniques (Gicquel et al., 1992; Meunier et al., 1995), dissolved (1 mM) in methanol 
(20 %) and stored at -20 °C. Mouse monoclonal anti-flotillin 1 antibody was obtained from 
Transduction Laboratories (Lexington, KY), rabbit polyclonal anti-GFP antibody and 
anti-GRK2 antibody were from Santa Cruz Biotechnology (TEBU, France), rabbit polyclonal 
anti-actin antibody was from Sigma (France). Horseradish peroxidase-conjugated goat 
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anti-rabbit and goat anti-mouse IgG were obtained from Jackson ImmunoResearch 
Laboratories (USA). 
 
2.2 Vector Construction 
    The plasmid with human NOP receptor cDNA encoding EGFP is a generous gift from Dr 
Maithé Corbani (Institut de Génomique Fonctionnelle, Montpellier) (Corbani et al., 2004). 
The construct was inserted into the Hind III-Not I restriction sites of the mammalian 
expression vector pcDNA 3.1 bearing the Hygromycin B selection marker. 
 
2.3 Cell culture and transfection 
    Human neuroblastoma SH-SY5Y cells were stably transfected with the hNPFF2 receptor 
(Mollereau et al., 2005) and named SH2D9. SH2D9 cells were grown in Dulbecco's modified 
Eagle's medium (4.5 g/l glucose, GlutaMAXI) containing 10 % fetal calf serum (FCS), 50 
μg/ml gentamicin (Invitrogen, France) and 400 μg/ml G418 (Invitrogen) to maintain 
selection. The SH2D9-hNOPr-EGFP cell line, which expresses stably the human NOP 
receptors fused to a green fluorescent protein, was obtained by transfecting SH2D9 cells 
using lipofectamine 2000 Transfection Reagent (Invitrogen, Fisher, France) according to the 
manufacturer‘s instructions. Stable cell lines were obtained by subcloning and selection 
with 200 µg/ml Hygromycin B (Life technologies) and 400 μg/ml G418 (Invitrogen). 
SH2D9-hNOPr-EGFP cells were grown in SH2D9 cells‘ medium added with 200 µg/ml 
Hygromycin B to maintain selection. Both cell lines were maintained at 37 °C in a 
humidified atmosphere containing 5 % CO2. Lipofectamine RNAiMAX (Invitrogen, Fisher, 
France) was used for transfection of siRNAs according to the manufacturer‘s instructions.  
 
2.4 Neuron preparation 
    The DRN and PAG neurons were obtained from young C57BI/6J mice (45–60 days) as 
previously described (Ding and Zajac, 2014). Experiments were performed in accordance 
with the European Communities Council Directive 86/609/EEC and approved by the local 
ethical committee. 
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2.5 Measurement of intracellular calcium concentration 
Ca2+ transients triggered by depolarization were monitored in living, perfused cells and 
neurons by quantitative photometry using the fluorescent Ca2+ indicator Fluo4-AM as 
previously described (Mollereau et al., 2005; Ding and Zajac, 2014). 
 
2.6 Measurement of cAMP 
    Cells (3×105) were seeded into 24-well plates the day before the assay. The culture 
medium was then replaced by 0.3 ml of fresh medium containing 0.1 μM adenine and 1 μCi 
of [3H]adenine. After 60-min incubation, the cells were rinsed twice with 0.5 ml of 
Krebs-Ringer-HEPES (KRH) (124 mM NaCl, 5 mM KCl, 1.25 mM MgSO4, 1.5 mM CaCl2, 1.25 
mM KH2PO4, 25 mM HEPES, 8 mM glucose, and 0.5 mg/ml BSA, pH 7.4) buffer. Prewarmed 
KRH (0.2 ml) was added to each well, and the reaction was initiated by addition of 0.1 ml of 
KRH containing 15 μM forskolin (Sigma), 0.3 mM 3-isobutyl-1-methylxanthine (Sigma), 0.3 
mM Ro 20-1724 (Fisher, Illkirch, France) and the agonist to be tested. After 10 min at 37 °C, 
the reaction was stopped by adding 0.03 ml of 2.2 N HCl. The [3H]cAMP content of each well 
was isolated by chromatography on acid alumina columns (Sigma) (Mollereau et al., 2002). 
 
2.7 Membrane preparation 
Cells were harvested in ice-cold PBS, frozen at -80 °C for 1 h, and homogenized in 50 
mM Tris-HCl, pH 7.4, in a Potter Elvehjem tissue grinder (VWR Int., Fontenay-sous-Bois, 
France). After 10 min centrifugation at 1000 g the supernatant was collected, and the total 
membrane pellet was collected after the centrifugation at 40 000 RPM in an ultracentrifuge 
(Rotor 50.2 Ti, Beckman Optima LE-80K) for 35 min. Protein concentration was determined 
by Bradford assay. 
 
2.8 Isolation of MLRs Fractions 
For MLRs preparation with detergent, cells were collected in ice-cold PBS, frozen at 
-80 °C for at least 1 h followed by resuspension the cells in 1.5 ml of MBS (25 mM MES and 
0.15 M NaCl) containing proteinase inhibitors (Complete Mini tablets; Roche Diagnostics, 
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Indianapolis, IN) and 0.2 % Triton X-100 (Sigma) for 30 min gentle agitation at 4 °C. The 
lysate was mixed with an equal volume of ice -cold 80 % sucrose in MBS buffer in 12 ml 
Polyallomer centrifuge tubes (Beckman Coulter, Fullerton, CA) on ice. The sucrose/cell 
lysate solution was overlaid with 6 ml of 30 % sucrose and 2.5 ml of 5 % sucrose in MBS, 
and centrifuged at 39 000 RPM for 18 h at 4 °C in an ultracentrifuge (Rotor SW41, Beckman 
Optima LE-80K). Twelve 1 ml fractions were collected from the top down. After checking the 
MLRs marker flotillin 1 by western blot, the 3rd and 4th fractions corresponding to 
low-density DRMs were pooled and mixed with 22 ml of 50 mM Tris-HCl, pH 7.4 containing 
1 mM EDTA, and centrifuged at 40 000 RPM (Rotor 50.2 Ti, Beckman Optima LE-80K) for 
2.5 h at 4 °C. The DRMs pellet was resuspended in 50 mM Tris-HCl, pH 7.4. Protein 
concentration was determined by Bradford assay. 
For MLRs preparation without detergent (Song et al., 1996), cells were harvested in 2 ml 
of ice-cold 500 mM sodium carbonate prepared in MBS (25 mM MES, 0.15 M NaCl), pH 11. 
The suspension was first homogenized 3×10 s using an Ultra-Turrax T25 (Janke & Kunkel, 
IKA-Labortechnik, Staufen, Germany) then 3×20 s using a VibraCell sonicator (Bioblock 
Scientific, Illkirch, France). The homogenate was then mixed at the bottom of 12 ml 
Polyallomer centrifuge tubes (Beckman, Fullerton, CA) with 2 ml of 90 % sucrose prepared 
in MBS containing proteinase inhibitors (Complete Mini tablets, Roche). This layer was 
overlaid with 4 ml of 35 % sucrose and 4 ml of 5 % sucrose in MBS containing 250 mM 
sodium carbonate. The protocol for centrifugation, collection of 12 fractions, washing and 
protein quantification was the same as with MLRs preparation with detergent, except that 
the 4th and 5th fractions were collected for washing. 
 
2.9 [35S]GTPγS binding assay 
The assay was performed in polypropylene tubes, for which the buffer consisted of 20 
mM HEPES, pH 7.4, 100 mM NaCl, 3 mM MgCl2 and 0.1 % BSA. The concentration of GDP 
to include in the buffer for optimal stimulation was 10 µM. Total membranes (10 µg) or 
DRMs preparation (7 µg) were incubated for 60 min at 30 °C in the presence of 10 µg 
saponin, 0.07 nM [35S]GTPγS and agonist at the desired concentration. Reaction was 
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stopped by rapid vacuum filtration through GF/B Whatman glass fiber filters, preincubated 
in the buffer at room temperature for 1 h, and washed three times with 4 ml ice-cold buffer. 
Membrane-bound radioactivity retained on the filters was determined by liquid scintillation 
spectrophotometry (94 % efficiency, Packard counter) after overnight extraction of the filters 
in 4 ml Ready Protein scintillation fluid (Beckman). 
 
2.10 Western blot analysis 
For the isolated MLRs fractions, an equal volume of each fraction was solubilized in 
SDS-PAGE sample buffer containing 5 % β-mercaptoethanol. For whole cells, equal 
amounts of them (approximately 30 000) were seeded in 24-well plate. After transfection 
with siRNAs, cells were rinsed with ice-cold PBS and scrapped directly in Laemmli sample 
buffer containing 5 % β-mercaptoethanol on ice. Proteins (from fractions or whole cells) 
were subjected to SDS-PAGE on 10 % polyacrylamide gels after 5 min boiling at 100 °C, and 
followed by liquid transfer on PVDF membranes (Immobilon-P, Millipore, Bedford, MA). ECL 
plus Western blotting detection kit (GE Healthcare, UK) was used to reveal the 
immunoreactivity after incubation with primary and corresponding secondary antibodies. 
X-ray films were scanned using a GS-800 Calibrated Densitometer (Bio-Rad, USA), and 
blots were quantified using Quantity One software (Bio-Rad, USA) relative to actin used as 
internal standard. 
 
2.11 Data analysis 
Data are presented as mean ± SEM with n values representing the number of 
independent experiments performed. Graph Prism 4.01 (GraphPad software Inc., USA) and 
ImageJ 1.49p (NIH, USA) were used for data analysis. The level of significance (* p < 0.05, ** 
p < 0.01) was determined using the two-tailed Student's t-tests for two-group comparison, 
one-way ANOVA with Bonferroni post hoc analysis for multi-group comparison. 
 
3. Results 
3.1 Effects of 1DMe, α-cyclodextrin and methyl-β-cyclodextrin on the neuronal 
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responses to N/OFQ 
By using calcium imaging technology, in mouse DRN neurons, the effect of the NPFF 
analog 1DMe was tested on N/OFQ activities on Ca2+ transients triggered by depolarization. 
On this anti-opioid model, the inhibition rate of N/OFQ on DRN neurons decreased from 
36.9 % to 13.4 % after 10 min of 1DMe perfusion (Fig. 1A, B). While 10 min perfusion with 
methyl-β-cyclodextrin alone had no effect on N/OFQ activities in DRN neurons on the Ca2+ 
transients triggered by depolarization, the addition of methyl-β-cyclodextrin with 1DMe 
significantly reversed the N/OFQ neuronal effect of 1DMe treatment from 13.4 % to 29.5 %. 
In contrast, α-cyclodextrin failed to modify 1DMe anti-N/OFQ effect (Fig. 1A, C). 
Similar results were observed in SH2D9 cells by testing N/OFQ action on the Ca2+ 
transients triggered by depolarization. The inhibition rate of N/OFQ in SH2D9 cells also 
could be inhibited, from 37.5 % to 19.7 %, by a 10 min 1DMe perfusion (Fig. 2). The addition 
of methyl-β-cyclodextrin, but not α-cyclodextrin, with 1DMe almost abolished 1DMe 
anti-N/OFQ effect (Fig. 2). However, 10 min perfusion with methyl-β-cyclodextrin alone had 
no effect on N/OFQ effect on the Ca2+ transient triggered by depolarization (Fig. 2). 
 
3.2 Effects of 1DMe and methyl-β-cyclodextrin on the neuronal responses to 
DAMGO 
In mouse PAG neurons, the inhibition rate, produced by DAMGO on Ca2+ transients 
triggered by depolarization, decreased from 34.6 % to 18.4 % after 10 min 1DMe perfusion 
(Fig. 3). However, by using the same protocol as for NOP receptors, only a slight potentiating 
effect of methyl-β-cyclodextrin on 1DMe anti-μ opioid effect could be observed (Fig. 3). 
Perfusion with methyl-β-cyclodextrin alone also did not change the neuronal responses of 
PAG neurons to DAMGO (Fig 3). 
Similar results were observed in SH2D9 cells. The anti-μ opioid effect of 1DMe was 
39.2 %, and the presence of methyl-β-cyclodextrin did not reverse but slightly potentiated 
1DMe anti-μ opioid effect (Fig. 4). Perfusion with methyl-β-cyclodextrin alone had no effect 
on DAMGO activity on Ca2+ transients triggered by depolarization (Fig 4). 
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3.3 Effects of 1DMe on NOP receptor activity on MLRs fractions and total 
membranes 
In order to verify our hypothesis that MLRs play as a necessary ―platform‖ in NPFF 
anti-opioid process, we used the classical approach for isolation of detergent resistance 
membranes (DRMs) to do further study. Flotillin-1, the classical marker of MLRs, was 
detected by western-blot in the fractions to confirm our preparation (Fig. 5A). 
Before the preparation of MLRs, we treated the cells with 1DMe for 10 min. By using 
[35S]GTPγS binding assay, we observed a significant 20 % decrease of the activity of NOP 
receptors in DRMs of SH2D9 cells (Fig. 5B). 
However, the same treatment did not modify the activity of NOP receptors in total 
membranes of the same cells (Fig. 5C). 
 
3.4 GRK2 protein, but not PKC, mediates the 1DMe anti-N/OFQ effect 
The Fig. 6A shows that GRK2 protein was strongly down-regulated after transfection of 
the specific siRNA compared to untransfected cells or cells transfected with a negative 
control siRNA. When GRK2 was knocked-down by siRNA, in SH2D9 cells, 1DMe lost 44.5 % 
of its ability to inhibit N/OFQ effect on Ca2+ transients triggered by depolarization (Fig. 6B). 
In contrast, a treatment with chelerythrine (PKC inhibitor) did not significantly modify 
the 1DMe anti-N/OFQ effect on Ca2+ transients triggered by depolarization in SH2D9 cells 
(Fig. 6C). 
 
3.5 Effects of 1DMe on GRK2 distribution in DRMs 
The sucrose gradient fractions of SH2D9 cells were prepared and the distribution of 
GRK2 was tested by western-blot using an antibody against GRK2 (Fig. 8A). 
As it is showed in Fig. 7B, the amount of GRK2 in DRMs signigicantly increased by 39 % 
after 1DMe treatment compared to control condition, supporting the role of GRK2 in 1DMe 
anti-N/OFQ effect. 
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3.6 Effects of 1DMe on NOP receptor distribution in DRMs 
In order to analyse the effect of 1DMe on the distribution of NOP receptors in MLRs, we 
overexpressed NOP receptors in SH2D9 cells. 
Because the expression level of endogenous NOP receptors in SH2D9 cells is very low, 
we did not observe any inhibitory effect of 100 nM N/OFQ on cAMP accumulation 
stimulated by Forskolin (15 µM) (Fig. 8A). After the transfection of hNOP receptors 
C-terminally fused to a green fluorescent protein EGFP, NOP receptors were functionally 
expressed at the plasma membrane of SH2D9-hNOPr-EGFP cells, while the functional 
expression of NPFF2 receptors had no changed (Fig. 8A, B). 
Following the same protocol, sucrose gradient fractions of SH2D9-hNOPr-EGFP cells 
were prepared and the percentage of NOP receptors distributed in DRMs was determined to 
be 15.7 % by western-blot using an antibody against GFP (Fig. 8C). 
As it is showed in Fig. 8D, 1DMe treatment had no effect on the distribution of NOP 
receptors in DRMs. 
 
4. Discussion 
In the present study, we observed a clear decrease of NPFF anti-N/OFQ effect on Ca2+ 
transients after adding methyl-β-cyclodextrin, both in acutely dissociated mouse neurons 
and SH2D9 human neuroblastoma cells, which was concomitant with a significant decrease 
of NOP receptor activity in DRMs but not in total membrane preparation of SH2D9 cells. 
These data clearly indicate a role of MLRs in NPFF anti-N/OFQ effect. In contrast, 
methyl-β-cyclodextrin did not modify the NPFF anti-µ opioid effect on Ca2+ transients, 
indicating that NPFF exhibits anti-opioid effect with different mechanisms for µ opioid and 
NOP receptors. GRK2, not PKC, was clearly involved in the NPFF anti-N/OFQ effect. 
Due to the technical limitations, precisely visualizing and studying of the MLRs is still 
difficult. However, despite these limitations, data from many studies conclusively support 
the existence of nanoscale, cholesterol-assisted, dynamic and selective assemblies (Simons 
and Gerl, 2010). Furthermore, it has been shown that these dynamic assemblies are 
involved in several aspects of cellular functions (Head et al., 2014). 
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There are two classical methods to study MLRs: isolation of MLRs fractions (detergent 
resistant membranes or non-detergent-based isolation of raft membranes) and disrupt the 
synthesis of MLRs by chelation or prevention of the synthesis of cholesterol. 
Methyl-β-cyclodextrin is the most commonly used reagent to deplete the membrane 
cholesterol. As plasma membranes can contain up to 40 mol% cholesterol (Kalvodova et al., 
2009), it is perhaps not surprising that many cellular functions can be perturbed by 
cholesterol depletion (Zidovetzki and Levitan, 2007). 
In order to minimal the side effects, such as lateral protein immobilization (Kenworthy, 
2008), led by methyl-β-cyclodextrin application, in our study, we used a relatively lower 
concentration (2 mg/ml, corresponding to 1.5 mM) and shorter incubation time (10 min). 
According to the morphology, depolarization status of the cells and the negative results on 
NPFF anti-µ opioid effect after methyl-β-cyclodextrin treatment, we concluded that the side 
effects of using this compound was not apparent in our study condition, both on acutely 
dissociated mouse neurons and SH2D9 cells. Combining with the control data of 
α-cyclodextrin treatment, obviously cholesterol plays important role in NPFF anti-N/OFQ 
effect. 
In order to verify our hypothesis that the cross-talk between NPFF and NOP receptors 
happens in MLRs, we chose to use [35S]GTPγS binding assay to test the function and activity 
of NOP receptors. Although with pitfalls, the biochemical methods of DRMs and detergent 
free rafts preparation are still good tools to study the potential role of MLRs. After the 
treatment with 1DMe, the activity of endogenously expressed NOP receptors in DRMs, but 
not in total membrane, decreased (about 20 %) significantly in SH2D9 cells. Thus, a possible 
explanation could be that the decrease of the activity of NOP receptors on DRMs was 
masked by the high percentage (about 84 %) of NOP receptors expressed on non-raft parts 
not modified by 1DMe. In other words, these data suggest that only NOP receptors located 
on MLRs could be inhibited by the activation of NPFF receptors after 1DMe treatment. 
We did not observe any activation of NOP receptors on non-detergent-based MLRs 
preparation. Data from total membrane preparation showed the high pH affects the binding 
property of N/OFQ with NOP receptors (data not shown). However, it is still possible that the 
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endogenous NOP receptors are expressed on MLRs fractions of non-detergent-based 
isolation, which needs very sensitive antibody to determine. 
The depletion of cholesterol by methyl-β-cyclodextrin did not affect the NPFF anti-µ 
opioid effect. One study from our laboratory, by using fluorescence recovery after 
photobleaching, showed that 1DMe treatment could increase the diffusion coefficient of 
MOP receptors on SH-SY5Y cells, suggesting that the activation of NPFF2 receptors removed 
MOP receptors from their micro-domain anchoring (Roumy et al., 2007). In contrary, 
another study also from our laboratory, by indirect biochemical fractionation of MLRs of 
SH-SY5Y cells, showed that MOP receptor distribution in lipid rafts is highly dependent 
upon the method of purification and 1DMe treatment did not modify the distribution profile 
of MOP receptors (Moulédous et al., 2008). It is therefore likely that the confinement of MOP 
receptor does not depend on MLRs. This is consistent with the fact that after using 
methyl-β-cyclodextrin, which removes the cholesterol from cells, the NPFF anti-µ opioid 
effect did not decrease. 
The possibility of GPCR dimer formation is now supported by numerous studies, from in 
vitro and in vivo assays to crystal structure of two GPCRs (Maurice et al., 2011), which 
makes the regulation of GPCR activity and trafficking much more complex. Our laboratory 
has demonstrated the heterodimerization of NPFF2 and MOP receptors on SH-SY5Y cells 
(Roumy et al., 2007), and proposed that GRK2-mediated trans-phosphorylation contributes 
to the loss of function of µ opioid receptors induced by activation of NPFF2 receptors 
(Moulédous et al., 2012). In addition, several studies showed that MOR agonists regulate 
the desensitization of NOP receptors through PKC, GRK2 or GRK3 pathways in a cell 
specific manner (Mandyam et al., 2000, 2002, 2003; Wang et al., 2005). So, we tested 
whether PKC or/and GRK2 also contribute to the NPFF anti-N/OFQ effect. Indeed, after the 
downregulation of GRK2 proteins, the anti-N/OFQ effect of NPFF was inhibited. Western 
blot data showed a 39 % increase of the GRK2 protein distributed in DRMs after 1DMe 
treatment, which also supported the role that GRK2 and MLRs played as a ―mediator‖ and a 
―platform‖, respectively, in 1DMe anti-N/OFQ effect. This effect is probably caused by a 
heterologous phosphorylation of NOP receptors induced by the activation of NPFF2 
 85 
Results & Discussion 
receptors, but specific antibodies against phosphorylated NOP receptors are needed to 
verify this point. In addition, the distribution of NOP receptors in DRMs did not change after 
1DMe treatment, which suggests MLRs act as a necessary dynamic ―platform‖ for the 
phosphorylation of NOP receptors mediated by GRK2. In contrast, the anti-N/OFQ effect of 
NPFF did not change after the treatment with a PKC inhibitor. 
In conclusion, the present work suggests that the membrane/lipid rafts play an 
important role in the process of NPFF anti-N/OFQ effect, but not in that of the anti-µ opioid 
effect. These data provide a new precise way to interpret the anti-opioid effect of 
Neuropeptide FF receptors: NPFF produces the anti-opioid effect to different opioid 
receptors through different mechanisms. 
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Figure 1: Effects of 1DMe on the neuronal responses to N/OFQ in DRN neurons. (A) The 1DMe concentration in 
all conditions was 100 nM, and open rectangles indicate 10 min perfusion but with different conditions: green, 
1DMe; blue, 1DMe + α-cyclodextrin (2 mg/ml); red, 1DMe + Methy-β-cyclodextrin (2 mg/ml); purple, 
Methy-β-cyclodextrin (2 mg/ml). N/OFQ was applied (300 nM, 1 min, horizontal lines) before and after different 
treatment. Each arrow indicates a depolarization pulse. (B) After the treatment with 1DMe, the inhibitory effect 
of N/OFQ on Ca2+ transients triggered by depolarization is reduced. (C) Results are expressed as percentage of 
the N/OFQ effect in control cells. Data are mean ± SEM. The number in columns means the number of neurons 
included. *** p < 0.001 compared to control group, #  p < 0.05 compared to 1DMe treated group, n.s. not 
significant. Two-tailed Student‘s t-tests for two-group comparison, one-way ANOVA with Bonferroni post hoc 
analysis for multiple-group comparison. 
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Figure 2: Effects of 1DMe on the neuronal responses to N/OFQ in SH2D9 cells. (A) The 1DMe concentration in all 
conditions was 100 nM, and open rectangles indicate  10 min perfusion but with different conditions: green, 
1DMe; blue, 1DMe + α-cyclodextrin (2 mg/ml); red, 1DMe + Methy-β-cyclodextrin (2 mg/ml); purple, 
Methy-β-cyclodextrin (2 mg/ml). N/OFQ was applied (300 nM, 1 min, horizontal lines) without (black graph) or 
after different treatment. Each arrow indicates a depolarization pulse. (B) After different treatment, the effect of 
N/OFQ on Ca2+ transients triggered by depolarization was compared. Data are mean ± SEM. The number in 
columns means the number of cells included. ** p < 0.01 compared to control group, ## p < 0.01 compared to 
1DMe treated group, n.s. not significant. One-way ANOVA with Bonferroni post hoc analysis. 
 
A 
B 
 88 
Results & Discussion 
A 
B 
0 500 1000 15000.0
0.5
1.0
1.5
2.0
t, s
F
/
F
0
1DMe treated
0 500 1000 15000.0
0.5
1.0
1.5
2.0
t, s
F
/
F
0
1DMe + M--CD treated
0 500 1000 15000.0
0.5
1.0
1.5
2.0
2.5
t, s
F
/
F
0
M--CD treated
   
Co
ntr
ol
1D
Me
 
tre
ate
d
1D
Me
 
+ 
M-
ß-C
D t
re
ate
d
M-
ß-C
D t
re
ate
d
0
25
50
75
100
125
19
18
13
D
A
M
G
O
 e
ff
e
c
t 
o
n
 C
a
2
+
 i
n
fl
u
x
 i
n
P
A
G
 n
e
u
ro
n
s
 (
%
 o
f 
c
o
n
tr
o
l)
**
50 ***
n.s.
n.s.
 
Figure 3: Effects of 1DMe on the neuronal responses to DAMGO in PAG neurons. (A) The 1DMe concentration in 
all conditions was 100 nM, and open rectangles indicate 10 min perfusion but with different conditions: green, 
1DMe; red, 1DMe + Methy-β-cyclodextrin (2 mg/ml); purple, Methy-β-cyclodextrin (2 mg/ml). DAMGO was 
applied (100 nM, 1 min, horizontal lines) before and after different treatment. Each arrow indicates a 
depolarization pulse. (B) Results are expressed as percentage of the DAMGO effect in control values. Data are 
mean ± SEM. The number in columns means the number of neurons included. ** p < 0.01 compared to control 
group, *** p < 0.001 compared to control group, n.s. not significant. One-way ANOVA with Bonferroni post hoc 
analysis. 
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Figure 4: Effects of 1DMe on the neuronal responses to DAMGO in SH 2D9 cells. (A) The 1DMe concentration in 
all conditions was 100 nM, and open rectangles indicate 10 min perfusion but with different conditions: green, 
1DMe; red, 1DMe + Methy-β-cyclodextrin (2 mg/ml); purple, Methy-β-cyclodextrin (2 mg/ml). DAMGO was 
applied (100 nM, 1 min, horizontal lines) without (black graph) or after different treatment. Each arrow indicates 
a depolarization pulse. (B) After different treatment, the effect of DAMGO on Ca2+ transients triggered by 
depolarization was compared. Data are mean ± SEM. The number in columns means the number of cells 
included. *** p < 0.001 compared to control group, n.s. not significant. One-way ANOVA with Bonferroni post 
hoc analysis. 
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Figure 5: Effects of 1DMe on the activity of NOP receptors. (A) Samples from each fraction were loaded on 10 % 
SDS-PAGE gel and immunoblotted using an antibody against flotillin-1. Data is a representative of at least three 
independent experiments. The [35S]GTPγS binding stimulated by N/OFQ (10 µM) on DRMs (n = 8) (B) or total 
membranes (n = 7) (C) of SH2D9 cells. Data are mean ± SEM and expressed as percentage of [35S]GTPγS binding 
in the absence of agonist (basal binding). * p < 0.05 compared to control group, n.s. not significant. Two-tailed 
Student‘s t-tests comparison. Data are from at least three independent experiments. 
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Figure 6: Effects of GRK2 knock-down or inhibition of PKC on NPFF anti-N/OFQ effect in SH2D9 cells. (A) 
Western-blot analysis showing knock-down of GRK2 in SH2D9 cells transfected with GRK2 siRNA. Control, 
transfection reagent treated; Control-SiRNA, negative control SiRNA transfected; GRK2-SiRNA, GRK2 siRNA 
transfected (n = 7). (B) Inhibitory effect of N/OFQ (1 µM) in control cells and effects of pre-treatment with 1DMe 
(100 nM, 10 min) in cells transfected with control-Si- or GRK2-Si-RNAs on Ca2+ transients triggered by 
depolarization. (C) Inhibitory effect of N/OFQ (1 µM) in control cells and effects of pre-treatment with 1DMe (100 
nM, 10 min) in control cells or cells treated (10 µM, 15 min) with Chelerythrine on Ca2+ transients triggered by 
depolarization. Results in (B) and (C) are expressed as % of N/OFQ effect in control cells. Data are mean ± SEM. 
The number in columns means the number of cells included. * p < 0.05 compared to control group, *** p < 0.001 
compared to control group, #  p < 0.05 compared to 1DMe Control-Si- group, ### p < 0.001 compared to Control 
SiRNA group, n.s. not significant. One-way ANOVA with Bonferroni post hoc analysis. 
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Figure 7: The distribution of GRK2 in DRMs of SH2D9 cells. (A) The DRMs fractions of SH2D9 cells were extracted 
and the distribution of GRK2 in DRMs was immunobolted by using antibody against GRK2.  Data is a 
representative of at least three independent experiments. (B) The change of the distribution of GRK2 in DRMs 
after 1DMe treatment (100 nM, 10 min) (n = 6). Data are mean ± SEM. * p < 0.05 compared to control group. 
Two-tailed Student‘s t-tests comparison.     
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Figure 8: Effects of 1DMe on distribution of NOP receptors in DRMs of SH2D9-hNOPr-EGFP cells. Comparison of 
N/OFQ (100 nM) (n = 5) (A) and 1DMe (100 nM) (n = 5) (B) effect on forskolin-induced cAMP accumulation in cells 
before (SH2D9 cells) and after transfection (SH2D9-hNOPr-EGFP cells) of hNOP receptors tagged EGFP. (C) The 
DRMs fractions of SH2D9-hNOPr-EGFP cells were extracted and the distribution of NOP receptors in DRMs was 
determined by using an antibody against GFP (n = 3). (D) The change of the distribution of NOP receptors in 
DRMs after 1DMe treatment (n = 6). Data are mean ± SEM. ** p < 0.01, *** p < 0.001 compared to control group, 
#  p < 0.05 compared to SH2D9 cells group, n.s. not significant. Two-tailed Student‘s t-tests comparison. 
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Part 2: Pharmacological effects of Neuropeptide FF, the in vivo 
behavioural study 
 
The potential role of Neuropeptide FF in antidepressant response 
 
1. Introduction 
Major depressive disorder (MDD) is characterized by low mood, feelings of 
despair, an inability to feel pleasure (also known as anhedonia) and loss of 
motivation (Charney and Nestler, 2005), which is one of the most prevalent and 
disabling mental disorders. Modern views consider this disorder as a result of 
maladaptive molecular and cellular changes of specific brain circuits in response to 
external stimuli (Vaidya and Duman, 2001; Mayberg, 2003). 
Dorsal raphe nucleus (DRN), also known as serotoninergic nucleus, is one of the 
most widely studies brain nucleus involving in antidepressant response, as selective 
serotonin reuptake inhibitors (SSRIs) are the current frontline class of 
antidepressant treatment and exert their primary pharmacological effects through 
the manipulation of 5-HT system. Although the frequency and severity of side effects 
are reduced with the treatment of SSRIs compared to the old antidepressant 
treatment by tricyclic drugs which inhibit the reuptake of monoamines or 
monoamine oxidase inhibitors (MAOIs) that inhibit their enzymatic degradation, 
current antidepressant treatments have a delayed onset of therapeutic action, and a 
significant number of patients are non-responsive. Except the development of new 
generation versions of SSRIs, an important complementary strategy is to identify 
novel treatment approaches. 
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Figure 1: Serotonin neurons from the raphé nuclei send diffuse projections throughout the central nervous 
system. Schematic representation of projections from raphe nuclei. DRN, dorsal raphe nucleus;  H, 
hypothalamus; HF, hippocampal formation; MRN, median raphe nucleus; RM, raphe magnus; RO, raphe 
obscurus; RPa, raphe pallidus; RPo, raphe pontis; Th, thalamus. From (Richerson and Buchanan, 2011)  
 
Recently, data from animal behavioural despair tests (forced swimming and tail 
suspension test) and chronic mild stress models showed that NOP receptor 
antagonists exhibit strong antidepressant action, which suggests a new target for 
antidepressant treatment (Gavioli and Calò, 2013). Furthermore, the decreased 
immobility time, in forced swimming and tail suspension test, of NOP receptor gene 
knockout mice compared with that of wild-type mice confirmed the potential role of 
NOP receptor antagonists in antidepressant. However, i.c.v. injection of N/OFQ 
didn‘t induce any behavioral modification in mice subjected to behavioral despair 
tests, but reversed the antidepressant response of NOP receptor antagonists (Gavioli 
et al., 2003, 2004). In particularly, N/OFQ reduced the firing of DRN neurons 
(Vaughan and Christie, 1996) and inhibited 5-HT release in DRN slices (Nazzaro et 
al., 2009), and DRN injection of N/OFQ decreased 5-HT efflux in the nucleus 
accumbens, while the NOP receptor antagonist [Nphe1]N/OFQ(1-13)-NH2 increased 
extracellular 5-HT in DRN after local injected into the same area (Tao et al., 2007). 
These electrophysiological and neurochemical studies suggest an important role 
played by monoaminergic, particularly the serotonergic system, in mediating the 
antidepressant effect of NOP receptor antagonists. 
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One recently published paper showed that i.c.v. injection of NPAF (NPFF related 
peptide, and from the same precursor proNPFFA with NPFF) induced an 
anti-depressant-like behavior in mice (Palotai et al., 2014). The research also 
demonstrated that the anti-depressant effect of NPAF was mediated, at least partly, 
through 5HT2-serotonergic and muscarinic cholinergic neurotransmissions (Palotai 
et al., 2014). Except the only one report, little is known about the potential role of 
NPFF in anti-depressant response. As NOP receptor antagonists exhibit strong 
anti-depressant action, and NPFF acts as a potent anti-N/OFQ peptide, it should be 
very interesting to further confirm the potential role of NPFF in antidepressant 
response, especially the hypothesis that NPFF could produce the antidepressant 
effect, fully or partly, because of their anti-N/OFQ property. 
In collaboration with Dr Bruno Guiard (UPS & Paris XI), at the present study, we 
investigated the antidepressant effect of NPFF by using tail suspension and splash 
test after local injection of the NPFF analog 1DMe into the DRN of C57BI/6J mice. 
 
2. Materials and methods 
2.1 Materials 
    1DMe, ([D-Tyr1, (N–Me) Phe3] NPFF) was synthesized using solid phase 
techniques (Gicquel et al., 1992) and dissolved in saline (0.9 %). RF9 was a generous 
gift from Dr Frederic Bihel (Laboratoire d'Innovation, CNRS, Strasbourg) and 
dissolved in 14% DMSO. 
 
2.2 Animals 
Male C57BI/6J mice (4 – 7 weeks of age) were housed five per cage under a 12-h 
light-dark cycle. The mice received food and water ad libitum. All experimental 
procedures were performed in accordance with the European Communities Council 
Directive 86/609/EEC and approved by the local ethical committee. 
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2.3 Surgery 
Mice were anesthetized with chloral hydrate (400 mg/kg; i.p.) and mounted in a 
stereotaxic frame (KOPF). Additional anesthesia (50–100 mg/kg; i.p.) was given as 
necessary to maintain a full anesthetic state. Body temperature was maintained at 
37 °C throughout the experiments using a thermistor-controlled heating pad 
(Astro-Med, Elancourt, France). Concentric iron cannulas (×0.30 mm outer 
diameter) were implanted within the dorsal raphe nucleus (DRN): 0.2–0.5 mm 
posterior to the interaural line on the midline and at a depth of 3.0 mm from the 
brain surface (Fig. 2A). When the guided cannulas implanted, they were fixed by 
dental cement to the skull of mice. 
The injection sites were examined at the end of all testes and only data from 
animals with correct injection were included (Fig. 2B). 
 
 
 
 
 
 
 
 
 
 
2.4 Administration of ligands  
    1DMe (5 ng in 0.5 μl per mice) and saline were injected into DRN through an 
intra cannula by electrical microsyringe at a flow rate of 0.1 µl/min for 5 minutes. 
RF9 (5 mg/kg in 14 % DMSO) and DMSO (14 %) were administrated by i.p. injection. 
In figure 5A, B, C, saline used as the control injection. While in figure 5D, E, 14 % 
DMSO used as the control injection, and 1DMe was injected after 20 min of 14 % 
DMSO (1DMe effect group) or RF9 (1DMe effect after RF9 injection group). 
 
 
Figure 2: Cannula at the Dorsal Raphe Nucleus (DRN) of mice (A) and confirmation of the injection sites 
(B) 
 
A 
B 
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2.5 Behavioural test 
    After the surgery, all mice were kept in their home cage for at least seven days 
recovery, and behavioural tests were performed after 30 min of the last injection. 
The tail suspension test was performed according to the procedure of Steru et al. 
(1985). C57BL/6J mice were individually suspended by their tails, using adhesive 
tape placed approximately 1 cm from the tip of the tail, on an aluminum suspension 
bar which was approximately 55 cm high above the tabletop. The immobility time of 
the mice was recorded for 6 min (Fig. 3). The mice were considered immobile when 
they hung down passively without movement, only small movements that are 
confined to the front legs but without the involvement of the hind legs and 
oscillations and pendulum like swings that are due to the momentum gained during 
the earlier mobility bouts. 
 
 
 
    Splash test was performed as previously described (David et al., 2009). This test 
consisted of squirting 200 µl of 10 % sucrose solution on the mouse‘s snout. Then, 
the grooming frequency of mice was recorded (Figure 4). 
 
Figure 3 
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Figure 4: The mouse splash test. (A) Squirting of sucrose solution on the mouse. (B) Counting of grooming 
frequency. 
 
3. Results and discussion 
    The tail-suspension test (TST) and splash test (ST) are mice behavioral tests 
useful in the screening of potential antidepressant drugs and assessing of other 
manipulations that are expected to affect depression related behaviors. 
As shown in figure 5A that 1DMe treatment strongly decreased the immobility 
time of the mouse in TST from 174 s to 118 s. The mouse locomotor activity test 
(Figure 5B) excluded the possibility that the decrease of immobility time after 1DMe 
treatment was due to an increase of animal locomotion activity. Similarly, in splash 
test, 1DMe treatment increased the grooming time of the mouse from 180 s to 224 s 
(Fig. 5C). 
As it is showed in figure 5D that 1DMe decreased the immobility time of the 
mouse in TST from 215 s to 157 s and RF9, the specific antagonist of NPFF receptors, 
reversed it to 189 s. However, RF9 administrated alone had no effect (Fig. 5E). Using 
DMSO as the vehicle of RF9 should be the cause for the statistic difference (p < 0.05, 
Student‘ t-tests, data not shown) between control values of Figure 5A (174 s) and 
Figure 5D (215 s). Nevertheless, 1DMe still decreased the immobility time of the 
mouse, and RF9 reversed the effect of 1DMe. 
    One recently published paper showed NPAF (from the same precursor of NPFF) 
produced anti-depressant effect on mouse forced swimming test (another animal 
model of depression). Furthermore, the authors demonstrated that the 
Grooming 
A B 
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anti-depressant effect of NPAF was mediated, at least partly, through 
5HT2-serotonergic and muscarinic cholinergic neurotransmissions (Palotai et al., 
2014). In addition, it has been reported previously that RFamide related peptides 
(RFRPs) (Soga et al., 2010) and Kisspeptin (KP) (Tanaka et al., 2013), both belong to 
RFamide peptide family, were regulated by citalopram (the most potent serotonin 
reuptake inhibitor antidepressant) in expression and produced antidepressant 
effect in mice forced swimming test, respectively. 
Our work supported the involving of RFamide peptides, particularly NPFF in the 
present study, in anti-depression through activation of their corresponding 
receptors. However, the mechanisms underlying the role of NPFF played in 
anti-depression were still unclear. Taking into account the potent anti-N/OFQ 
property of NPFF in vitro and the potential role of NOP receptor antagonists in 
anti-depression in vivo, it should be very interesting to test the hypothesis that NPFF 
could produce the anti-depressant effect, fully or partly, because of their 
anti-N/OFQ property. 
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Figure 5: 1DMe treatment produced anti-depressant effect on mice models of depression. Same dose of 1DMe (5 
nmol/mouse) was used in each test. (A) 1DMe effect in mice tail suspension test after dorsal raphe nucleus (DRN) 
injection. (B) 1DMe effect in mice locomotion activity after DRN injection. (C) 1DMe effect in mice splash test 
after DRN injection. (D) The reverse of 1DMe effect by RF9 (5 mg/kg) i.p. injection. (E) RF9 effect in mice tail 
suspension test after i.p. injection. Data are mean + SEM. The number in columns means the number of mice 
included. * p < 0.05, ** p < 0.01, *** p < 0.001 compared to control group, # p < 0.05 compared to 1DMe treated 
group, n.s. not significant. Two-tailed Student‘s t-tests for two-group comparison, one-way ANOVA with 
Bonferroni post hoc analysis for multiple-group comparison.
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Conclusions & Perspectives 
 
Activation of NPFF receptors could directly inhibit the Ca2+ transient induced by 
depolarization in mouse dorsal raphe nucleus (DRN) neurons. However, to produce 
a similar inhibition effect in rat dorsal root ganglia (DRG) neurons, the threshold 
concentration of NPFF was much lower (Roumy and Zajac, 1996), and in rat DRN 
neurons the direct activity of NPFF receptors on Ca2+ transient was not observed 
(Roumy and Zajac, 1999). In addition, in mouse DRN neurons, the threshold 
concentration of NPFF producing the anti-N/OFQ effect was also much lower than 
that of producing the direct effect on Ca2+ transients (Ding and Zajac, 2014). These 
data suggested: 1) DRN neurons of mice and rats may have different sensitivities to 
NPFF stimulation; 2) in mouse DRN neurons, the anti-N/OFQ activity of NPFF 
receptors was not a direct consequence of their direct activities on Ca2+ transients; 3) 
in the brain, it‘s possible that the pivotal role of NPFF system is to modulate the 
opioid system functions but not to directly modulate the Ca2+ channel. 
In the future, it would be interesting to compare the sensitivity of NPFF 
receptors distributed in central nervous system and peripheral nervous system, and 
the possible relationship of their sensitivities to the physiological or pathological 
processes. 
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Figure 1: Direct and anti-N/OFQ activities of NPFF receptors in DRN neurons. (A) The Ca2+ transient triggered by 
depolarization could be inhibited by the activation of NOP receptors. (B) After using a low concentration of the 
NPFF receptor agonist, like 1DMe, the inhibitory effect of NOP receptors on Ca2+ transients could be inhibited. (C) 
After using a high concentration of 1DMe, NPFF receptors could produce  both the direct effect on Ca2+ transients 
and the anti-N/OFQ effect. 
 
The data that indicates the potential role of membrane/lipid rafts (MLRs) played 
in NPFF anti-N/OFQ, but not anti-μ opioid effect, helps us to interpret the NPFF 
anti-opioid effect in a more precise way: NPFF could produce the anti-opioid effect 
through different mechanisms to different opioid receptors. After 1DMe treatment, 
although the distribution of NOP receptors in DRMs had no obvious change, the 
GRK2 was significantly enriched. These data could be interpreted as the activation 
of NPFF receptors recruited GRK2 into this ―platform‖, and GRK2 could 
phosphorylate the NOP receptors that originally or newly associated with MLRs. 
Nevertheless, this ―platform‖ is dynamic, which means, to NOP receptors, it‘s only 
the place for phosphorylation but not gathering. After the phosphorylation, NOP 
receptors would leave this ―platform‖ for further signaling transductions or to be 
dephosphorylated. 
A 
B C 
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In addition, the [35S]GTPγS binding stimulated by 1DMe (100 nM) was observed 
(more than 30%, data not shown) in both DRMs and non-detergent MLRs 
preparation of SH-SY5Y cells, which suggests the presence of NPFF2 receptors on 
MLRs. However, it‘s hard to conclude whether certain part (on or out of MLRs) or all 
receptors could inhibit the activity of NOP receptors. 
In the future, specific antibodies against phosphorylated NOP receptors are 
needed to verify the reality of this process. Furthermore, nowadays, all the 
technologies used for MLRs study have pitfalls. There is no doubting that the 
breakthrough of methodology should be the key to confirm the roles that MLRs 
played in NPFF anti-opioid effect. Moreover, whether certain part or all NPFF 
receptors on the membrane could produce the anti-opioid effect is also worthy to be 
examined. 
 
 
 
Figure 2: Putative process of NPFF anti-N/OFQ effect. The activation of NPFF2 receptors could recruit GRK2 into 
MLRs and only the activity of NOP receptors that localized on MLRs could be inhibited. 
 
Combining the previous data and this thesis work (Soga et al., 2010; Tanaka et 
al., 2013; Palotai et al., 2014), we believe RFamide peptides are implicated in 
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depression. In particularly, in the present study, NPFF produced an antidepressant 
effect through the activation of NPFF receptors after being injected into the DRN of 
mice. Palotai et al. demonstrated that the antidepressant effect of NPAF was 
mediated, at least partly, through 5HT2-serotonergic and muscarinic cholinergic 
neurotransmissions (Palotai et al., 2014). Nevertheless, the mechanisms under this 
process are still not clear. 
Taking into account the potent anti-N/OFQ property of NPFF in vitro and the 
potential role of NOP receptor antagonists in anti-depression in vivo, it should be 
very interesting to test the hypothesis that NPFF could produce the anti-depressant 
effect, fully or partly, because of their anti-N/OFQ property. 
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